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Background: Many glaucoma referrals from the community to hospital eye services 
(HES) are unnecessary. Imaging technologies can potentially be useful to triage this 
population.  
 
Objectives: To assess the diagnostic performance and cost-effectiveness of imaging 
technologies, as triage tests, for identifying people with glaucoma. 
 
Design: Within patient comparative diagnostic accuracy study.  Markov economic 
model comparing the cost effectiveness of a triage test with usual care.  
 
Setting: Secondary care  
 
Participants: Adults referred from the community to HES for possible glaucoma. 
 
Interventions: Heidelberg Retinal Tomogram (including two diagnostic algorithms, 
HRT-GPS and HRT-MRA), scanning laser polarimetry (GDx), and optical coherence 
tomography (OCT). The reference standard was clinical examination by a consultant 
ophthalmologist with glaucoma expertise including visual field testing and intraocular 
pressure measurement (IOP).  
 
Main outcome measures: 1) Diagnostic performance of imaging: the eye with most 
severe disease was used.  2) Composite triage test performance (imaging test, IOP 
measurement and visual acuity measurement), using data from both eyes, in correctly 
identifying clinical management decisions, that is, ‘discharge’ or ‘do not discharge’. 
Outcome measures were sensitivity and specificity, incremental cost per quality 
adjusted life year (QALY). 
 
Results: Data from 943 of 955 participants were included in the analysis. The average 
age was 60.5 (SD 13.8) years, and 51.1% were females. Glaucoma was diagnosed by 
the clinician in at least one eye in 16.8%.  37.9% of participants were discharged after 
the first visit.    
Regarding diagnosing glaucoma, HRT-MRA had the highest sensitivity (87.0%, 95% 
CI (80.2,92.1)) but lowest specificity (63.9%, 95% CI (60.2,67.4)), GDx had the 
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lowest sensitivity (35.1%, 95% CI (27.0,43.8)) but the highest specificity (97.2%, 
95% CI (95.6,98.3)). HRT-GPS had sensitivity (81.5%, 95% CI (73.9,87.6)) and 
specificity (67.7%, 95% CI (64.2,71.2)), and OCT had sensitivity (76.9%, 95% CI 
(69.2,83.4)) and specificity (78.5, 95% CI (75.4,81.4)).   Regarding triage accuracy, 
triage using HRT-GPS had the highest sensitivity (86.0%, 95% CI (82.8,88.7)) but 
lowest specificity (39.1%, 95% CI (34.0,44.5)), GDx had the lowest sensitivity 
(64.7%, 95% CI (60.7,68.7)) but the highest specificity (53.6%, 95% CI (48.2,58.9)). 
 
Introducing a composite triage station into the referral pathway to identify appropriate 
referrals was cost-effective. All triage strategies resulted in a cost reduction compared 
with standard care (consultant led diagnosis) but with an associated reduction in 
effectiveness.  GDX was the least costly and least effective strategy. OCT and HRT-
GPS were not cost effective. Compared to GDX, the cost per QALY gained for HRT-
MRA is £22,904. The cost per QALY gained with current practice is £156,985 
compared to HRT-MRA. Large savings could be made by implementing HRT-MRA 
but some benefit to patients will be forgone. Results were sensitive to the triage costs. 
 
Conclusions: Automated imaging can be effective to aid glaucoma diagnosis  among 
individuals referred from the community to HES. A model of care using a triage 
composite test appears to be cost-effective.   
 
Future work: There are uncertainties about glaucoma progression under routine care, 
and cost of providing health care.  Acceptability of implementing a triage test needs to 
be explored.  
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Scientific summary 
 
Background 
Glaucoma describes a group of chronic age-related eye diseases in which there is 
progressive damage of the optic disc and characteristic visual field loss. Glaucoma is 
a significant public health problem as it is the second leading cause of blindness in the 
UK.  
 
Glaucoma care constitutes a major proportion of the workload of hospital eye services 
(HES). In England there are over one million glaucoma related outpatient visits to the 
acute sector annually.  Considerable NHS resources are required to assess referrals to 
HES for possible glaucoma that are typically initiated by community optometrists. 
However, less than one quarter of referrals have glaucoma, and nearly 50% of referred 
individuals are discharged after their first visit.   If referrals could be triaged in an 
effective and cost-effective manner, resources could be better utilised for other needs.  
 
Glaucoma is diagnosed by clinicians detecting structural changes of the optic nerve 
head, [the optic disc] and corresponding visual field defects.  New imaging techniques 
for assessment of the structural changes have emerged: scanning laser 
ophthalmoscopy, commercially available as the Heidelberg Retina Tomograph; 
(including two diagnostic algorithms, Moorfields Regression Analysis [HRT-MRA] 
and Glaucoma Probability Score [HRT-GPS]) and scanning laser polarimetry, 
commercially available as the GDx, and spectral domain optical coherence 
tomography (OCT), with several commercial devices available.   
 
Imaging technologies are being introduced into glaucoma services but their role in the 
diagnostic pathway is unclear.  Imaging tests are user friendly, safe,  provide 
automated classifications and potentially could reduce the need for an examination by 
a clinician.   
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Aim 
To assess the relative performance and cost-effectiveness of diagnostic imaging 
technologies, as triage tests in secondary care, for identifying people with glaucoma. 
 
Objectives 
Primary objective: To compare the diagnostic performance (in terms of sensitivity 
and specificity), in a cohort of patients referred to HES with possible glaucoma, of: 
• four imaging tests (HRT-MRA, HRT-GPS, GDx, OCT) for diagnosis of 
glaucoma  
• a composite triage  test (combining imaging tests, visual acuity and intraocular 
pressure (IOP) measurements) in correctly identifying patients to be discharged 
from secondary care.  
 
Secondary objectives: 
a) To explore alternative thresholds for determining abnormal tests; 
b) To evaluate the diagnostic performance of combinations of imaging tests; 
c) To evaluate the performance of the tests across the spectrum of glaucoma (mild, 
moderate, severe); 
d) To evaluate the cost-effectiveness of incorporating imaging in a triage test in HES  
compared with current practice of diagnostic examination by a clinician; 
e) To evaluate patient preferences of different imaging technologies. 
 
Methods 
We designed a pragmatic within-patient comparative diagnostic and triage evaluation 
of imaging techniques for glaucoma.  Participants were adult patients referred from 
community optometrists or general practitioners with any possible glaucoma-related 
findings. Five UK NHS centres participated: three academic centres and two district 
general hospitals.   
 
Participants received all imaging tests: HRT-GPS, HRT-MRA, GDx and OCT.  
Possible tests results were: within normal limits; borderline; outside normal limits.   
The Heidelberg Retina Tomograph (HRT) uses confocal laser scanning to allow 
quantitative structural measurement of the optic disc anatomy. There are two main 
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classification tools to relate measurements to normative data (a) Moorfields 
Regression Analysis (HRT-MRA) which requires user definition of the optic disc 
boundary and (b) Glaucoma Probability Score (HRT-GPS) which is fully automated.  
 
The GDx scanning laser polarimeter measures the retinal nerve fibre layer (RNFL) 
thickness surrounding the optic disc utilising the birefringent properties of the RNFL.   
The software provides a discriminating classifier termed the Nerve Fiber Indicator 
(NFI), which is fully automated.  
 
Spectral Domain Optical Coherence Tomography (OCT) is an optical imaging 
technique providing high resolution, cross-sectional, imaging of the retina analogous 
to B-scan ultrasonography but utilising light instead of sound. The Spectralis OCT 
(Heidelberg Engineering) was used in this study.  
 
The reference standard was a full clinical examination, including visual field testing, 
by a consultant ophthalmologist with glaucoma expertise to determine (a) a diagnosis 
of glaucoma (mild, moderate or severe) according to well defined criteria (diagnosis 
analysis), and (b) whether the patient would be discharged or should be 
monitored/treated within HES (triage analysis).    
 
Statistical analysis 
Sample size calculations were based on standard (McNemar) diagnostic accuracy 
study methods. A 5% significance level based upon a 2-sided test was used which 
required a study of 897 individuals to have 90% power to detect an accuracy 
difference of 9% for the primary outcome of glaucoma diagnosis. Including a 6% 
indeterminacy rate increased the sample size to 954.  
 
Two diagnostic performance analyses were undertaken: a diagnosis and a triage 
analysis. For the diagnosis analysis (classification of glaucoma), one eye per patient 
was used: the eye with most severe disease except for one sensitivity analysis. The 
test “abnormal” definition was an imaging test result of “outside normal limits”, with 
borderline cases classified as “normal”. This was compared with a reference standard 
diagnosis of “glaucoma”.  
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For the triage analysis, a composite test (including three components: imaging; IOP 
measurement; visual acuity) was compared with a reference standard of clinical 
decision “do not discharge”. The test categorised a patient as needing evaluation by a 
clinician if any elements of the composite triage test were themselves “abnormal” in 
either eye: imaging classification “outside normal limits” or IOP>21mmHg or visual 
acuity of 6/12 or poorer. 
 
Primary diagnostic performance outcomes were sensitivity and specificity of tests. 
Secondary diagnostic performance outcomes were likelihood ratio and diagnostic 
odds ratio (DOR). The proportions of indeterminate test results and low quality 
imaging and need for pupil dilation were measured and patient preference for the tests 
was ranked.  The test performance was assessed with respect to the glaucoma 
spectrum (mild, moderate, severe), when including glaucoma suspects in the reference 
standard diagnosis, and when including “borderline” results as abnormal. The 
diagnostic performance of combinations of tests was also evaluated. 
 
Economic analysis  
A current practice pathway model was developed where patients referred to HES were 
seen by a nurse for visual acuity assessment, a technician for visual field 
measurement, and by a clinician. 
 
In an alternative triage care pathway model, individuals were seen by a nurse for 
visual acuity examination and IOP measurement and a technician for imaging 
assessment. The triage test results classified patients as needing referral for clinician 
diagnosis, or discharged. Those referred were seen by a technician for visual field 
measurement and examined by a clinician.  
  
The cost-effectiveness of four triage pathways, using IOP, visual acuity and each of 
the four imaging technologies (which varied by their diagnostic ability and capital 
cost) and their subsequent care management pathways were assessed using a multi-
state Markov model compared with current practice. 
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The cohort started in one of six health states: normal; at risk of glaucoma; mild, 
moderate, severe glaucoma; sight impaired. The sensitivity and specificity of each 
triage strategy determined if diagnosis was correct, and depending on this, the health 
state patients would move to and associated progression of any underlying glaucoma.  
Modelled care pathways were developed in consultation with the study team and the 
independent steering committee and utilised our previous models in this area, 
reviewed guidelines, study data and expert opinion.  
 
Consequences were considered in terms of monetary costs (of testing and subsequent 
management of the patient’s condition) to the NHS and in terms of the effects on 
quality of life (by assigning utility weights). Combining these data with the 
probabilities of events occurring over time enabled cost, patient outcomes and quality 
adjusted life years (QALYs) to be estimated for a hypothetical cohort of patients 
undergoing each modelled strategy. 
 
Model results were analysed as incremental cost per QALYs and incorporated: (i) 
costs (of testing) and triage diagnostic outcomes, (ii) costs (of testing and subsequent 
management) and (iii) QALYs. The base-case analysis used a cohort of 40 year-old 
males using prevalence data from the GATE study and for a 50 year time horizon. 
Cycle length was 1 year. Results were presented in incremental cost effectiveness 
ratios (ICERs).   
 
Several deterministic sensitivity analyses were explored which varied: the annual 
probability of discharged patients having a sight test; the cost of triage tests; the start 
age of the cohort; the performance of the diagnosing clinician; the diagnostic 
performance of imaging technologies; the prevalence of glaucoma in referred 
population; utility weights for those “at risk of glaucoma”. The possibility of a 
hypothetical pathway, in which patients diagnosed as “at risk of glaucoma” were 
discharged from the service, was explored to investigate the impact in terms of costs 
and QALYs.  
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Results 
Between April 2011 and July 2013, 2088 participants were identified as potentially 
eligible: 2013 were invited to take part. Of those invited, 966 (48%) agreed to take 
part. Following consent, 11 participants were found to be ineligible and did not 
participate and 12 were excluded as they did not receive all 4 imaging tests. Therefore 
943 participants were available for the comparisons of tests. 
 
The average age of participants was 60.5 (SD 13.8) years, and 51.1% were females.  
Non participants had similar age and gender balance.  Most participants (89.2%) were 
of “White British” ethnicity.  The average IOP at referral was 20 mmHg.  The most 
common diagnosis was “no glaucoma-related findings” (31.7% of participants).  Co-
morbidities were uncommon, except for cataract that was reported in 8.3% of right 
eyes and 7.4% of left eyes. Glaucoma was diagnosed in at least one eye in 16.8% of 
the GATE cohort and 6.5% had glaucoma in both eyes at referral. 37.9% of GATE 
participants were discharged after the first visit.   
 
Performance of the imaging tests in diagnosing glaucoma differed. HRT-MRA had 
the highest sensitivity (87.0%, 95% CI (80.2,92.1)) but lowest specificity (63.9%, 
95% CI (60.2,67.4)), GDx had the lowest sensitivity (35.1%, 95% CI (27.0,43.8)) but 
the highest specificity (97.2%, 95% CI (95.6,98.3)), and the other two tests providing 
intermediate results (HRT-GPS sensitivity (81.5%, 95% CI (73.9,87.6)) and 
specificity (67.7%, 95% CI (64.2,71.2)), and OCT sensitivity (76.9%, 95% CI 
(69.2,83.4)) and specificity (78.5, 95% CI (75.4,81.4)).  
 
Likelihood ratios showed evidence of both being able to rule in and out the presence 
of glaucoma for all four imaging tests (95% CIs did not contain 1.0). DORs ranged 
from 9.24 for HRT-GPS to 18.48 for GDx.  
 
When including borderline imaging results as test positive, the sensitivity increased 
but with a corresponding decrease in specificity.  In this sensitivity analysis, HRT-
MRA had the highest sensitivity (94.9%, 95% CI (89.8,97.9)) but the second lowest 
specificity (43.9%, 95% CI (40.2,47.6)), GDx had the lowest sensitivity (60.4%, 95% 
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CI (51.6,68.8)) but the highest specificity (82.8%, 95% CI (79.8,85.5)), and the other 
two tests providing intermediate results.  
 
The impact of combining two imaging tests improved detection of glaucoma but the 
effect was marginal and smaller than the loss of specificity. 
 
When considering a definition of disease of severe glaucoma only OCT had the 
highest sensitivity (95.2%, 95% CI (76.2,99.9)) and the second highest specificity 
(70.9%, 95% CI (67.7, 73.9)), GDx had the lowest sensitivity (78.9%, 95% CI 
(54.4,93.9)) but the highest specificity (93.7%, 95% CI (91.8,95.2)), and the other two 
tests providing intermediate results. 
 
The performance of triage tests (a composite assessment comprising imaging test, IOP 
and visual acuity assessments) in correctly identifying patients to be discharged from 
secondary care showed that triage including HRT-GPS had the highest sensitivity 
(86.0%, 95% CI (82.8,88.7)) but lowest specificity (39.1%, 95% CI (34.0,44.3)), GDx 
had the lowest sensitivity (64.7%, 95% CI (60.7,68.7)) but the highest specificity 
(53.6%, 95% CI (48.2,58.9)), the other two tests providing intermediate results (HRT-
MRA values were very similar to the HRT-GPS results (sensitivity 86.0%, 95% CI 
(82.8,88.7), and specificity (53.6 95% CI (48.2|,58.9)), and OCT had lower sensitivity 
75.4%, 95% CI (71.6,78.9)) but higher specificity (41.0 95% CI (35.8|,46.3)) values 
than HRT-GPS and HRT-MRA). Likelihood ratios (and 95% CI) showed evidence of 
all four triage tests being able to rule in and out the presence of abnormalities for all 
four triage tests (CIs did not contain 1.0). DORs ranged from 2.1 for GDx to 3.9 for 
HRT-GPS.  
 
Participant preference was collected for 890 participants (94%). Almost half of 
responders (48.2%) had no preference. Of those participants who gave a preference, 
OCT was ranked as most preferred (27.6%) followed by GDx (11.9%) and HRT 
(5.1%). Average time taken to perform the test varied from 5.2 minutes (SD 3.0) for 
OCT to 7.6 minutes (SD 5.0) for HRT.  
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Economic analysis results 
All triage strategies were more cost-effective than current practice but resulted in 
reduced health due to missing cases (i.e. fewer expected QALYs).  The base-case 
results suggest that, of the triage pathways modelled, a triage including IOP, visual 
acuity and HRT-MRA is the most cost-effective strategy. GDX was shown to be the 
least costly and least effective. OCT and HRT-GPS were not cost effective. Compared 
to GDX, the cost per QALY gained for HRT-MRA was £22,904.The cost per QALY 
gained with current practice was £156,985 compared to HRT-MRA. Large savings 
could be made by implementing HRT-MRA but some benefit to patients would be 
forgone. .  
 
These results should be interpreted with some caution, particularly in terms of 
differences among triage strategies since the diagnostic accuracy of all tests (except 
GDx) and their unit costs are very similar. The incremental cost-effectiveness of the 
triage strategies compared to current practice is very sensitive to costs included in the 
model. Indeed, current practice becomes cost-effective when the total cost of a triage 
test increases to £30 and above. A key assumption used in the model was that 
clinicians are 100% accurate in their diagnostic ability. Relaxing this assumption 
increased further the incremental cost effectiveness ratios (favouring triage strategies).  
 
Conclusions 
Implications for health care 
Imaging technologies can be effective to aid the diagnosis of glaucoma. An alternative 
pathway for patients referred from community to HES with possible glaucoma using a 
triage test that includes imaging, IOP and visual acuity appears to be cost-effective 
compared with current practice. Our findings are based on a relatively inexpensive 
composite triage test (£<30). The most cost-effective strategy would include HRT-
MRA imaging.  However, triaging would be associated with a loss of health, and the 
acceptability of this option among users and clinicians has not been evaluated.  
 
Recommendations for research 
• acceptability to patients and health care providers of implementing an efficient 
triage glaucoma diagnostic system but with reduced health. 
xxiv 
 
• data on glaucoma disease progression, specifically including patients classified 
as glaucoma suspects and ocular hypertension, associated utility, and cost of 
providing health care  
• investigation of varying the results of the imaging tests beyond the standard 
options, since the recommended classification may not be the one best suited 
to the population which GATE recruited from 
• the effectiveness of implementation of a composite triage test  
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This project was funded by the NIHR Health Technology Assessment programme 
(09/22/111) and will be published in full in Health Technology Assessment; Vol. X, 
No. X. See the HTA programme website for further project information. 
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Plain English summary 
 
Glaucoma is a life-long eye disease.  Treatment is usually effective to slow the 
progression of glaucoma. About 4000 people are registered with sight impairment 
each year because of glaucoma.  Many healthy subjects are unnecessarily referred 
from the community to hospital eye services to rule out glaucoma. 
 
New imaging tests that investigate the back of the eye can aid the diagnosis of 
glaucoma, and are safe and easy to perform.  These technologies measure with high 
accuracy the tissues in the back of the eye that are typically thinned in glaucoma.  
This study was designed to evaluate the performance of four imaging tests at 
identifying, among patients referred to hospital, those who have glaucoma or are at 
risk and those who do not have any eye disease. We compared the imaging test results 
with an experienced eye doctor’s diagnosis, and evaluated how well a possible care 
pathway would perform using imaging results combined with measurements of the 
eye pressure and vision, to identify whether the individual needed to see an eye 
doctor.  
 
955 individuals were recruited.  The best performing test correctly diagnosed 
glaucoma in 87 out of 100 patients.  If imaging tests with an eye pressure test and a 
visual acuity test were used to screen out people without eye disease, there would be 
substantial savings to the health service, but not all patients with disease would be 
picked up.  A relatively small proportion of patients with glaucoma and at risk of 
glaucoma would be missed (approximately 1 in 7).   
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Chapter 1  Introduction 
 
Glaucoma describes a group of eye diseases in which there is progressive damage of 
the optic nerve. It is characterised by a specific pattern of optic nerve head and visual 
field loss leading to impaired vision and sometimes blindness if inadequately treated. 
Primary glaucoma can be classified as open angle glaucoma (OAG) or angle closure 
glaucoma, the former being the most common.2 Glaucoma is a significant public 
health problem, second to macular degeneration as the most common cause of 
blindness in the UK,3-5 and is the leading cause of irreversible blindness worldwide.6 
The impact on patients is considerable with the risks of moderate visual field loss 
(which affects the ability to drive) and long term blindness reported as the most 
important consequences.7 Late detection is a major risk factor for glaucoma 
blindness.8 However, if glaucoma is identified in the early stages, treatment is 
effective at reducing progressive disease.9  
 
There are a number of factors which increase the risk of developing glaucoma, 
including elevated intraocular pressure (IOP), older age, ethnic background and 
family history of glaucoma. Of these, the level of IOP is the most important risk factor 
and is the only one which is treatable. Ocular hypertension, generally defined as an 
IOP of ≥21mmHg (2 standard deviations above the mean) used to be considered as a 
part of the definition of glaucoma, but population studies have consistently found that 
many people with glaucoma have an IOP below this level.10-14 However, the risk of 
developing glaucoma, and for worsening of existing disease, increases with increasing 
IOP.15-17 This is supported by the fact that those presenting with advanced glaucoma 
at diagnosis are more likely to have higher IOP.13,18     
 
The estimated prevalence of glaucoma in the UK is over 1% of the population over 40 
years of age.19-22 Approximately 4000 new cases of severe sight impairment due to 
glaucoma are registered every year in the UK. Many more glaucoma patients have 
sight impairment not severe enough to be registered but with significant impact on 
their quality of life (e.g. loss of driving licence). In England and Wales, in 2007 there 
were over 5 million outpatient attendances at hospital eye services (around 10% of all 
annual outpatient attendances) in the NHS. Of these, approximately 1,400,000 were 
2 
 
new patients (costing over £140 million). As the population ages these numbers are 
likely to increase.23 
 
Estimates based on official population projections and epidemiological prevalence 
surveys have predicted that the number of glaucoma cases in England and Wales will 
increase by one third by 2021 and continue to increase at a similar pace until 2031.24  
 
Management of patients with glaucoma and those at risk of suffering from glaucoma 
constitutes a major part of the workload of any secondary care eye services. In two 
independent surveys, between 8%25 and 13%26 of all new referrals to secondary eye 
care were due to glaucoma, and 25% of all follow-up attendances were glaucoma 
related. In England alone there are over one million glaucoma related outpatient visits 
in the NHS hospital eye service annually (approximately 1% of all outpatient 
activity).27 Currently, referrals for suspected glaucoma are usually initiated by a 
community optometrist and are assessed in hospital eye services by clinicians. 
However, the reported referral accuracy of glaucoma by optometrists is suboptimal. 
Less than a quarter of referrals actually have glaucoma, and nearly 50% of referred 
individuals are discharged after the first visit.28 Thus, many referrals are unnecessary 
and overburden the already busy hospital eye services. It also causes distress and 
worry to the patient which could be avoided. Interventions such as glaucoma 
training29 or agreed guidelines30 may not always have an effect in the rates of false 
positives referrals by community optometrists.  
 
Diagnosing glaucoma 
Glaucoma is diagnosed primarily by detecting glaucomatous optic neuropathy (i.e. 
characteristic changes of the optic nerve head-the optic disc) and a compatible visual 
field defect. According to current NICE guidelines,27  a definitive glaucoma diagnosis 
is based on the expertise of a clinician who subjectively interprets the appearance of 
the optic disc and the results of visual field testing. In addition to diagnosing 
glaucoma, the clinical examination will include a visual acuity test (to measure central 
vision), anterior chamber angle exam (to determine the mechanism of glaucoma, e.g. 
open-angle or angle-closure), and intraocular pressure measurement (which is a risk 
factor for glaucoma and also for disease progression). 
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Accurate clinical diagnosis of glaucoma is limited by subjectivity, reliance on the 
examiner’s experience, and a wide variation of optic disc structure in the population. 
Imaging techniques for assessment of the structural changes at the optic nerve head 
and retinal nerve fibre layer (RNFL) have emerged and are in routine use in the NHS: 
the Heidelberg Retinal Tomogram (HRT-III), scanning laser polarimetry (GDx), and 
spectral domain optical coherence tomography (SD-OCT). These techniques can be 
easily performed by trained technicians and provide an automatic glaucoma 
classification index. Some clinicians now routinely incorporate the information from 
such imaging technologies to help make a diagnosis of glaucoma, although there is no 
strong evidence of their effectiveness.  
 
Using an automated imaging quantitative test for glaucoma diagnosis may have 
advantages over visual field testing in that the majority of people can be imaged. 19 
 
Comparison of glaucoma diagnostic technologies 
In 1997 the HTA programme funded a study entitled "The effectiveness of the 
Heidelberg Retina Tomograph and laser diagnostic glaucoma scanning system (GDx) 
in detecting and monitoring glaucoma".31  At the time, this study was the largest and 
most rigorous head to head comparison of tests for diagnosing glaucoma. However, 
this study used the first prototypes of the HRT and GDx, now outdated. Another 
serious limitation was the small study sample (250 participants), in addition to a 
potentially biased selection of patients as these were not consecutively selected.  
 
A systematic review of the performance of technologies for detecting glaucoma both 
as screening or diagnostic tests for glaucoma identified that the evidence is of poor 
quality and that no one test was clearly superior.19 In this systematic review it was 
also found that populations studied were varied and biased. Furthermore, there were 
only six studies that performed a direct comparison of the available diagnostic 
instruments (with the average size of the studies less than 300 patients), the threshold 
for definitions of glaucoma cases were not consistent, and there were no studies 
reporting on the performance of GDx and OCT that met the inclusion criteria for this 
systematic review. However, the review did suggest that some diagnostic technologies 
have better performance than others (e.g. HRT performed relatively well), but the 
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credible intervals around the estimates were wide, reflecting considerable uncertainty, 
and therefore recommended that the available diagnostic tests need to be evaluated in 
an appropriately powered directly comparative study. 
 
In the published NICE guideline27 the authors searched for evidence comparing the 
diagnostic performance of HRT, GDx and OCT with expert clinical examination. No 
studies met the inclusion criteria for the guideline review (Section 4.6.1, Page 85, 
NICE).  
 
Triage tests in secondary care eye services 
There are considerable NHS resources required to assess all patients referred to 
hospital eye services with suspected glaucoma. In June 2009, the chairman published 
on behalf of the Professional Standards Committee of the Royal College of 
Ophthalmology a statement that the interpretation of NICE glaucoma guidelines was 
putting considerable strain onto secondary care eye services through the increase in 
false–positive referrals from community optometrists. The statement proposed that 
Eye Departments should consider innovative and efficient clinics for the initial 
assessment of patients.32 
 
If referrals could be triaged, to identify suitable referrals and discharge unsuitable 
referrals, in an effective and cost-effective manner, the resources could be better 
utilised for patient eye care services. Imaging technologies are being introduced into 
glaucoma services in both hospital and community settings but their role in the 
diagnostic pathway either as triage, replacement or add on tests has not been 
evaluated. The tests to be evaluated in this study are the currently available imaging 
technologies with characteristics that suggest that they could be valuable triage tests, 
and are in current use in the NHS. They do not require patient input, are user 
friendly,33 provide automated quantitative classifications and potentially could reduce 
the need for an extensive examination by an expert glaucoma clinician. The diagnostic 
performance of these imaging technologies has not been evaluated in a triage setting 
and in a robust manner.  
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Research question, aims and research objectives 
Research question 
What is the relative performance and the cost-effectiveness of new diagnostic imaging 
technologies, as triage tests in secondary care, for identifying people with glaucoma? 
 
Aim 
To assess the relative performance and the cost-effectiveness of new diagnostic 
imaging technologies, as triage tests in secondary care, for identifying people with 
glaucoma. 
 
Research objectives 
Primary objective 
To compare the performance of imaging technologies (HRT-MRA, HRT-GPS, GDx, 
and OCT) as diagnostic and triage tests for patients referred to hospital eye services 
with possible glaucoma. Triage tests include an imaging technology, visual acuity and 
intraocular pressure. 
 
Secondary objectives 
a) to explore alternative thresholds for determining test positivity 
b) to evaluate the diagnostic performance of combinations of the imaging tests 
c) to evaluate the performance of the tests across the spectrum of glaucoma (mild, 
moderate, severe) 
d) to evaluate the cost-effectiveness of adopting individual tests or combination of 
tests as triage tests compared with the current practice of diagnostic examination 
by a clinician in a secondary care setting 
e) to evaluate patient preferences of different imaging technologies. 
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Chapter 2  Methods 
 
This chapter describes the GATE (Glaucoma Automated Tests Evaluation) study 
design and methods for the diagnostic performance evaluation, and follows the 
STAndards for the Reporting of Diagnostic accuracy studies (STARD).34 The 
methods for the health economic evaluation are described separately (see Chapter 6). 
 
Overview of the study design 
An overview of the GATE study design is shown in Figure 1. The GATE study is a 
pragmatic within-patient comparative diagnostic evaluation of four imaging 
techniques for glaucoma in patients referred to hospital eye services. Specifically this 
study was designed to evaluate (1) diagnostic accuracy of imaging tests for detecting 
glaucoma in an eye; and (2) diagnostic accuracy of triage tests that consisted of a 
combination of an imaging test, visual acuity and intraocular pressure (IOP) 
measurement, for identifying patients requiring referral to hospital eye services.  
 
All patients recruited to the study received four different imaging tests (using three 
different devices) which were compared with a reference standard (i.e. a 
comprehensive clinical examination). The study was co-ordinated from a central study 
office in the Health Services Research Unit, University of Aberdeen.  
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APPROACH
All new glaucoma referrals sent invitation letter and patient information sheet prior to first 
appointment at hospital. (logged on clinic log)
CONSENT
Baseline and referral data collected 
(Research officer data collection form)
Not recruited
•Ineligible
•Declined
•Missed 
INDEX TESTS (imaging)
All patients imaged with all three imaging devices (random order) 
giving four imaging test results
HRT -MRA HRT-GPS GDx OCT (Spectralis)
REFERENCE STANDARD
Comprehensive clinical examination by ophthalmologist with glaucoma expertise , masked to index test results 
Biomicroscopy of optic nerve head, evaluation of visual field with standard automated perimetry
Humphrey 24-2 SITA strategy, IOP measurement (GAT), evaluation of anterior chamber angle 
(Clinician Case Report form) 
IMAGING PREFERENCE COLLECTED
(Participant preference questionnaire)
 
 
 
Participants 
Inclusion criteria 
Adult patients referred from community optometrists or general practitioners to 
hospital eye services with any glaucoma-related findings, including those with ocular 
hypertension.  
 
Exclusion criteria 
Patients referred to hospital eye services because of other ocular disease; patients < 18 
years old; patients who could not give informed consent; patients who had already 
been diagnosed with glaucoma; and patients referred from within secondary care. 
 
Setting 
Five NHS hospital eye services in the UK participated in this study: Aberdeen Royal 
Infirmary (Aberdeen), Bedford Hospital (Bedfordshire), Hinchingbrooke Hospital, 
Huntingdon (Cambridgeshire), Moorfields Eye Hospital (London) and St. Paul’s Eye 
Unit (Liverpool). The participating units consisted of three academic units of different 
size and two district general hospitals (Hinchingbrooke and Bedford).  
Figure 1  Overview of study design 
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Identification of participants and recruitment process  
Consecutive eligible patients referred from community optometrists to hospital eye 
services with a glaucoma-related finding were identified by the research officer in 
each centre at the time of referral. Patients were identified from their referral letter as 
being referred with a possible glaucoma diagnosis or glaucoma-related finding, 
including high IOP, possible abnormalities in the optic disc or visual field tests, and 
possible narrow anterior chamber angle. To ensure a full cross-section of referrals 
were identified, existing referral refinement schemes in two of the participating 
centres were suspended for the duration of the study in order not to introduce 
selection bias. In the largest centre (Moorfields Eye Hospital) only those patients 
booked to see a clinician trained in the study protocol to provide the reference 
standard were identified as eligible. Information about this study was sent to 
potentially eligible patients together with the date of the appointment (see Appendix 
2). Patients were approached by the local research officer on their first visit to hospital 
eye services to discuss the study and those patients who agreed to participate and 
signed the consent form (see Appendix 2) were enrolled (i.e. before their consultation 
with the ophthalmologist). Each research centre kept a clinic log of eligible patients 
invited (see Appendix 3) which included patient demographics (age, gender) and, for 
those who declined to take part or were found to be ineligible, reason for not taking 
part if given. 
 
Diagnostic technologies being assessed (index tests) 
Four diagnostic tests from three imaging devices were evaluated: 
(i) HRT-3: Confocal laser scanning imaging technology, employed by the 
Heidelberg Retina Tomograph (Heidelberg Engineering) exploits the principle 
of confocal laser scanning to allow quantitative structural information of the 
optic disc anatomy. The topographic image is derived from multiple optical 
sections at consecutive focal depth planes. Each image consists of numerous 
pixels, with each pixel corresponding to the retinal height at its location. 
Images are given a measure of quality – the mean topography standard 
deviation (SD) which the manufacturer recommends should be ≤40 µm.  
There are two main classification tools to define normality/outside normal 
limits: (a) the Moorfields Regression Analysis (MRA)35 which requires the 
user to draw a contour line to define the optic disc boundary and (b) the 
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Glaucoma Probability Score (GPS)36 which is fully automated and 
independent of operator input.  
a. The HRT-MRA produces an overall (“global”) classification as well as by 
6 segments (“temporal”, “temporal superior”, “temporal inferior”, “nasal”, 
“nasal superior” and “nasal inferior”) of the eye. For each a classification 
of “within normal limits”, “borderline” and “outside normal limits” is 
given based upon whether the observed value is within the 95% prediction 
interval, between the 95.0% and the 99.9% prediction interval, or below 
the 99.9% predictions interval of the preset data, respectively. The final 
classification is based upon the most abnormal of any of the 7 
classifications. If any one of these are “outside normal limits” then overall 
classification is “outside normal limit”. Where there are none “outside 
normal limits” but at least one “borderline” then the final classification is 
“borderline”. Only where the global and all 6 segment probabilities are 
“within normal limits” is the final classification “within normal limits”.  
b. HRT-GPS produces an overall probability of the presence of glaucoma 
(“global”) and by segment (“temporal”, “temporal superior”, “temporal 
inferior”, “nasal”, “nasal superior” and “nasal inferior”) for each eye. The 
default “final” classification is based upon applying cut-off to the overall 
and 6 segment probabilities; 0<0.28 is “within normal limits”, >=0.28 and 
< 0.65 is “borderline” and ≥0.65 is “outside normal limits”.36 If any one of 
these are “outside normal limits” then overall classification is “outside 
normal limit”. Where there are none “outside normal limits” but at least 
one “borderline” then the final classification is “borderline”. Only where 
the global and all 6 segment probabilities are “within normal limits” is the 
final classification “within normal limits”.  
 
(ii) GDx-ECC: Scanning Laser Polarimetry measures the retinal nerve fibre layer 
(RNFL) thickness (Carl Zeiss Meditec). Measurements are based on the 
birefringent properties of the RNFL, which has its neurotubules disposed in an 
organised, parallel fashion. The software provides a discriminating classifier 
of glaucoma/normality, the Nerve Fiber Indicator (NFI) value, which is fully 
automated and is calculated for each eye. The manufacturers’ reported cut-
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offs for the GDx-ECC NFI value are based upon 95 and 99% coverage of the 
normative database population and are 1-35 (“normal”), 36-55 ( “abnormal 
95”) and 56+ (“abnormal 99”)(GDxPro Manual). The difference between 
“abnormal 95” and “abnormal 99” maybe viewed in a similar manner to the 
“borderline” category for HRT-GPS, HRT-MRA and OCT classifications. 
The “TSNIT” parameters used in the calculation of the NFI are also produced 
overall and by eye segment (superior and inferior) and an inter-eye symmetry 
is also produced. Images are given a quality figure (Q) which the 
manufacturer recommends should be ≥7.  In this study GDx-ECC 
measurements were made using either the GDx-Pro (3 centres) or GDx-VCC 
with updated ECC module (2 centres). 
 
(iii) OCT: Spectral Domain Optical Coherence Tomography (Spectralis, 
Heidelberg Engineering) is an optical imaging technique capable of providing 
high resolution, cross-sectional, imaging of the human retina in a fashion 
analogous to B-scan ultrasonography but utilising light instead of sound. OCT 
utilises the principles of low coherence interferometry using light echoes from 
the scanned structure to determine the thickness of the tissue. The glaucoma 
detection software of the Spectralis machine used in this study produces an 
average RNFL thickness value for the global and 6 segments of the eye  and 
automatically compares sectors of RNFL thickness with a normative database 
An overall assessment of “within normal limits”, “borderline”  or “outside 
normal limits” is produced35  based upon the global and the 6 individual 
segments. Inter-eye symmetry is also produced for each segment. Images are 
given a quality figure (Q) which the manufacturer recommends should be 
>15.   
 
Sample reports generated by each of the imaging tests are shown in Appendix 4.   
 
Reference standards 
Eye level (i.e. for the diagnostic performance analysis) 
The glaucoma diagnosis reference standard chosen for this study represents current 
clinical practice in the UK, which consists of clinical examination (biomicroscopy) of 
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the appearance of the optic nerve head, and evaluation of the visual field with 
standard automated perimetry (SAP) Humphrey 24-2 SITA strategy by an 
ophthalmologist with glaucoma expertise. In addition the clinician measured the 
intraocular pressure and examined the anterior chamber angle. The imaging tests were 
not available to the ophthalmologist when measuring the reference standard. The 
clinician recorded the status of each eye as described in Table 1 (i.e. glaucoma, OHT, 
glaucoma suspect, other eye morbidities or normal). If a clinical diagnosis could not 
be established at the first visit (e.g. unreliable visual field measurement requiring 
repeated measurement at a further appointment), an inconclusive diagnosis was 
recorded. In order to ensure valid and consistent application of the agreed reference 
standard, a limited number of consultant ophthalmologists provided the reference 
standard (1 or 2 clinicians in four centres, and 5 different clinicians at one centre). 
Principal investigators collaborating in each of the participating units gathered at the 
start of the project to review and agree on the reference standard (definitions of 
glaucoma, OHT, glaucoma suspect and normal) and how to define the spectrum of the 
disease (mild, moderate and severe). For this purpose training material was used 
including a series of cases with glaucoma related findings and also with normal subjects. 
Clinicians who were incorporated into the study at a later date to recruit and provide the 
reference standard were trained individually by the chief investigator with the same 
material.  
 
For the eye level analysis, reference standard positive was classified as a diagnosis of 
glaucoma based upon the “worse” eye. Sensitivity analyses explored the diagnostic 
performance of the tests when also including glaucoma suspects in the definition of 
reference standard positive along with using the “best” eye (see Statistical analysis 
methods below for full details). 
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Table 1  Clinical diagnosis definitions  
Diagnosis Definition 
Glaucoma Severe  Evidence of glaucomatous optic neuropathy* and a characteristic visual field loss**  
Severe: MD worse than or equal to -12.01 dB  
Moderate  Evidence of glaucomatous optic neuropathy* and a characteristic visual field loss**  
Moderate: MD between -6.01dB and -12 dB 
Mild  Evidence of glaucomatous optic neuropathy* and a characteristic visual field loss**  
Mild: MD better than or equal to -6 dB 
Glaucoma 
suspect 
Disc suspect Appearance suggestive of glaucomatous optic neuropathy but may also represent a 
variation of normality, with normal visual fields (with or without high IOP) 
Visual field suspect Visual field loss suggestive of glaucoma, but may also represent a variation of normality, 
with normal appearance of the optic disc (with or without high IOP) 
Visual field and disc 
suspect 
Both the optic disc and visual field have some features that resemble glaucoma but may 
also represent a variation of normality (with or without high IOP) 
Ocular Hypertension (OHT)   When both the visual field and optic nerve appear normal in the presence of elevated 
pressure  
> 21mmHg 
Primary Angle Closure (PAC) Closed anterior chamber angle (appositionally or synechial) in at least 270°, and at least 
one of the following two: IOP > 21 mmHg and/or presence of peripheral anterior 
synechiae. Both visual field and optic nerve appear normal 
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PAC suspect   Closed anterior chamber angle (appositionally without any synechiae) in at least 270°, 
with IOP < 21 mmHg. Both visual field and optic nerve appear normal 
 
 
*  Evidence of optic nerve damage from any of the following:  Optic disc or retinal nerve fibre layer structural abnormalities. Diffuse 
thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles. Documented, progressive 
thinning of the neuroretinal rim with an associated increase in cupping of the optic disc. Diffuse or localised abnormalities of the 
peripapillary retinal nerve fibre layer, especially at the inferior or superior poles. Disc rim or peripapillary retinal nerve fibre layer 
haemorrhages. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue.  
**  Reliable visual field abnormality considered a valid representation of the subject's functional status. Visual field damage consistent 
with retinal nerve fibre layer damage (e.g. nasal step, arcuate field defect, or paracentral depression in clusters of test sites). Visual field 
loss in one hemifield that is different from the other hemifield, i.e. across the horizontal midline (in early/moderate cases). Absence of 
other known explanations.  
REFERENCE STANDARD: For the eye level analysis, reference standard positive was classified as a diagnosis of glaucoma. Sensitivity 
analyses explored the diagnostic performance of the tests when also including glaucoma suspects in the definition of reference standard 
positive (see Statistical analysis methods below for full details) 
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Patient level (i.e. for the triage performance analysis) 
For each patient the clinical management decision made was recorded, that is, 
“discharge” or “don’t discharge”. Additionally, the reason for non-discharge (and 
which eye(s) it refers to) of “treatment” or “monitoring” was also collected.  
Clinicians were advised to follow NICE guidelines in deciding whether to discharge 
or not.27 
 
Outcomes 
For each of the four tests (HRT-MRA, HRT-GPS, GDx and OCT) the following 
outcomes were measured: 
 
Diagnostic performance of imaging technologies  
The primary diagnostic performance outcomes were sensitivity and specificity. 
Secondary diagnostic performance outcomes were likelihood ratio, and diagnostic 
odds ratio. The overall diagnostic performance of combinations of these four tests was 
also evaluated (HRT-MRA with each of the other three tests), and their relative 
performance. The diagnostic performance of the tests (and corresponding 
combinations) was also assessed according to the spectrum of glaucoma (mild, 
moderate, severe), as defined by the glaucoma expert.  
 
Other outcomes 
The proportions of indeterminacy results, and low quality imaging according to the 
manufacturer’s recommendation, along with the participant’s preference regarding the 
four tests were recorded for each test. Additionally, the number of participants who 
required pupil dilation to perform the imaging was also recorded.  Dilation was 
attributed to the first imaging technology. Where a high quality test result was not 
available for a participant (“no result”), one of the following categorises applied: 
A. test performed and imaging report produced but quality is lower than 
manufacturer quality cut-off 
B. test performed and imaging report produced but no overall classification 
generated by machine 
C. test performed but there was a clear imaging artefact on the report;  
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D. test attempted but no imaging could be acquired from the patient’s eyes – no 
report generated 
E. missing imaging output (due to study related or data collection issues).  
 
Indeterminacy of the result was calculated as categories B-D over the total number of 
non-missing cases. The proportion of low quality imaging was A over the total 
number of non-missing cases minus categories A-D. 
 
Diagnostic performance of a triage test (imaging test, visual acuity and intraocular 
pressure measurement)  
As for the diagnosis analyses, the primary diagnostic performance outcomes of the 
triage test were sensitivity and specificity in correctly identifying patients who would 
be discharged from secondary care. Clinicians were advised to follow NICE 
guidelines in deciding whether to discharge or not.27  Secondary diagnostic 
performance outcomes included likelihood ratios and the diagnostic odds ratios. 
 
Delivery of interventions and data collection 
Enrolled participants attended a diagnostic station for imaging (index test) and visual 
field measurement immediately prior to their meeting with the ophthalmologist. In 
three centres (Hinchingbrooke, Bedford, Liverpool), the visual field and imaging 
measurements took place on a separate day prior to the ophthalmologist appointment 
(within 2 weeks). Pupils were not routinely dilated. However, in those patients in 
whom adequate quality imaging could not be obtained, pupil dilatation could be used 
to try to improve image quality.  In exceptional circumstances, where dilation was 
required in centres offering split visits, some or all of the imaging tests could be 
delayed until the clinic appointment, but always ahead of the clinical reference 
standard. Imaging technicians and the patient were therefore masked to the patient’s 
underlying condition at the time of testing. In the remaining two centres (Aberdeen 
and Moorfields) all measurements were undertaken on the same day. All participants 
in each of the centres underwent testing with the three imaging devices, in a random 
order (to avoid bias when collecting participant preference) in one sitting. The random 
test order was automatically generated for each patient from the study website.  
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Imaging technicians employed at each centre performed the imaging tests. Between 
one and three technicians were identified at each centre and trained in study 
procedures prior to recruitment (see Appendix 5). There was no restriction for the 
same technician to perform all imaging tests on an individual. Across all centres, most 
technicians were experienced in performing the test prior to the study; where 
technicians were not already experienced they received training from the 
manufacturer or local imaging lead prior to collecting study data.  
  
With the exception of HRT-MRA which required an experienced user to identify a 
contour line at the optic disc margin, all imaging tests generated the glaucoma 
classification automatically once an image had been acquired. The research officer 
kept printed copies of the images and uploaded the imaging results to the study 
website. Imaging reports were identified using a unique study number and date of 
birth.  
 
The participant was asked to grade the tests in order of preference, or record no 
preference, using a standard form (see Appendix 3). Visual field measurements were 
undertaken with standard automated perimetry Humphrey SITA 24-2 strategy (Carl 
Zeiss Meditec) for each participant after all imaging tests had been completed. In 
exceptional circumstances, visual field measurements were undertaken ahead of the 
imaging tests due to clinic demand for equipment. Participants were then examined by 
an experienced glaucoma clinician who performed a comprehensive ocular 
examination including intraocular pressure (IOP) measurement with Goldmann 
applanation tonometry (GAT), gonioscopy, biomicroscopic examination of the optic 
disc (with pupil dilated in patients without narrow anterior chamber angle), and 
evaluated the visual field test results. The clinician provided the reference standard 
masked to the results of the imaging technologies and completed a clinical data 
collection form (see Appendix 3).  
 
The research officer collated the results for each participant (see Appendix 3) 
including a copy of the visual field test, completed forms for each participant, 
uploaded the information onto the webpage, and posted original consent forms to the 
central office. Information uploaded onto the webpage included demographics, 
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referral IOP, refractive error, patient preference, need for pupil dilation, and 
Humphrey visual field reliability and global indices MD, PSD and VFI.  
 
Data management  
A web-based secure study database was developed for the GATE study which 
research staff could access remotely. Password protected access was provided such 
that centres could only view data from their own centre. All data collected during the 
course of the research was kept strictly confidential and accessed only by members of 
the study team. Minimal patient details were recorded and were stored under the 
guidelines of the 1988 Data Protection Act. Patients were allocated an individual 
study number and this number was used to identify study paperwork. Study data were 
entered and imaging reports uploaded onto the database by the research officer 
working in each centre. Whenever possible, drop-down boxes were employed to 
select appropriate responses and minimise typographical errors. Automated range 
checks and validation were inbuilt to ensure that inappropriate values could not be 
recorded.  
 
Staff in the Study Office monitored data centrally and worked closely with local 
research officers to ensure that the data were as complete and accurate as possible. 
Missing forms and primary outcome data were automatically identified on the study 
website and distributed to local research officers on a regular basis. Uploaded imaging 
reports for each participant were checked by the central office, following an agreed 
checklist, and errors flagged for correction to the appropriate research team on a 
regular basis. This resulted in a low percentage of missing primary outcome data (1% 
reference standard: 1-3% imaging data). The content of approximately 50 case report 
forms and imaging reports selected at random were checked against entered data to 
ensure data entry accuracy. If consistent errors or discrepancies were found this 
triggered a further training session with the research officer to discuss and resolve 
data collection and entry issues.  
 
The chief investigator checked a random sample of HRT-MRA imaging reports from 
each centre (5 reports for each operator at each centre) for accurate location of the 
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optic disc margin. A high error rate (more than 2 of 5 checked) at one centre triggered 
a complete check of the data at that centre: images with incorrectly placed contour 
lines were excluded from the default analysis and classified as artefact as described in 
Chapter 4. 
 
Statistical analyses  
Sample size  
The sample size calculation and analysis were based on standard diagnostic accuracy 
study methods.37 The sensitivity and specificity of each of the automated imaging 
tests were compared. A 5% significance level based upon a 2-sided test was used in 
the sample size calculations. A study of 897 individuals would have 90% power to 
detect a difference in accuracy of 9% for the primary outcome of diagnosis of 
glaucoma. This is based upon conservative assumptions of a probability of 
disagreement of 0.18 (maximum level possible), a glaucoma rate of 25% (as seen in 
similar populations) and a sensitivity of 86% as found in a systematic review for 
HRT.19  Given this sample size, there would also be 80% power for detecting a 6% 
difference in accuracy should the sensitivity be 93% (the current best estimate from 
meta analyses of high quality diagnostic studies). For specificity, we would have over 
90% power to detect a 5% difference. Based upon current available evidence, a rate of 
6% indeterminacy of tests results was assumed which increased the sample size to 954 
in total. A sample of this size would be of sufficient size for other measures of 
diagnostic performance (e.g. the sensitivity and specificity of individual technologies 
would be estimated to a 95% confidence interval (CI) of width 10% and 5% 
respectively). 
 
Overview of planned analyses 
To address the primary objective, two sets of pre-planned statistical analyses and 
sensitivity analyses of the diagnostic performance were carried out. They were:  
1. “glaucoma diagnosis” analyses focused upon the clinical diagnosis of 
glaucoma (see Chapter 4) 
2. “triage” analyses those focused upon the clinical discharge decision (see 
Chapter 5) 
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Glaucoma diagnosis analyses of diagnostic performance 
The diagnostic performance of the four imaging tests (HRT-GPS and HRT-MRA 
outputs, GDx-ECC, and OCT) from three imaging devices for detecting glaucoma 
was calculated and compared. The “worst” eye of each participant as defined by the 
clinical reference standard was used in these analyses except for one sensitivity 
analysis which used the “best” eye of each participant. The reference standard was a 
clinical diagnosis of glaucoma (mild, moderate or severe) by an ophthalmologist (see 
section ‘Reference standards’ above). Diagnosis was ranked in order of decreasing 
severity as severe glaucoma, moderate glaucoma, mild glaucoma, glaucoma suspect 
(of any kind), PAC, OHT, normal (including all other diagnoses). The “worst” eye on 
the basis of comparing eyes using this ranking was used. If the two eyes had a similar 
spectrum of disease then a random eye was chosen. The primary analysis definition 
did not include a glaucoma suspect (whether disc and/or visual field based suspicion). 
The initial “positive” test definition under the respective imaging assessment was a 
test result of “outside normal limits” for HRT-MRA, HRT-GPS, OCT and NFI≥56 for 
GDx, with borderline cases classified as “negative”. 
 
Triage analyses of diagnostic performance 
This set of analyses focussed upon the clinical decision for the management of a 
participant (discharged or not discharged). The reference standard for these analyses 
was person level clinical decision (“not discharged” or “discharged”). “Not 
discharged” was defined a “positive” test result for the reference standard. The 
decision to “not discharge” a patient may have been due to the diagnosis of an eye 
condition which needs treatment (glaucoma or otherwise) or the need for monitoring 
in one or both eyes. As visual acuity and IOP influence the clinical decision to 
discharge or not a patient for conditions other than glaucoma, and are routinely 
collected, these data were incorporated and a composite triage test was defined. In 
these analyses the discharge status of the patient was compared with a composite 
“test” which will be a combination of results from: an imaging test, the measurement 
of IOP, and visual acuity. 
 
Following the statistical analysis plan, the diagnosis results (according to diagnosis 
performance and proportion of indeterminate tests) were considered prior to conduct 
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of the triage analysis. Corresponding triage analyses of all four imaging tests were 
then conducted according to the following definitions. An “abnormal” result for the 
imaging component was defined as including borderline as “abnormal”. An 
“abnormal” result for the IOP measurement component was a pressure of greater than 
21mmHg as measured by the ophthalmologist. Similarly for visual acuity, an 
“abnormal” test result was defined as 6/12 or poorer as measured prior to referral by 
an optometrist. The visual acuity cut-off point (6/12) was chosen because below this 
level patients would not be able to drive and would merit further investigation to 
justify the reduced vision. Visual acuity was assumed not to be abnormal if it was not 
mentioned in the referral letter. The composite test was classified as “abnormal” if 
any of three components tests were judged to be abnormal for either eye. 
 
Statistical analysis methods 
Diagnostic performance analysis methods 
Diagnostic measures (sensitivity, specificity, likelihood ratios and diagnostic odds 
ratio) were calculated for each test with appropriate CI.38,39 All analyses were 
conducted at a 5% (2 sided) significance level with 95% CIs produced where 
appropriate. Under the diagnoses analyses, the diagnostic performance (sensitivity and 
specificity) of the alternative imaging tests was compared using McNemar’s test 
(default analyses only).37 Corresponding CIs for the paired difference were 
generated.40 No missing imaging, IOP or reference standard data was imputed. Visual 
acuity was assumed not to meet the abnormal criteria if not reported.  
 
Sensitivity analyses of diagnostic performance  
A range of sensitivity analyses were conducted for the diagnosis and/or triage 
analyses. These were: 
• varying the imaging test cut-off to explore possible threshold effects. This was 
done by classifying borderline as diseased for the overall classification and 
also by utilising the parameters reported by each imaging test. A Receiver 
operation characteristic (ROC) curve and the area under the curve with the 
corresponding 95% confidence interval was calculated for each parameter 
using a non-parametric approach (SAS Logistic command). The results of the 
threshold assessment are given in Appendix 6 [diagnosis analysis only] 
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• varying the reference standard definition of abnormal (e.g. inclusion of 
glaucoma suspects for diagnoses analyses) [both diagnosis and triage analyses] 
• removing the imaging quality requirement and/or assuming indeterminate 
results were abnormal [both diagnosis and triage analyses] 
• using a combination of (two) tests for diagnostic performance. The choice of 
combinations was informed by the individual imaging test glaucoma diagnosis 
analyses [diagnosis analysis only] 
• assess the impact of using “best” eye instead of the “worst” eye for each 
participant as defined by the clinical reference standard [diagnosis analysis] 
• varying the IOP cut-off value for the pressure component of the test to be 
classified as “abnormal”. A further analysis using a cut-off of IOP> 25mmHg 
was carried out [triage analysis only] 
• using the referral IOP measurement instead of the ophthalmologist’s 
measurement to define the positive IOP component of the triage test. For this 
analysis IOP >21 mmHg will be used as the cut-off for OHT [triage analysis 
only] 
• varying the threshold for the visual acuity component of the composite test to 
be classified as “abnormal” [triage analyses only]  
• utilising a composite test without a visual acuity component (i.e. only imaging 
and IOP components) [triage analyses only]. 
 
Diagnostic analyses to populate the Health economic model 
A third set of analyses were produced in order to provide the most appropriate 
diagnostic performance data to populate the economic model (see Appendix 7 for the 
results). Under these analyses, the reference standard was detection of glaucoma and 
those “at risk” of glaucoma (i.e. a patient who was a glaucoma suspect of any kind, 
PAC or OHT).  This is because people with these potential diagnoses need to remain 
monitored in secondary care according to the NICE guidelines. Any modelled triage 
system would need to reflect standard practice.27   
 
Other outcomes 
Two other outcomes were used to evaluate each of the four tests: Indeterminacy of 
tests and participant preferences. Indeterminacy of tests was quantified as the 
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proportion of tests that are indeterminate for each of the four imaging tests. This 
outcome was calculated in two ways, those which meet the manufacturer’s suggested 
quality requirements and those for which a test result was produced. Participants’ 
preference ranking of the three imaging technologies was summarised. 
 
Patient and public involvement 
Representatives from a UK based charity for glaucoma patients, the International 
Glaucoma Society, were involved in the study oversight throughout the project 
through the steering committee.  This included: review and development of the study 
protocol and patient paperwork; monitoring the study progress; review and discussion 
of the final results of the study, including the care pathways and sensitivity analyses 
for the economic analyses, with particular reference to the patient perspective; 
proposing further research priorities particularly the acceptability of this new model of 
care.  Additionally a patient with glaucoma reviewed and commented on the lay 
summary of the report.   
 
Study oversight and management arrangements 
The University of Aberdeen sponsored the study. An independent Trial Steering 
Committee (TSC) was established. The TSC comprised an independent chairperson 
(Ophthalmologist and senior academic), three further independent members (two 
Ophthalmologists and the chief executive of a UK based charity for glaucoma 
patients, the International Glaucoma Association), and the study grant-holders. The 
TSC met approximately annually over the course of the study. A patient (I.R.) agreed 
to provide advice on certain aspects of the study, but was not a member of the TSC. 
No Data Monitoring Committee was used as there were no safety concerns as the 
diagnostic technologies under evaluation were non-invasive, were routinely 
performed in clinical settings, and patient management did not change.  
 
The day-to day running of the study was the responsibility of the chief investigator 
(Azuara-Blanco) supported by the research manager, research fellow and data support 
staff. A project management group consisting of the co-applicants provided strategic, 
management and content expertise to the study. 
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Ethical arrangements and regulatory approvals 
The study and subsequent amendments were reviewed and given a favourable opinion 
by the North of Scotland Research Ethics Committee (reference 10/S0801/58) and 
local Research and Development Departments. The study was conducted according to 
the principles of Good Clinical Practice.  
 
Protocol amendments after study initiation 
A number of minor protocol revisions were made after study initiation.  
 
Versions of the study protocol 
Version 1, 28th July 2010 
Version 1.1, 31 January 2011 (minor typographical changes) 
Version 1.2, 17 April 2012 (extension of recruitment timescale)  
Version 1.3, 11April 2013 (extension of recruitment timescale) 
Version 1.4 4 July 2013 (updated list of grant holders and TSC members)  
 
These are included in Appendix 1. 
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Chapter 3  Participant characteristics 
 
This chapter provides an overview of the baseline characteristics of participants in the 
GATE study.  
 
Recruitment of participants 
Between April 2011 and July 2013, 2088 participants were identified as potentially 
eligible to take part in the study: 2013 were sent letters of invitation and patient 
information sheets. Of those invited, 966 (48%) agreed to take part, and 265 (13%) 
expressed a preference for not participating. Characteristics of non-participants are 
detailed in Table 2. 
 
Following consent, 11 participants were subsequently excluded from the study: 10 
were ineligible (4 had pre-existing glaucoma, 4 were referred from secondary care, 2 
were not referred for glaucoma) and 1 person withdrew from the study. Therefore 955 
participants were available for the index test comparison. Additionally, due to 
administrative and research processes, imaging was not implemented for all imaging 
tests in 12 participants and these were excluded from all analyses. The baseline 
measurements presented in this chapter relate to the remaining 943 participants.  
 
Figure 2 shows a consort style diagram of the recruitment to the study. Full details of 
patient flow through the diagnostic performance analysis are described within the 
results Chapters 4 and 5.  
 
Aberdeen and Hinchingbrooke were the highest recruiting centres (Table 3). Over 2/3 
of GATE participants were recruited from these two sites.  
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Table 2  Characteristics of non-participants 
Characteristic Value 
N 
Agea Mean – (SD) 
1122 
61.7 (15.1) 
Female – n (%) 592  (52.8) 
Reasons for not taking part n (%)  
Screened but not sent information sheet 75    (6.7) 
 Refusal 265  (23.6) 
 Equipment malfunction 33    (2.9) 
 Missed 93    (8.3) 
 Non-attendance 134  (11.9) 
 Other reason  247  (22.0) 
 Reason not given 275  (24.5) 
aAge calculated as (year of test-year of birth) 
  
Figure 2  Consort style diagram showing recruitment to the study 
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Table 3  Centre recruitment 
Centre Participants recruited n (%) 
Aberdeen Royal Infirmary 353 (37.0) 
Bedford Hospital 74   (7.7) 
Hinchingbrooke Hospital NHS Trust, Huntingdon 343 (35.9) 
Moorfields Eye Hospital, London 157 (16.4) 
Royal Liverpool Hospital 28   (2.9) 
TOTAL 955 
 
Baseline characteristics of participants 
Demographic characteristics of participants and non-participants were similar, with an 
average age slightly above 60 years of age (Tables 2 and 4) and similar gender 
distribution. Among participants, nearly 90% were of White British ethnicity (self 
reported ethnicity, Table 4).  
 
Ocular characteristics recorded in the referral letter from the optometrist are detailed 
in Table 5. In the majority of referrals (77%), the optometrist had highlighted 
abnormalities in both eyes (referral eye). The average IOP at referral was 20 mmHg. 
Where the method of IOP measurement was reported on the referral letter (52%), the 
most commonly reported method of measurement was non-contact tonometry (NCT). 
Data on visual acuity and refractive error at referral are summarised in Table 5  
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Table 4  Baseline demographics of included participants 
Characteristic Value 
 All 
participants 
Glaucoma  Non -glaucoma 
N 943 158 770 
Age Mean - (SD) 60.5(13.8) 67.4 (12.7) 59.2(13.6) 
Female - n (%) 482 (51.1) 74 (46.8) 401 (52.1) 
Ethnicitya – n (%)    
Black or Black-Caribbean 25 (2.7) 4 (2.5) 21 (2.7) 
Black or Black British-African 20 (2.1) 6 (3.8) 14 (1.8) 
Asian or Asian British-Indian  18 (1.9) 5 (3.2) 13 (1.7) 
Asian or Asian British-Pakistani 4 (0.4) 0 (0) 4 (0.5) 
Chinese 1 (0.1) 1 (0.6) 0 (0) 
Other Asian Background 4 (0.4) 1 (0.6) 3 (0.4) 
Mixed-White and Black African  1 (0.1) 1 (0.6) 0 (0) 
White- British 826(89.2) 140 (88.6) 686(89.1) 
Other 29 (3.1) 0 (0) 29 (3.8) 
a There was no ethnicity recorded in 15 participants 
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Table 5  Ocular characteristics of participants at referral 
Characteristic Right eye    Left eye 
Referral eye n/N (%) 97/939 (10.3) 116/939 (12.3) 
Both eyes 725/939 (76.9) 
Not answered  1/939 (0.1) 
IOP on referral (mmHg) Mean (SD), n  19.6 (5.7), 918 19.9 (5.6), 918 
Method Of IOP Assessment n/N (%)   
Non-contact tonometry 260/943 (27.6) 
Goldmann applanation tonometry 231/943 (24.5) 
Othera  452/943 (47.9) 
Refraction   
Mean sphere (dp) Mean (SD), n 0.4 (3.3), 571 1.0 (3.6), 561 
Myopes greater than -5dp  n/N (%) 37/943 (3.9) 36/943 (3.8) 
Hyperopes greater than +5dp n/N (%) 38/943 (4.0) 51/943 (5.4) 
Astigmatics greater than 3dp  n/N (%) 16/943 (1.7) 16/943 (1.7) 
Visual acuity Mean (SD) 
 
 
BCVA Snellenb 1.0 (0.3), 925 1.0 (0.3), 926 
Log MARc 0.0 (0.3), 925 0.0 (0.3), 926 
a Includes those where the method of assessment was not recorded on referral 
b Best corrected visual acuity, Snellen chart 
c Logarithm of the Minimum Angle of Resolution chart 
 
Reference standard diagnosis characteristics 
Tables 6 to 14 describe the tests used to determine the reference standard, and the 
diagnoses in the GATE population. The average clinician IOP measured with GAT 
was similar to the referral IOP (see Table 6), and highest among patients with OHT 
and glaucoma (see Table 7). Visual field testing was outside the manufacturer 
recommended reliability in one quarter of participants. The average MD among those 
diagnosed with glaucoma and with reliable VF tests was -6.0 (SD 6.4) dB in the right 
eye and -7.5 (SD 6.8) dB in the left eye (see Table 7).  
 
Table 8 displays the diagnosis of the GATE population per eye according to the 
agreed reference standard (see Chapter 2). The most common diagnosis 
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(approximately 40%) was “no glaucoma-related findings”. Glaucoma was diagnosed 
in about 11% of eyes. Co morbidities were uncommon, except for cataract that was 
reported in approximately 8% of eyes (see Table 9).  
 
Among those eyes with glaucoma, mild disease was most prevalent (above half), 
while severe glaucoma was diagnosed in a relatively small proportion of eyes with the 
disease (28 of 219 eyes, 12.7%, see Table 10).  
 
Over 1/3 of the GATE participants were discharged after the first visit (see Table 11). 
Table 13 describes the diagnosis by worst eye (ranked as shown) and by best eye. 
Glaucoma was diagnosed in at least one eye in 16.8% of the GATE cohort and 6.5% 
had glaucoma in both eyes at referral (see Table 12).  
 
Table 6  Data from hospital eye service examination. Visual field and intra-
ocular pressure 
Characteristic Right eye Left eye 
Visual field reliabilitya - n/N (%)   
Reliable  706/941 (75.0) 707/940 (75.2) 
Unreliable  212/941 (22.5) 210/940 (22.3) 
Not done    23/941 (2.4)   23/940 (2.4) 
Reliable Visual field measures - Mean (SD), n 
MD (dB)   -1.9 (4.0), 703  -2.2 (4.1), 702 
PSD (dB)    2.8 (2.6), 703   2.8 (2.6), 702 
VFI (%)  95.0 (10.1), 688 94.9 (10.3), 682 
Visual Field Measures Including Unreliable- Mean (SD), n  
 MD (dB)   -1.8 (4.0), 893  -2.0 (4.1), 887 
 PSD (dB)    2.8 (2.5), 893   2.8 (2.5), 887 
 VFI (%)   95.0 (10.2), 866 95.0 (10.1), 859 
IOP(mmHg) – Ophthalmologist GAT- Mean (SD), n  
  19.2 (5.1), 932 19.3 (5.1), 932 
a Visual field reliability as defined by Humphrey VF output 
Table 7  Data from hospital eye service examination. IOP and MD by diagnosis  
 Right eye- Mean (SD), n Left eye- Mean (SD), n 
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IOP (mmHg)GAT   
   Glaucoma 23.0 (6.4), 116 22.6 (6.9), 103 
   Glaucoma Suspects 17.9 (4.4), 201 18.8 (5.2), 194 
   OHT 25.2 (3.5), 122 25.2 (3.1), 123 
   PAC/PAC Suspect 17.8 (4.1), 120 17.8 (3.8), 126 
   Normal 17.1 (3.2), 367 17.2 (3.1), 379 
Reliable Visual Field MD (dB)   
   Glaucoma -6.0 (6.4), 85 -7.5 (6.8), 77 
   Glaucoma Suspects -2.2 (3.4), 150 -2.2 (3.4), 153 
   OHT -0.6 (2.2), 85 -0.8 (2.0), 92 
   PAC/PAC Suspect -1.1 (3.0), 91 -1.4 (2.9), 89 
   Normal -1.1 (3.0), 280 -1.3 (3.0), 279 
All Visual Field MD (dB) including unreliable  
   Glaucoma -5.6 (6.1), 103 -7.2 (6.6), 89 
   Glaucoma Suspects -2.2 (3.5), 195 -2.0 (3.3), 187 
   OHT -0.3 (2.3), 113 -0.7 (2.1), 111 
   PAC/PAC Suspect -0.9 (2.9), 115 -1.3 (2.9), 121 
   Normal -1.1 (3.4), 352 -1.4 (3.4), 364 
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Table 8  Data from hospital eye service examination. Diagnosis 
Diagnosis Right Eye - n (%) Left Eye - n (%) 
N 932 931 
Glaucoma 116 (12.4) 103 (11.1) 
Disc Suspect 146 (15.6) 126 (13.5) 
VF Suspect   29 (3.1)   35 (3.8) 
VF+Disc Suspect   26 (2.8)   33 (3.5) 
OHT 122 (13.0) 123 (13.2) 
PAC   30 (3.2)   29 (3.1) 
PAC Suspect   90 (9.6)   97 (10.4) 
No glaucoma - related findings 367 (39.2) 379 (40.7) 
Undetermined     6 (0.6)     6 (0.6) 
 
 
Table 9  Data from hospital eye service examination. Co-morbidity 
Co-morbidity  Right Eye 
n (%) 
Left Eye  
n (%) 
N 936 936 
Age-related Macular Degeneration (AMD)   7 (0.7) 11 (1.2) 
Cataract 78 (8.3) 70 (7.4) 
Neurological   6 (0.6)   8 (0.8) 
Other 65 (6.9) 63 (6.7) 
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Table 10  Data from hospital eye service examination. Glaucoma severity 
Glaucoma Severitya  Right Eye - n (%) Left Eye - n (%) 
N 116 103 
Mild 69 (59.5) 53 (51.5) 
Moderate 31 (26.7) 29 (28.2) 
Severe 11 (9.5) 17 (16.4) 
 Severity not recorded   5 (4.3)   4 (3.9) 
a see Chapter 2 for severity definitions 
 
 
Table 11  Data from hospital eye service examination. Action after first 
consultation 
Action  n (%) 
N 933 
Discharged – person level 357 (38.3) 
For those not discharged  Right eye Left eye 
Treat 291 (31.2) 287 (30.8) 
Monitor Only 214 (22.9) 216 (23.2) 
Repeat Assessment Required   33 (3.5)   39 (4.1) 
Not recorded   37 (4.0)   33 (3.5) 
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Table 12  Data from hospital eye service examination. Diagnosis by worst eye 
and best eye 
 Worst eye   
n  (%)  
Best eye  
n (%) 
N 932 931 
Diagnosis by clinician    
Glaucoma 158  (17.0)   61 (6.6) 
Disc Suspect 170  (18.2) 102 (11.0) 
VF Suspect   36  (3.9)   28 (3.0) 
VF+ Disc Suspect   36  (3.9)   23 (2.5) 
OHT 115  (12.3) 130 (14.0) 
PAC   31  (3.3)   28 (3.0) 
PAC Suspect   83  (8.9) 104 (11.2) 
No glaucoma - related findings 299  (32.1) 447 (48.0) 
Undetermined     4  (0.4)     8 (0.8) 
Co-morbidity   
AMD     9  (1.0)     9 (1.0) 
Cataract    75  (8.0)   73 (7.7) 
Neurological     7  (0.7)     7 (0.7) 
Other   68  (7.2)   60 (6.4) 
Action   
Treat 320  (33.9) 258 (27.4) 
Monitor Only 210 (22.3) 220 (23.3) 
Repeat Assessment Required   39 (4.1)   33 (3.5) 
 
  
34 
 
Table 13  Data from hospital eye service examination. Severity of disease by 
worst and best eye for those diagnosed with glaucoma 
 Worst eye n (%) Best eye n(%) 
N 158 61 
Glaucoma severity    
 Mild 78 (49.4) 19 (31.1) 
 Moderate 45 (28.5) 27 (44.3) 
 Severe  26 (16.5) 15 (24.6) 
 Severity not recorded   9 (5.7)   0 (0) 
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Table 14  Data from hospital eye service examination. Glaucoma mechanism for 
those diagnosed with glaucoma or glaucoma suspect, by worst and best eye 
 Worst Eye Best Eye 
Clinical diagnosis n/N (%)   
Glaucoma  158/936 (16.8) 61/936 (6.5) 
Open angle 123   46 
Angle closure   26   12 
Other     1     0 
Missing     8     3 
Disc Suspect 170/936 (18.0) 102/936 (10.8) 
Open angle 150   94 
Angle closure   11     6 
Other     2     0 
Missing     7     2 
VF Suspect 36/936 (3.8) 28/936 (3.0) 
Open angle   27   21 
Angle closure     6     5 
Other     1     2 
Missing     2     0 
VF+ Disc Suspect 36/936 (3.8) 23/936 (2.4) 
Open angle   33   21 
Angle closure     3     2 
Other     0     0 
Missing     0     0 
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Chapter 4  Diagnostic analysis results 
 
Overview 
This chapter reports the results of the diagnosis analyses which aimed to assess the 
diagnostic performance of the four imaging tests (HRT-MRA, HRT-GPS, GDx and 
OCT) and the other outcomes associated with the imaging tests (indeterminacy and 
participant preference). Results of the triage analyses are provided in the following 
chapter. The specific diagnostic performance analyses covered in this chapter are the 
default diagnosis analysis, five sensitivity analyses (diagnosis sensitivity analyses 1-
5) and the use of a combination of the imaging tests (Combination of tests analysis –
.see Table 15) for a list with definitions. The default analysis was defined as one 
where the reference standard definition of disease was a clinical diagnosis of 
glaucoma only, the imaging test definition of an abnormal result was “outside normal 
limits” for the overall classification of the respective imaging test (see Chapter 2). 
 
Additionally, only cases where there was a good quality image with an overall 
classification available were included (see Chapter 2). The five sensitivity analyses 
assessed the impact of varying assumptions made in the default analysis relating to the 
reference standard definition of disease (including all types of glaucoma suspects as 
diseased), the definition of an abnormal test result (including borderline results as 
abnormal), and how cases where the test did not produce an overall classification 
were handled in the analysis. There were four test related reasons why an overall 
classification may not have been available in addition to missing data (see no results 
categories, Table 15). Sensitivity analyses assessed the impact of removing the 
requirement of a “good” quality image and using the provided assessment, along with 
setting other cases which did not produce an overall classification result as abnormal. 
 
The combination of test analysis investigated using pairs of imaging tests to produce a 
composite imaging test result, under the same assumptions as the default analysis. 
Given the findings of the default and sensitivity analyses, only three pairs of test 
combinations were evaluated; HRT-MRA with each of the other tests respectively. 
For all analyses, a STARD flow diagram34,37 was produced which shows the flow of 
participants. The subset of participants who received all four tests and were 
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considered in the statistical analyses are separated out into three groups according to 
whether each imaging test result was “abnormal”, “normal”, or “no result” (the 
imaging test result was not available whether because the test was inconclusive or the 
result was missing). For each of these three groups the group status according to the 
reference standard (“glaucoma present” or “glaucoma absent”) for each participant is 
given or alternative the reference standard was stated to be missing or inconclusive. 
The final categorisations of the imaging test result by reference standard status 
provides the four possible combinations (true and false positive, false and true 
negative) from which the diagnostic performance can be assessed.  Sensitivity, 
specificity, likelihood ratios and DOR are provided with associated 95% CIs 
summarised for each analysis. 
 
Of the 966 (46%) who agreed to take part in GATE, 11 were excluded from the study: 
10 were ineligible and 1 person withdrew prior to participating in the study.  
Additionally, due to administrative and research processing errors, imaging was not 
implemented for all 4 imaging tests in 12 participants and these were excluded from 
all analyses. The analyses in this chapter pertain to the remaining 943 participants. Of 
these, no reference standard finding was available for 11 participants with an 
inconclusive finding in a further 4 cases. 
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Table 15  Diagnosis analyses 
Analysis Reference standard 
definition of disease 
Abnormal test result Handling of ‘no 
result’ categories 
Figure 
no. 
Table 
no. 
Default diagnostic analysis Glaucoma in the 
“worse” eye 
Outside normal limits A-E excluded 
 
3 16, 17, 18, 19 
Diagnosis sensitivity analysis 1 Glaucoma in the 
“worse” eye 
Outside normal limits  
or borderline 
A-E excluded 4 22 
Diagnosis sensitivity analysis 2 Glaucoma or 
glaucoma suspect in 
the “worse” eye 
Outside normal limits A-E excluded 5 23 
Diagnosis sensitivity analysis 3 Glaucoma or 
glaucoma suspect in 
the “worse” eye 
Outside normal limits 
or borderline 
A-E excluded 6 24 
Diagnosis sensitivity analysis 4 Glaucoma or 
glaucoma suspect in 
the “worse” eye 
Outside normal limits 
or  borderline 
A imaging 
classification 
B-D abnormal 
E excluded 
7 25 
Diagnosis sensitivity analysis 5 Glaucoma in the 
“worse” eye 
Outside normal limits A imaging 
classification 
B-D abnormal 
E  excluded 
8 26 
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Diagnosis sensitivity analysis 6 Glaucoma in the 
“best” eye 
Outside normal limits A-E excluded 
 
9 27 
Combinations of diagnosis 
imaging tests 
 
Glaucoma in the 
“worse” eye 
Outside normal limits A-E excluded 10 28 
No result categories  
A: test performed and imaging report produced but quality is lower than manufacturer quality cut-off 
B: test performed and imaging report produced but no overall classification generated by machine 
C: test performed but there was a clear imaging artefact on the report 
D: test attempted but no imaging could be acquired from the patient’s eyes – no report generated 
E: missing imaging output (due to study related or data collection issues)  
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Default diagnosis analysis 
The results for the default diagnosis analysis are presented in three sections:  
• diagnostic performance of the imaging tests 
• paired comparisons of imaging tests 
• diagnostic performance with restricted reference standard definition of disease.  
 
Diagnostic performance of the imaging tests 
For the default analysis, abnormal imaging test results were those classified as 
‘outside normal limits’ and the corresponding reference standard definition of disease 
was a diagnosis of glaucoma in the ‘worse’ eye. Only participants with an imaging 
test output with an overall classification which met the manufacturer quality cut-off 
were included in the analysis. 
 
The flow of study participants according to the default diagnosis analysis is shown in 
Figure 3 with respective number of abnormal, normal and ‘no result’ cases by 
imaging test, and the corresponding reference standard finding shown. Of the 943 
patients for whom all four tests were performed, 158 were classified as disease 
positive and 770 as disease negative. The reference standard was missing and 
inconclusive for 11 and 4 participants respectively. The diagnostic performance for 
the four tests is given in Table 16. Results showed a trade-off between detection of 
glaucoma and correctly identifying non-glaucoma cases: HRT-MRA had the highest 
sensitivity (87.0%, 95% CI (80.2,92.1)) but lowest specificity (63.9%, 95% CI 
(60.2,67.4)), GDx had the lowest sensitivity (35.1%, 95% CI (27.0,43.8)) but the 
highest specificity (97.2%, 95% CI (95.6,98.3)), and the other two tests provided 
intermediate results (HRT-GPS values were very similar to the HRT-MRA results, 
and OCT had very similar sensitivity and specificity values). Likelihood ratios (and 
95% CI) showed evidence of both being able to rule in and out the presence of 
glaucoma for all 4 imaging tests (CIs did not contain 1.0). DORs ranged from 9.24 for 
HRT-GPS to 18.48 for GDx.  
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Figure 3 Flow diagram: default diagnostic analysis 
  
Reference standard definition: glaucoma
Test abnormal: outside normal limits
Handling of no result: A-E excluded
No reference standard
HRT-MRA n=  3
HRT-GPS n=  2
GDx n= 1
OCT n= 2
No reference standard
HRT-MRA n= 1
HRT-GPS n= 2
GDx n= 3
OCT n= 2
No reference standard
HRT-MRA n= 7
HRT-GPS n= 7
GDx n= 7
OCT n= 7
Reference standard
HRT-MRA n= 82
HRT-GPS n= 84
GDx n= 90
OCT n= 45
Reference standard
HRT-MRA n= 379
HRT-GPS n= 339
GDx n= 68
OCT n= 272
Reference standard
HRT-MRA n= 471
HRT-GPS n=509
GDx n= 774
OCT n= 615
Inconclusive 
reference standard
HRT-MRA n= 3
HRT-GPS n= 0
GDx n= 1
OCT n= 1
Inconclusive 
reference standard
HRT-MRA n= 0
HRT-GPS n= 3
GDx n= 3
OCT n= 3
Inconclusive 
reference standard
HRT-MRA n= 1
HRT-GPS n= 1
GDx n= 0
OCT n= 0
Disease
present (TP)
HRT-MRA n= 120
HRT-GPS n= 110
GDx n= 47
OCT n= 113
Disease
present (FN)
HRT-MRA n= 18
HRT-GPS n= 25
GDx n= 87
OCT n= 34
Disease
absent (FP)
HRT-MRA n=256
HRT-GPS n= 229
GDx n= 20
OCT n= 158
Disease
present
HRT-MRA n= 20
HRT-GPS n= 23
GDx n= 24 
OCT n= 11
Disease
absent (TN)
HRT-MRA n= 453
HRT-GPS n= 481
GDx n= 684
OCT n= 578
Disease
absent
HRT-MRA n= 61
HRT-GPS n= 60
GDx n= 66
OCT n= 34
No result
HRT-MRA n= 89
HRT-GPS n= 91
GDx n= 97
OCT n= 52
Abnormal result
HRT-MRA n= 382
HRT-GPS n= 341
GDx n= 69
OCT n= 274
Normal result
HRT-MRA n= 472
HRT-GPS n= 511
GDx n= 777
OCT n= 617
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• Withdrawn = 1
Available for index test
n= 955
Completed all four index tests
n= 943
Imaging not performed for all four index 
tests
n= 12
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Table 16  Diagnostic performance: default diagnosis analysis 
Test Diagnostic 
parameter 
Point           
Estimate 
95% CI 
Lower Upper 
HRT-MRA Sensitivity % 87.0 80.2 92.1 
 Specificity % 63.9 60.2 67.4 
 
Positive Likelihood 
Ratio 
2.41 2.14 2.71 
 
Negative Likelihood 
Ratio 
0.20 0.13 0.32 
 DOR 11.80 7.02 19.81 
HRT-GPS Sensitivity % 81.5 73.9 87.6 
 Specificity % 67.7 64.2 71.2 
 
Positive Likelihood 
Ratio 
2.53 2.21 2.89 
 
Negative Likelihood 
Ratio 
0.27 0.19 0.39 
 DOR 9.24 5.82 14.67 
GDx  Sensitivity % 35.1 27.0 43.8 
 Specificity % 97.2 95.6 98.3 
 
Positive Likelihood 
Ratio 
12.35 7.57 20.14 
 
Negative Likelihood 
Ratio 
0.67 0.59 0.76 
 DOR 18.48 10.46 32.63 
OCT Sensitivity % 76.9 69.2 83.4 
 Specificity % 78.5 75.4 81.4 
 
Positive Likelihood 
Ratio 
3.58 3.04 4.22 
 
Negative Likelihood 
Ratio 
0.29 0.22 0.40 
 DOR 12.16 7.97 18.54 
 
  
43 
 
Paired comparisons of imaging tests 
Table 17 shows the paired difference (with 95% CI) and corresponding McNemar’s 
test p-value for comparisons between pairs of tests. There was evidence that the 
sensitivity of all tests differed from each other except for HRT-GPS versus OCT.   
 
HRT-MRA and GDx had the highest and lowest sensitivity respectively. Differences 
varied from -6.7% (HRT-GPS versus HRT-MRA) to 55.6% (HRT-MRA versus 
GDx). Similarly there was evidence that all specificities of all tests varied from each 
other (according to McNemar’s test);37 the 95% paired difference CI for HRT-GPS 
versus HRT-MRA just overlapped with zero. 
  
44 
 
Table 17  Paired comparisons of sensitivity and specificity between the imaging 
tests 
Tests 
Compared 
Parameter  Test  Value (95% CI) P-value 
(McNemar’s) 
HRT-GPS  vs   Sensitivity HRT-GPS 81.1 (74.2 to 88.1)  
GDx  GDx 34.4 (26.0 to 42.9)  
  Difference 46.7 (37.0 to  54.9) <.001 
 Specificity HRT-GPS 67.5 (64.0 to 71.1)  
  GDx 97.5 (96.3 to 98.7)  
  Difference -30.0 (-33.6 to -26.3) <.001 
GDx  vs   Sensitivity GDx 36.4 (28.1 to 44.7)  
OCT  OCT 77.5 (70.3 to 84.7)  
  Difference -41.1 (-49.2 to -31.6) <.001 
 Specificity GDx 97.5 (96.3 to 98.7)  
  OCT 79.8 (76.8 to 82.8)  
  Difference 17.7 (14.9 to 20.8) <.001 
GDx  vs   Sensitivity GDx 33.1 (24.8 to 41.3)  
HRT-MRA  HRT-MRA 88.7 (83.1 to 94.3)  
  Difference -55.6 (-63.8 to -45.6) <.001 
 Specificity GDx 97.3 (96.1 to 98.5)  
  HRT-MRA 63.7 (60.1 to 67.4)  
  Difference 33.6 (29.8 to 37.3) <.001 
HRT-GPS  vs   Sensitivity HRT-GPS 81.3 (74.7 to 87.9)  
HRT-MRA  HRT-MRA 88.1 (82.6 to 93.5)  
  Difference -6.7 (-13.2 to  -0.6) <.001 
 Specificity HRT-GPS 67.8 (64.3 to 71.3)  
  HRT-MRA 64.1 (60.5 to 67.6)  
  Difference 3.7 (-0.1 to 7.5) <.001 
HRT-MRA vs   Sensitivity HRT-MRA 86.5 (80.7 to 92.3)  
OCT  OCT 75.2 (67.8 to 82.5)  
  Difference 11.3(3.4 to  19.2) <.001 
 Specificity HRT-MRA 63.9 (60.3 to 67.5)  
  OCT 79.4 (76.4 to 82.4)  
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Tests 
Compared 
Parameter  Test  Value (95% CI) P-value 
(McNemar’s) 
  Difference -15.5 (-19.8 to -11.2) <.001 
HRT-GPS  vs   Sensitivity HRT-GPS 82.3 (75.7 to 88.9)  
OCT  OCT 75.4 (68.0 to 82.8)  
  Difference 6.9(-1.6 to  15.4) 0.106 
 Specificity HRT-GPS 67.7 (64.2 to 71.2)  
  OCT 79.7 (76.7 to 82.7)  
  Difference -12.0 (-16.3 to -7.6) <.001 
 
Impact of severity of disease  
Two further analyses looked at the impact of changing the reference standard 
definition of disease to moderate and severe glaucoma only and severe glaucoma (see 
Chapter 2 for disease definitions). The only change from the default analysis was in 
terms of the reference standard. The diagnostic performance for the four imaging tests 
where the reference standard definition of disease was moderate and severe glaucoma 
only is given in Table 18.  
 
Results showed a trade-off between detection of glaucoma and correctly identifying 
non-glaucoma cases: HRT-GPS had the highest sensitivity (92.7%, 95% CI (82.4, 
98.0)) but with the second lowest specificity (63.5%, 95% CI (60.1, 66.9)), GDx had 
the lowest sensitivity (60.0%, 95% CI 45.9,73.0)) but the highest specificity (95.7%, 
95% CI (94.0,97.0)), and the other two tests provided intermediate results (HRT-
MRA values were very similar to the HRT-GPS results, and OCT had a similar 
sensitivity but higher specificity). Likelihood ratios (and 95% CI) showed evidence of 
both being able to rule in and out the presence of glaucoma for all 4 imaging tests (CIs 
did not contain 1.0). DORs ranged from 12.44 for HRT-MRA to 33.04 for GDx. 
Compared to the default analysis, the diagnostic performance of GDx and OCT both 
performed relatively better and HRT-GPS and HRT-MRA relatively poorer.  
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Table 18  Diagnostic performance: default diagnosis analysis (reference standard 
definition of disease of moderate and severe glaucoma) 
Test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Diagnostic
parameter 
Point
Estimate 
95% CI 
Lower  Upper  
HRT-MRA Sensitivity % 89.7 78.8 96.1 
 Specificity % 58.9 55.4 62.4 
 
Positive Likelihood 
Ratio 
2.18 1.93 2.46 
 
Negative Likelihood 
Ratio 
0.18 0.08 0.38 
 DOR 12.44 5.28 29.30 
HRT-GPS Sensitivity % 92.7 82.4 98.0 
 Specificity % 63.5 60.1 66.9 
 
Positive Likelihood 
Ratio 
2.54 2.26 2.86 
 
Negative Likelihood 
Ratio 
0.11 0.04 0.29 
 DOR 22.22 7.95 62.12 
GDx Sensitivity % 60.0 45.9 73.0 
 Specificity % 95.7 94.0 97.0 
 
Positive Likelihood 
Ratio 
13.82 9.32 20.47 
 
Negative Likelihood 
Ratio 
0.42 0.30 0.58 
 DOR 33.04 17.43 62.65 
OCT Sensitivity % 89.1 78.8 95.5 
 Specificity % 73.9 70.7 76.9 
 
Positive Likelihood 
Ratio 
3.41 2.95 3.94 
 
Negative Likelihood 
Ratio 
0.15 0.07 0.30 
 DOR 23.02 10.34 51.25 
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The diagnostic performance for the four imaging tests where the reference standard 
definition of disease was severe glaucoma only is given in Table 19. Results showed a 
trade-off between detection of glaucoma and correctly identifying non-glaucoma 
cases: OCT had the highest sensitivity (95.2%, 95% CI (76.2,99.9)) and the second 
highest specificity (70.9%, 95% CI (67.7, 73.9)), GDx had the lowest sensitivity 
(78.9%, 95% CI (54.4,93.9)) but the highest specificity (93.7%, 95% CI (91.8,95.2)), 
and the other two tests providing intermediate results (HRT-GPS and HRT-MRA 
results were very similar and had a similar sensitivity to OCT though lower a 
specificity). Likelihood ratios (and 95% CI) showed evidence of both being able to 
rule in the presence of glaucoma for all 4 imaging tests (CIs did not contain 1.0) 
though not always ruling out the disease. DORs ranged from 23.63 for HRT-MRA to 
55.31 for OCT. Compared to the default analysis, the diagnostic performance of GDx 
and OCT both performed relatively better and HRT-GPS and HRT-MRA relatively 
poorer. 
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Table 19  Diagnostic performance: default diagnosis analysis (reference standard 
definition of disease of severe glaucoma) 
Test Diagnostic 
parameter 
Point 
Estimate 
95% CI 
Lower  Upper  
HRT-MRA Sensitivity % 94.7 74.0 99.9 
 Specificity % 56.8 53.3 60.2 
 
Positive Likelihood 
Ratio 
2.19 1.92 2.50 
 
Negative Likelihood 
Ratio 
0.09 0.01 0.63 
 DOR 23.63 3.14 177.85 
HRT-GPS Sensitivity % 94.7 74.0 99.9 
 Specificity % 61.1 57.7 64.5 
 
Positive Likelihood 
Ratio 
2.44 2.13 2.79 
 
Negative Likelihood 
Ratio 
0.09 0.01 0.58 
 DOR 28.32 3.76 213.16 
GDx Sensitivity % 78.9 54.4 93.9 
 Specificity % 93.7 91.8 95.2 
 
Positive Likelihood 
Ratio 
12.43 8.75 17.66 
 
Negative Likelihood 
Ratio 
0.22 0.09 0.54 
 DOR 55.31 3.76 172.63 
OCT Sensitivity % 95.2 76.2 99.9 
 Specificity % 70.9 67.7 73.9 
 
Positive Likelihood 
Ratio 
3.27 2.84 3.77 
 
Negative Likelihood 
Ratio 
0.07 0.01 0.2 
 DOR 48.69 6.50 364.73 
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Other outcomes 
Indeterminacy results are shown in Table 20. GDx had the highest percentage of low 
quality imaging results followed by HRT-GPS and HRT-MRA, with OCT giving the 
lowest percentage number of low quality results. 
 
Table 20  Classification and quality of imaging results (default analysis) 
Class HRT-MRA 
n (%) 
N=943 
HRT-GPS  
n (%) 
N=943 
GDx  
n (%) 
N=943 
OCT  
n (%) 
N=943 
Normal 319 (33.8) 310 (32.9) 640 (67.9) 447 (47.4) 
Borderline 153 (16.2) 201 (21.3) 137 (14.5) 170 (18.0) 
Abnormal 382 (40.5) 341 (36.2) 69 (7.3) 274 (29.1) 
Indeterminacy 
(No result categories A-D) 
58 (6.3) 75 (8.0) 79 (8.4) 40 (4.2) 
Missing data 
(No result category E) 
31 (3.2) 16 (1.7) 18 (1.9) 12 (1.3) 
 
Qualitya  
 
N=887 
 
N=887 
 
N=907 
 
N=906 
Good quality 854 (96.3) 852 (96.1) 846 (93.3)  891 (98.3) 
Low quality 33 (3.7) 35 (3.9) 61 (6.7)  15 (1.7) 
a excluding ‘no result’ categories B-E 
 
Table 21 shows the participants’ preference ranking of imaging tests (HRT-GPS and 
HRT-MRA have the same results), time taken to conduct the test and the proportion 
which received dilation also shown. Participant preference was collected for 890 
participants (94%).   Almost half of responders (48.2%) had no preference.  Of those 
participants who gave a preference, OCT was ranked as most preferred (27.6%) 
following by GDx (11.9%) and HRT-GPS/HRT-MRA with the lowest preference 
(5.1%). Average time taken to perform the test varied from 5.2 (OCT) to 7.6 (HRT-
GPS/HRT-MRA) minutes. More participants received dilation under HRT-GPS/HRT-
MRA (2.2%) than the other two tests. No adverse events were reported during the 
study. 
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Table 21  Participant preference, test conduct time and dilation results 
Test  Test 
Preference  
N=890 
Test conduct time  
(minutes)        
Mean (SD) 
Dilation  
N=918 
HRT(MRA/GPS)  1 49 (5.1) N=900 20 (2.2) 
 2 150 (15.6) 7.6 (5.0) - 
 3 229 (23.9) - - 
GDx 1 114 (11.9) N=886 16 (1.7) 
 2 162 (16.9) 7.5 (5.1) - 
 3 152 (15.8) - - 
OCT  1 265 (27.6) N=904 6 (0.7) 
 2 116 (12.1) 5.2 (3.0) - 
 3   44 (4.6) - - 
All None 462 (48.2) - - 
 
Diagnosis sensitivity analysis 1 
Diagnosis sensitivity analysis 1 differed from the default analysis in that a borderline 
finding on the imaging test was also classified as an abnormal result.  
For diagnosis sensitivity analysis 1, abnormal imaging test results were those 
classified as ‘outside normal limits’ and ‘borderline’ and the corresponding reference 
standard definition of disease was a diagnosis of glaucoma in the ‘worse’ eye. Only 
participants with an imaging test output with an overall classification which met the 
manufacturer quality cut-off were included in the analysis. 
 
The flow of study participants according to sensitivity analysis 1 is shown in Figure 4 
with the respective number of abnormal, normal and ‘no result’ cases given by 
imaging test, and the corresponding reference standard finding shown. Of the 943 
patients for whom all four tests were performed, 158 were classified as disease 
positive, and 770 as disease negative. The reference standard was missing and 
inconclusive for 11 and 4 participants respectively. The diagnostic performance for 
the four tests is given in Table 22. Results showed a trade-off between detection of 
glaucoma and correctly identifying non-glaucoma cases: HRT-MRA had the highest 
sensitivity (94.9%, 95% CI (89.8,97.9)) but the second lowest specificity (43.9%, 
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95% CI (40.2,47.6)), GDx had the lowest sensitivity (60.4%, 95% CI (51.6,68.8)) but 
the highest specificity (82.8%, 95% CI (79.8,85.5)), and the other two tests providing 
intermediate results (HRT-GPS values were very similar to the HRT-MRA results 
though marginally lower, and OCT had a high sensitivity and moderate specificity in 
relation to the other tests). Sensitivity was higher for all tests than under the default 
analysis but with correspondingly lower specificity. Likelihood ratios (and 95% CI) 
showed evidence of both being able to rule in and out the presence of glaucoma for all 
4 imaging tests (CIs did not contain 1.0). DORs ranged from 7.36 for GDx to 14.62 
for HRT-MRA.  
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Reference standard definition: glaucoma
Test abnormal: outside normal limits or borderline
Handling of no result: A-E excluded
Abnormal result
HRT-MRA n= 535
HRT-GPS n= 542
GDx n= 206
OCT n= 444
Normal result
HRT-MRA n= 319
HRT-GPS n= 310
GDx n= 640
OCT n= 447
No result
HRT-MRA n= 89
HRT-GPS n= 91
GDx n= 97
OCT n= 52
No reference standard
HRT-MRA n=  3
HRT-GPS n=  3
GDx n= 3
OCT n= 2
No reference standard
HRT-MRA n= 1
HRT-GPS n= 1
GDx n= 1
OCT n= 2
No reference standard
HRT-MRA n= 7
HRT-GPS n= 7
GDx n= 7
OCT n= 7
Reference standard
HRT-MRA n= 82
HRT-GPS n=  84
GDx n= 90
OCT n= 45
Reference standard
HRT-MRA n= 532
HRT-GPS n= 539
GDx n= 203
OCT n= 442
Reference standard
HRT-MRA n= 318
HRT-GPS n= 309
GDx n= 639
OCT n= 445
Inconclusive
reference standard
HRT-MRA n= 3
HRT-GPS n= 2
GDx n= 1
OCT n= 3
Inconclusive
reference standard
HRT-MRA n= 0
HRT-GPS n= 1
GDx n= 3
OCT n= 1
Inconclusive
reference standard
HRT-MRA n= 1
HRT-GPS n= 1
GDx n= 0
OCT n= 0
Disease
present (TP)
HRT-MRA n= 131
HRT-GPS n= 125
GDx n= 81
OCT n= 129
Disease
present (FN)
HRT-MRA n= 7
HRT-GPS n= 10
GDx n= 53
OCT n= 18
Disease
absent (FP)
HRT-MRA n= 398
HRT-GPS n= 412
GDx n= 121
OCT n= 310
Disease
present
HRT-MRA n= 20
HRT-GPS n= 23
GDx n= 24 
OCT n= 11
Disease
absent (TN)
HRT-MRA n= 311
HRT-GPS n= 298
GDx n= 583
OCT n= 426
Disease
absent
HRT-MRA n= 61
HRT-GPS n= 60
GDx n= 66
OCT n= 34
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• Withdrawn = 1
Available for index test
n= 955
Completed all four index tests
n= 943
Imaging not performed for all four index 
tests
n= 12
Figure 4  Flow diagram: diagnostic sensitivity analysis 1 
53 
 
Table 22  Diagnostic performance: diagnosis sensitivity analysis 1 
Test Diagnostic 
parameter 
Point 
Estimate 
95% CI 
Lower  Upper  
HRT-MRA Sensitivity % 94.9 89.8 97.9 
 Specificity % 43.9 40.2 47.6 
 
Positive Likelihood 
Ratio 
1.69 1.57 1.82 
 
Negative Likelihood 
Ratio 
0.12 0.06 0.24 
 DOR 14.62 6.74 31.73 
HRT-GPS Sensitivity % 92.6 86.8 96.4 
 Specificity % 42.0 38.3 45.7 
 
Positive Likelihood 
Ratio 
1.60 1.47 1.73 
 
Negative Likelihood 
Ratio 
0.18 0.10 0.32 
 DOR 9.04 4.67 17.51 
GDx Sensitivity % 60.4 51.6 68.8 
 Specificity % 82.8 79.8 85.5 
 
Positive Likelihood 
Ratio 
3.52 2.84 4.35 
 
Negative Likelihood 
Ratio 
0.48 0.39 0.59 
 DOR 7.36 4.95 10.96 
OCT Sensitivity % 87.8 81.3 92.6 
 Specificity % 57.9 54.2 61.5 
 
Positive Likelihood 
Ratio 
2.08 1.88 2.31 
 
Negative Likelihood 
Ratio 
0.21 0.14 0.33 
 DOR 9.85 5.89 16.49 
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Diagnosis sensitivity analysis 2 
Diagnosis sensitivity analysis 2 differed from the default analysis in that the reference 
standard definition of disease incorporated all glaucoma suspects (irrespective of 
type). For diagnosis sensitivity analysis 2, abnormal imaging test results were those 
classified as ‘outside normal limits’ and the corresponding reference standard 
definition of disease was a diagnosis of glaucoma in the ‘worse’ eye. Only 
participants with an imaging test output with an overall classification which met the 
manufacturer quality cut-off were included in the analysis. 
 
The flow of study participants according to sensitivity analysis 2 is shown in Figure 5 
with respective number of abnormal, normal and ‘no result’ cases by imaging test, and 
the corresponding reference standard finding shown. Of the 943 patients for whom all 
four tests were performed, 400 were classified as disease positive and 528 as disease 
negative. The reference standard was missing and inconclusive for 11 and 4 
participants respectively. The diagnostic performance for the four tests is given in 
Table 23. Results showed a trade-off between detection of glaucoma and correctly 
identifying non-glaucoma cases: HRT-MRA had the highest sensitivity (74.0%, 95% 
CI (69.1,78.5)) but lowest specificity (76.5%, 95% CI (72.5,80.1)), GDx had the 
lowest sensitivity (16.5%, 95% CI (12.8,20.8)) but the highest specificity (98.2%, 
95% CI (96.5,99.2)), and the other two tests providing intermediate results (HRT-GPS 
had lower sensitivity than HRT-MRA but a slightly higher specificity, and OCT had 
the second lowest sensitivity but the second highest specificity values). Sensitivity 
was lower for all tests than under the default analysis but with correspondingly higher 
specificity.  Likelihood ratios (and 95% CI) showed evidence of both being able to 
rule in and out the presence of glaucoma for all 4 imaging tests (CIs did not contain 
1.0). DORs ranged from 5.44 for OCT to 10.51 for GDx.  
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Reference standard definition: glaucoma or glaucoma suspect
Test abnormal: outside normal limits
Handling of no result: A-E excluded
Abnormal result
HRT-MRA n= 382
HRT-GPS n= 341
GDx n= 69
OCT n= 274
Normal result
HRT-MRA n= 472
HRT-GPS n= 511
GDx n= 777
OCT n= 617
No result
HRT-MRA n= 89
HRT-GPS n= 91
GDx n= 97 
OCT n= 52
No reference standard
HRT-MRA n=  3
HRT-GPS n=  2
GDx n= 1
OCT n= 2
No reference standard
HRT-MRA n= 1
HRT-GPS n= 2
GDx n= 3
OCT n= 2
No reference standard
HRT-MRA n= 7
HRT-GPS n= 7
GDx n= 7
OCT n= 7
Reference standard
HRT-MRA n= 82
HRT-GPS n= 84
GDx n= 90
OCT n= 45
Reference standard
HRT-MRA n= 379
HRT-GPS n= 339
GDx n= 68
OCT n= 272
Reference standard
HRT-MRA n= 471
HRT-GPS n= 509
GDx n= 774
OCT n= 615
Inconclusive
reference standard
HRT-MRA n= 3
HRT-GPS n= 0
GDx n= 1
OCT n= 1
Inconclusive
reference standard
HRT-MRA n= 0
HRT-GPS n= 3
GDx n= 3
OCT n= 3
Inconclusive
reference standard
HRT-MRA n= 1
HRT-GPS n= 1
GDx n= 0
OCT n= 0
Disease
present (TP)
HRT-MRA n= 259
HRT-GPS n= 232
GDx n= 58
OCT n= 192
Disease
present (FN)
HRT-MRA n= 91
HRT-GPS n= 121
GDx n= 293
OCT n= 189
Disease
absent (FP)
HRT-MRA n= 117
HRT-GPS n= 107
GDx n= 9
OCT n= 79
Disease
present
HRT-MRA n= 50
HRT-GPS n= 47
GDx n= 49
OCT n= 19
Disease
absent (TN)
HRT-MRA n= 380
HRT-GPS n= 385
GDx n= 478
OCT n= 423
Disease
absent
HRT-MRA n= 31
HRT-GPS n= 36
GDx n= 41
OCT n= 26
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• Withdrawn = 1
Available for index test
n= 955
Completed all four index tests
n= 943
Imaging not performed for all four index 
tests
n= 12
Figure 5  Flow diagram: diagnostic sensitivity analysis 2 
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Table 23  Diagnostic performance: diagnosis sensitivity analysis 2 
Test Diagnostic 
parameter 
Point 
Estimate 
95% CI 
Lower  Upper  
HRT-MRA Sensitivity % 74.0 69.1 78.5 
 Specificity % 76.5 72.5 80.1 
 
Positive Likelihood 
Ratio 
3.14 2.65 3.73 
 
Negative Likelihood 
Ratio 
0.34 0.28 0.41 
 DOR 9.24 6.74 12.68 
HRT-GPS Sensitivity % 65.7 60.5 70.7 
 Specificity % 78.3 74.3 81.8 
 
Positive Likelihood 
Ratio 
3.02 2.51 3.63 
 
Negative Likelihood 
Ratio 
0.44 0.38 0.51 
 DOR 6.90 5.08 9.38 
GDx Sensitivity % 16.5 12.8 20.8 
 Specificity % 98.2 96.5 99.2 
 
Positive Likelihood 
Ratio 
8.94   4.49 17.80 
 
Negative Likelihood 
Ratio 
0.85 0.81 0.89 
 DOR 10.51 5.13 21.54 
OCT Sensitivity % 50.4 45.3 55.5 
 Specificity % 84.3 80.8 87.3 
 
Positive Likelihood 
Ratio 
3.20 2.56 4.01 
 
Negative Likelihood 
Ratio 
0.59 0.53 0.66 
 DOR 5.44 3.98 7.44 
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Diagnosis sensitivity analysis 3 
Diagnosis sensitivity analysis 3 differed from the default analysis in that a borderline 
finding on the imaging test was classified as an abnormal test result and the reference 
standard definition of disease incorporated all glaucoma suspects (irrespective of 
type).  
For diagnosis sensitivity analysis 3, abnormal imaging test results were those 
classified as ‘outside normal limits’ or ‘borderline’ and the corresponding reference 
standard definition of disease was a diagnosis of glaucoma or glaucoma suspect in the 
‘worse’ eye. Only participants with an imaging test output with an overall 
classification which met the manufacturer quality cut-off were included in the 
analysis. 
The flow of study participants according to sensitivity analysis 3 is shown in Figure 6 
with respective number of abnormal, normal and ‘no result’ cases by imaging test, and 
the corresponding reference standard finding shown. Of the 943 patients for whom all 
four tests were performed, 400 were classified as disease positive and 528 as disease 
negative. The reference standard was missing and inconclusive for 11 and 4 
participants respectively. The diagnostic performance for the four tests is given in 
Table 24. Results showed a trade-off between detection of glaucoma and correctly 
identifying non-glaucoma cases: HRT-MRA had the highest sensitivity 88.9%, 95% 
CI (85.1,92.0)) but the second lowest specificity (56.1%, 95% CI (51.6,60.6)), GDx 
had the lowest sensitivity (39.0%, 95% CI (33.9,44.4)) but the highest specificity 
(86.7%, 95% CI (83.3,89.5)), and the other two tests providing intermediate results 
(HRT-GPS values were very similar to the HRT-MRA results, and OCT had very 
similar sensitivity and specificity values). Sensitivity was slightly higher for GDx, 
HRT-GPS and HRT-MRA than under the default analysis but with correspondingly 
lower specificity. OCT however had a slightly lower sensitivity and specificity than 
under the default analysis. 
 
Likelihood ratios (and 95% CI) showed evidence of both being able to rule in and out 
the presence of glaucoma for all 4 imaging tests (CIs did not contain 1.0). DORs 
ranged from 4.04 for OCT to 10.21 for HRT-MRA.  
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Reference standard definition: glaucoma or glaucoma suspect
Test abnormal: outside normal limits or borderline
Handling of no result: A-E excluded
Abnormal result
HRT-MRA n= 535
HRT-GPS n= 542
GDx n= 206
OCT n= 444
Normal result
HRT-MRA n= 319
HRT-GPS n= 310
GDx n= 640
OCT n= 447
No result
HRT-MRA n= 89
HRT-GPS n= 91
GDx n= 97
OCT n= 52
No reference standard
HRT-MRA n=  3
HRT-GPS n=  3
GDx n= 3
OCT n= 2
No reference standard
HRT-MRA n= 1
HRT-GPS n= 1
GDx n= 1
OCT n= 2
No reference standard
HRT-MRA n= 7
HRT-GPS n= 7
GDx n= 7
OCT n= 7
Reference standard
HRT-MRA n= 82
HRT-GPS n=  84
GDx n= 90
OCT n= 45
Reference standard
HRT-MRA n= 532
HRT-GPS n= 539
GDx n= 203
OCT n= 442
Reference standard
HRT-MRA n= 318
HRT-GPS n= 309
GDx n= 639
OCT n= 445
Inconclusive
reference standard
HRT-MRA n= 3
HRT-GPS n= 2
GDx n= 1
OCT n= 3
Inconclusive
reference standard
HRT-MRA n= 0
HRT-GPS n= 1
GDx n= 3
OCT n= 1
Inconclusive
reference standard
HRT-MRA n= 1
HRT-GPS n= 1
GDx n= 0
OCT n= 0
Disease
present (TP)
HRT-MRA n= 311
HRT-GPS n= 306
GDx n= 137
OCT n= 262
Disease
present (FN)
HRT-MRA n= 39
HRT-GPS n= 47
GDx n= 214
OCT n= 119
Disease
absent (FP)
HRT-MRA n= 218
HRT-GPS n= 231
GDx n= 65
OCT n= 177
Disease
present
HRT-MRA n= 50
HRT-GPS n= 47
GDx n= 49 
OCT n= 19
Disease
absent (TN)
HRT-MRA n= 279
HRT-GPS n= 261
GDx n= 422
OCT n= 325
Disease
absent
HRT-MRA n= 31
HRT-GPS n= 36
GDx n= 41
OCT n= 26
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• Withdrawn = 1
Available for index test
n= 955
Completed all four index tests
n= 943
Imaging not performed for all four index 
tests
n= 12
Figure 6  Flow diagram: diagnostic sensitivity analysis 3 
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Table 24  Diagnostic performance: diagnosis sensitivity analysis 3 
Test Diagnostic 
parameter 
Point 
Estimate 
95% CI 
Lower  Upper  
HRT-MRA Sensitivity % 88.9 85.1 92.0 
 Specificity % 56.1 51.6 60.6 
 
Positive Likelihood 
Ratio 
2.03 1.82 2.25 
 
Negative Likelihood 
Ratio 
0.20 0.15 0.27 
 DOR 10.21 7.00 14.88 
HRT-GPS Sensitivity % 86.7 82.7 90.1 
 Specificity % 53.0 48.5 57.5 
 
Positive Likelihood 
Ratio 
1.85 1.67 2.05 
 
Negative Likelihood 
Ratio 
0.25 0.19 0.33 
 DOR 7.36 5.16 10.49 
GDx Sensitivity % 39.0 33.9 44.4 
 Specificity % 86.7 83.3 89.5 
 
Positive Likelihood 
Ratio 
2.92 2.25 3.80 
 
Negative Likelihood 
Ratio 
0.70 0.64 0.77 
 DOR 4.16 2.96 5.83 
OCT Sensitivity % 68.8 63.8 73.4 
 Specificity % 64.7 60.4 68.9 
 
Positive Likelihood 
Ratio 
1.95 1.70 2.24 
 
Negative Likelihood 
Ratio 
0.48 0.41 0.57 
 DOR 4.04 3.04 5.37 
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Diagnosis sensitivity analysis 4 
Diagnosis sensitivity analysis 4 has the same reference standard and definition of an 
abnormal imaging test as sensitivity analysis 3 differing by including the imaging test 
related ‘no result’ cases (the overall classification was used irrespective of the quality 
indicator and the types were all classified as abnormal).  
For diagnosis sensitivity analysis 4, abnormal imaging test results were those 
classified as ‘outside normal limits’ or ‘borderline’ and the corresponding reference 
standard definition of disease was a diagnosis of glaucoma or glaucoma suspect in the 
‘worse’ eye. The analysis included participants with a low quality imaging output if a 
classification was given; other imaging test results which did not provide an overall 
classification were included as abnormal . 
 
The flow of study participants according to sensitivity analysis 4 is shown in Figure 7 
with respective number of abnormal, normal and ‘no result’ cases, and the 
corresponding reference standard finding shown. Of the 943 patients for whom all 
four tests were performed, 400 were classified as disease positive and 528 as disease 
negative. The reference standard was missing and inconclusive for 11 and 4 
participants respectively. The diagnostic performance for the four tests is given in 
Table 25. 
 
Results showed a trade-off between detection of glaucoma and correctly identifying 
non-glaucoma cases: HRT-MRA had the highest sensitivity (89.2%, 95% CI 
(85.7,92.1)) but second lowest specificity (55.1%, 95% CI (50.7,59.5)), GDx had the 
lowest sensitivity (41.9%, 95% CI (37.0,47.0))) but the highest specificity (85.6%, 
95% CI (82.3,88.5)), and the other two tests providing intermediate results (HRT-GPS 
values were similar to the HRT-MRA results, and OCT had similar sensitivity and 
specificity values). Sensitivity was higher for all tests than under the default analysis 
but with correspondingly lower specificity. Likelihood ratios (and 95% CI) showed 
evidence of both being able to rule in and out the presence of glaucoma for all 4 
imaging tests (CIs did not contain 1.0). DORs ranged from 3.89 for OCT to 10.19 for 
HRT-MRA.  
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Reference standard positive: glaucoma or glaucoma suspect
Test abnormal: outside normal limits or borderline
Handling of no result: A imaging classification
B-D abnormal
E excluded
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• Withdrawn = 1
Available for index test
n= 955
Completed all four index tests
n= 943
Imaging not performed for all four index 
tests
n= 12
Abnormal result
HRT-MRA n= 585
HRT-GPS n= 609
GDx n= 245
OCT n= 480
Normal result
HRT-MRA n= 327
HRT-GPS n= 318
GDx n= 680
OCT n= 451
Inconclusive result
HRT-MRA n= 31
HRT-GPS n= 16
GDx n= 18
OCT n= 12
No reference standard
HRT-MRA n= 3
HRT-GPS n= 3
GDx n= 3
OCT n= 2
No reference standard
HRT-MRA n= 1
HRT-GPS n= 1
GDx n= 1
OCT  n= 2
No reference standard
HRT-MRA n= 7
HRT-GPS n= 7
GDx n= 7
OCT n= 7
Reference standard
HRT-MRA n= 24
HRT-GPS n= 9
GDx n= 11
OCT n= 5
Reference standard
HRT-MRA n= 582
HRT-GPS n= 606
GDx n= 242
OCT n= 478
Reference standard
HRT-MRA n= 326
HRT-GPS n= 317
GDx n= 679
OCT n= 449
Inconclusive
reference standard
HRT-MRA n= 3
HRT-GPS n= 3
GDx n= 1
OCT n= 3
Inconclusive
reference standard
HRT-MRA n= 0
HRT-GPS n= 1
GDx n= 3
OCT n= 1
Inconclusive
reference standard
HRT-MRA n= 1
HRT-GPS n= 0
GDx n= 0
OCT n= 0
Disease
present (TP)
HRT-MRA n= 348
HRT-GPS n= 348
GDx n= 166
OCT n= 279
Disease
present (FN)
HRT-MRA n= 42
HRT-GPS n= 51
GDx n= 230
OCT n= 120
Disease
absent (FP)
HRT-MRA n= 231
HRT-GPS n= 255
GDx n= 75
OCT n= 196
Disease
present
HRT-MRA n= 10
HRT-GPS n= 1
GDx n= 4 
OCT n= 1
Disease
absent (TN)
HRT-MRA n= 284
HRT-GPS n= 265
GDx n= 446
OCT n= 328
Disease
absent
HRT-MRA n= 13
HRT-GPS n= 8
GDx n= 7
OCT n= 4
Figure 7  Flow diagram: diagnostic sensitivity analysis 4 
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Table 25  Diagnostic performance: diagnosis sensitivity analysis 4 
Test Diagnostic 
parameter 
Point 
Estimate 
95% CI 
Lower  Upper  
HRT-MRA Sensitivity % 89.2 85.7 92.1 
 Specificity % 55.1 50.7 59.5 
 
Positive Likelihood 
Ratio 
1.99 1.80 2.20 
 
Negative Likelihood 
Ratio 
0.20 0.15 0.26 
 DOR 10.19 7.08 14.66 
HRT-GPS Sensitivity % 87.2 83.5 90.3 
 Specificity % 51.0 46.6 55.3 
 
Positive Likelihood 
Ratio 
1.78 1.62 1.96 
 
Negative Likelihood 
Ratio 
0.25 0.19 0.33 
 DOR 7.09 5.04 9.97 
GDx Sensitivity % 41.9 37.0 47.0 
 Specificity % 85.6 82.3 88.5 
 
Positive Likelihood 
Ratio 
2.91 2.29 3.70 
 
Negative Likelihood 
Ratio 
0.68 0.62 0.74 
 DOR 4.29 3.13 5.89 
OCT Sensitivity % 69.9 65.2 74.4 
 Specificity % 62.6 58.3 66.7 
 
Positive Likelihood 
Ratio 
1.87 1.64 2.12 
 
Negative Likelihood 
Ratio 
0.48 0.41 0.57 
 DOR 3.89 2.95 5.14 
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Diagnosis sensitivity analysis 5 
Diagnosis sensitivity analysis 5 differed from the default analysis in that the imaging 
test related ‘no result’ cases were all classified as an abnormal result.  
For sensitivity analysis 5, abnormal imaging test results were those classified as 
‘outside normal limits’ and the corresponding reference standard definition of disease 
was a diagnosis of glaucoma in the ‘worse’ eye. The analysis included participants 
with a low quality imaging output if a classification was given; other imaging test 
results which did not provide an overall classification were included as abnormal . 
 
The flow of study participants according to sensitivity analysis 5 is shown in Figure 8 
with respective number of abnormal, normal and ‘no result’ cases by imaging test, and 
the corresponding reference standard finding shown. Of the 943 patients for whom all 
four tests were performed, 158 were classified as disease positive and 770 as disease 
negative. The reference standard was missing and inconclusive for 11 and 4 
participants respectively. The diagnostic performance for the four tests is given in 
Table 26. Results showed a trade-off between detection of glaucoma and correctly 
identifying non-glaucoma cases: HRT-MRA had the highest sensitivity (87.3%, 95% 
CI (81.0,92.0)) but lowest specificity (61.8%, 95% CI (58.2,65.3)), GDx had the 
lowest sensitivity (37.6%, 95% CI (30.0,45.7)) but the highest specificity (95.4%, 
95% CI (93.7,96.8)), and the other two tests providing intermediate results (HRT-GPS 
values were very similar to the HRT-MRA results, and OCT had very similar 
sensitivity and specificity values). Likelihood ratios (and 95% CI) showed evidence of 
both being able to rule in and out the presence of glaucoma for all 4 imaging tests (CIs 
did not contain 1.0). DORs ranged from 8.96 for HRT-GPS to 12.47 for GDx.  
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Figure 4.6  Flow diagram: diagnostic sensitivity analysis 5 
Reference standard definition: glaucoma
Test abnormal: outside normal limits
Handling of no result: A imaging classification used 
B-D abnormal
E excluded
Abnormal result
HRT-MRA n= 429
HRT-GPS n= 400
GDx n= 96
OCT n= 305
Normal result
HRT-MRA n= 483
HRT-GPS n= 527
GDx n= 829
OCT n= 626
No result
HRT-MRA n= 31
HRT-GPS n= 16
GDx n= 18
OCT n= 12
No reference standard
HRT-MRA n= 3
HRT-GPS n= 2
GDx n= 1
OCT n= 2
No reference standard
HRT-MRA n= 1
HRT-GPS n= 2
GDx n= 3
OCT n= 2
No reference standard
HRT-MRA n= 7
HRT-GPS n= 7
GDx n= 7
OCT n= 7
Reference standard
HRT-MRA n= 24
HRT-GPS n= 9
GDx n= 11
OCT n= 5
Reference standard
HRT-MRA n= 426
HRT-GPS n= 398
GDx n= 95
OCT n= 303
Reference standard
HRT-MRA n= 482
HRT-GPS n= 525
GDx n= 826
OCT n= 624
Inconclusive 
reference standard
HRT-MRA n= 3
HRT-GPS n= 0
GDx n= 1
OCT n= 1
Inconclusive 
reference standard
HRT-MRA n= 0
HRT-GPS n= 4
GDx n= 3
OCT n= 3
Inconclusive 
reference standard
HRT-MRA n= 1
HRT-GPS n= 0
GDx n= 0
OCT n= 0
Disease
present (TP)
HRT-MRA n= 137
HRT-GPS n= 131
GDx n= 59
OCT n= 123
Disease
present (FN)
HRT-MRA n= 20
HRT-GPS n= 27
GDx n= 98
OCT n= 35
Disease
absent (FP)
HRT-MRA n= 286
HRT-GPS n= 267
GDx n= 35
OCT n= 179
Disease
present 
HRT-MRA n= 1
HRT-GPS n= 0
GDx n= 1 
OCT n= 0
Disease
absent (TN)
HRT-MRA n= 462
HRT-GPS n= 494
GDx n= 725
OCT n= 586
Disease
absent
HRT-MRA n= 22
HRT-GPS n= 9
GDx n= 10
OCT n=5
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• Withdrawn = 1
Available for index test
n= 955
Completed all four index tests
n= 943
Imaging not performed for all four index 
tests
n= 12
Figure 8  Flowdiagram: diagnostic sensitivity analysis 5 
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Table 26  Diagnostic performance: diagnosis sensitivity analysis 5 
Test Diagnostic 
parameter 
Point 
Estimate 
95% CI 
Lower  Upper  
HRT-MRA Sensitivity % 87.3 81.0 92.0 
 Specificity % 61.8 58.2 65.3 
 
Positive Likelihood 
Ratio 
2.28 2.05 2.54 
 
Negative Likelihood 
Ratio 
0.21 0.14 0.31 
 DOR 11.07 6.77 18.09 
HRT-GPS Sensitivity % 82.9 76.1 88.4 
 Specificity % 64.9 61.4 68.3 
 
Positive Likelihood 
Ratio 
2.36 2.10 2.66 
 
Negative Likelihood 
Ratio 
0.26 0.19 0.37 
 DOR 8.96 5.78 13.94 
GDx Sensitivity % 37.6 30.0 45.7 
 Specificity % 95.4 93.7 96.8 
 
Positive Likelihood 
Ratio 
8.16 5.57 11.95 
 
Negative Likelihood 
Ratio 
0.65 0.58 0.74 
 DOR 12.47 7.81 19.2 
OCT Sensitivity % 77.8 70.6 84.1 
 Specificity % 76.6 73.4 80.0 
 
Positive Likelihood 
Ratio 
3.33 2.86 3.88 
 
Negative Likelihood 
Ratio 
0.29 0.22 0.39 
 DOR 11.50 7.63 17.35 
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Diagnosis sensitivity analysis 6 
Diagnosis sensitivity analysis 6 differed from the default analysis in that the diagnosis 
of the participants’ ‘best’ eye according to the reference standard was used. Abnormal 
imaging test results were those classified as ‘outside normal limits’ and the 
corresponding reference standard definition of disease was a diagnosis of glaucoma. 
Only participants with an imaging test output with an overall classification which met 
the manufacturer quality cut-off were included in the analysis. 
 
The flow of study participants according to sensitivity analysis 6 is shown in Figure 9 
with respective number of abnormal, normal and ‘no result’ cases by imaging test, and 
the corresponding reference standard finding shown. Of the 943 patients for whom all 
four tests were performed, 61 were classified as disease positive and 862 as disease 
negative. The reference standard was missing and inconclusive for 12 and 8 
participants respectively. The diagnostic performance for the four tests is given in 
Table 27. Results showed a trade-off between detection of glaucoma and correctly 
identifying non-glaucoma cases: HRT-GPS had the highest sensitivity (82.4%, 95% 
CI (69.1,91.6)) but also the second lowest specificity (67.8%, 95% CI (64.5,77.1)), 
GDx had the lowest sensitivity (26.9%, 95% CI (15.6,41.0)) but the highest specificity 
(96.7%, 95% CI (95.2,97.8)), and the other two tests providing intermediate results 
(HRT-MRA had a slightly lower sensitivity and specificity than HRT-GPS but a 
slightly higher specificity, and OCT had the second lowest sensitivity but the second 
highest specificity values). Sensitivity was slight lower for all HRT-MRA, GDx and 
OCT than under the default analysis but with a slightly higher specificity. HRT-GPS 
has very similar results to before. Likelihood ratios (and 95% CI) showed evidence of 
both being able to rule in and out the presence of glaucoma for all 4 imaging tests (CIs 
did not contain 1.0). DORs ranged from 6.85 for MRA to 10.83 for GDx.  
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Reference standard definition: glaucoma in ‘best eye’
Test abnormal: outside normal limits
Handling of no result: A imaging classification used 
B-D abnormal
E excluded
Abnormal result
HRT-MRA n= 324
HRT-GPS n= 301
GDx n= 42
OCT n= 205
Normal result
HRT-MRA n= 540
HRT-GPS n= 555
GDx n= 809
OCT n= 687
No result
HRT-MRA n= 79
HRT-GPS n= 87
GDx n= 92
OCT n= 51
No reference standard
HRT-MRA n= 3
HRT-GPS n= 2
GDx n= 1
OCT n= 2
No reference standard
HRT-MRA n= 1
HRT-GPS n= 2
GDx n= 3
OCT n= 2
No reference standard
HRT-MRA n= 8
HRT-GPS n= 8
GDx n= 8
OCT n= 8
Reference standard
HRT-MRA n= 71
HRT-GPS n= 79
GDx n= 84
OCT n= 43
Reference standard
HRT-MRA n= 321
HRT-GPS n= 299
GDx n= 41
OCT n= 203
Reference standard
HRT-MRA n= 539
HRT-GPS n= 553
GDx n= 806
OCT n= 685
Inconclusive 
reference standard
HRT-MRA n= 4
HRT-GPS n= 1
GDx n= 1
OCT n= 2
Inconclusive 
reference standard
HRT-MRA n= 3
HRT-GPS n= 4
GDx n= 4
OCT n= 4
Inconclusive 
reference standard
HRT-MRA n= 1
HRT-GPS n= 3
GDx n= 3
OCT n= 2
Disease
present (TP)
HRT-MRA n= 43
HRT-GPS n= 42
GDx n= 14
OCT n= 39
Disease
present (FN)
HRT-MRA n= 12
HRT-GPS n= 9
GDx n= 38
OCT n= 16
Disease
absent (FP)
HRT-MRA n= 274
HRT-GPS n= 256
GDx n= 26
OCT n= 162
Disease
present 
HRT-MRA n= 6
HRT-GPS n= 10
GDx n= 9
OCT n= 6
Disease
absent (TN)
HRT-MRA n= 524
HRT-GPS n= 540
GDx n= 764
OCT n= 665
Disease
absent
HRT-MRA n= 64
HRT-GPS n= 66
GDx n= 72
OCT n=35
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• Withdrawn = 1
Available for index test
n= 955
Completed all four index tests
n= 943
Imaging not performed for all four index 
tests
n= 12
Figure 9  Flow diagram: diagnostic sensitivity analysis 6 
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Table 27  Diagnostic performance: diagnosis sensitivity analysis 6 
Test Diagnostic 
parameter 
Point 
Estimate 
95% CI 
Lower  Upper  
HRT-MRA Sensitivity % 78.2 65.0 88.2 
 Specificity % 65.7 62.3 69.0 
 
Positive Likelihood 
Ratio 
2.28 1.92 2.70 
 
Negative Likelihood 
Ratio 
0.33 0.20 0.55 
 DOR 6.85 3.55 13.21 
HRT-GPS Sensitivity % 82.4 69.1 91.6 
 Specificity % 67.8 64.5 71.1 
 
Positive Likelihood 
Ratio 
2.56 2.18 3.01 
 
Negative Likelihood 
Ratio 
0.26 0.14 0.47 
 DOR 9.84 4.72 20.53 
GDx Sensitivity % 26.9 15.6 41.0 
 Specificity % 96.7 95.2 97.8 
 
Positive Likelihood 
Ratio 
8.18 4.55 14.70 
 
Negative Likelihood 
Ratio 
0.76 0.64 0.89 
 DOR 10.83 5.23 22.39 
OCT Sensitivity % 70.9 57.1 82.4 
 Specificity % 80.4 77.5 83.1 
 
Positive Likelihood 
Ratio 
3.62 2.91 4.50 
 
Negative Likelihood 
Ratio 
0.36 0.24 0.55 
 DOR 10.01 5.45 18.35 
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Combinations of imaging tests 
HRT-MRA was combined with the other imaging test to form three combined tests 
and the diagnostic performance assessed. The reference standard and the definition of 
an abnormal imaging test result was the same as for the default analysis (abnormal 
imaging test ‘outside normal limits’; reference standard diagnosis of glaucoma in the 
‘worse’ eye; and only participants with an imaging test output with an overall 
classification which met the manufacturer quality cut-off were included in the 
analysis.). The corresponding flow of study participants is shown in Figure 10 with 
respective number of abnormal, normal and no results cases by combination imaging 
test, and the corresponding reference standard finding shown.  The diagnostic 
performance for the four tests is given in Table 27. Results showed a trade-off 
between detection of glaucoma and correctly identifying non-glaucoma cases: HRT-
MRA combined with OCT had the highest sensitivity (91.7%, 95% CI (85.7, 95.8)) 
but the second lowest specificity (53.8%, 95% CI (50.0,57.5)), HRT-MRA combined 
with GDx had the lowest sensitivity (89.5%, 95% CI (82.7,94.3)) but the highest 
specificity (62.8%, 95% CI (59.0,66.5)). Likelihood ratios (and 95% CI) showed 
evidence of both being able to rule in and out the presence of glaucoma all 3 
combination imaging tests (CIs did not contain 1.0). DORs ranged from 11.34 for 
HRT-MRA combined with HRT-GPS, to 14.43 for HRT-MRA combined with GDx.  
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Reference standard definition: glaucoma
Test abnormal: outside normal limits
Handling of no result: A-E excluded
Abnormal result
HRT-GPS+HRT-MRA n= 457
HRT-MRA+OCT n= 447
HRT-MRA+GDx n= 365
Normal result
HRT-GPS+HRT-MRA n= 380
HRT-MRA+OCT n= 383
HRT-MRA+GDx n= 433
No result
HRT-GPS+HRT-MRA n= 106
HRT-MRA+OCT n= 113
HRT-MRA+GDx n= 145
No reference standard
HRT-GPS+HRT-MRA n=  3
HRT-MRA+OCT n= 3
HRT-MRA+GDx n= 3
No reference standard
HRT-GPS+HRT-MRA(HRT) n= 1
HRT-MRA+OCT n= 1
HRT-MRA+GDx n= 1
No reference standard
HRT-GPS+HRT-MRA n= 7
HRT-MRA+OCT n= 7
HRT-MRA+GDx n= 7
Reference standard
HRT-GPS+HRT-MRA n=99
HRT-MRA+OCT n=106
HRT-MRA+GDx n= 138
Reference standard
HRT-GPS+HRT-MRA n= 454
HRT-MRA+OCT n= 444
HRT-MRA+GDx n= 362
Reference standard
HRT-GPS+HRT-MRA n= 379
HRT-MRA+OCT n= 382
HRT-MRA+GDx n= 432
Inconclusive reference 
standard
HRT-GPS+HRT-MRA n= 3
HRT-MRA+OCT n= 3
HRT-MRA+GDx n= 3
Inconclusive reference 
standard
HRT-GPS+HRT-MRA n= 0
HRT-MRA+OCT n= 0
HRT-MRA+GDx n= 0
Inconclusive 
reference standard
HRT-GPS+HRT-MRA n= 1
HRT-MRA+OCT n= 1
HRT-MRA+GDx n= 1
Disease
present (TP)
HRT-GPS+HRT-MRA
n= 122
HRT-MRA+OCT 
n= 122
HRT-MRA+GDx
n= 111
Disease
present (FN)
HRT-GPS+HRT-MRA 
n= 12
HRT-MRA+OCT
n= 11
HRT-MRA+GDx
n= 13
Disease
absent (FP)
HRT-GPS+HRT-MRA 
n= 329
HRT-MRA+OCT 
n= 319
HRT-MRA+GDx
n= 248
Disease
present
HRT-GPS+HRT-MRA 
n= 24
HRT-MRA+OC
n= 25
HRT-MRA+GDx
n= 34
Disease
absent (TN)
HRT-GPS+HRT-MRA 
n= 367
HRT-MRA+OCT
n= 371
HRT-MRA+GDx
n= 419
Disease
absent
HRT-GPS+HRT-MRA 
n= 74
HRT-MRA+OCT 
n= 80
HRT-MRA+GDx
n= 103
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• Withdrawn = 1
Available for index test
n= 955
Completed all four index tests
n= 943
Imaging not performed for all four index 
tests
n= 12
Figure 10  Flow diagram: combination of imaging tests 
71 
 
Table 28  Diagnostic performance: diagnostic performance of test combinations 
Test Diagnostic 
parameter 
Point 
Estimate 
95% CI 
Lower  Upper  
HRT-MRA + 
HRT-GPS 
Sensitivity % 91.0 84.9 95.3 
 Specificity % 52.7 48.9 56.5 
 
Positive Likelihood 
Ratio 
1.93 1.75 2.12 
 
Negative 
Likelihood Ratio 
0.17 0.10 0.29 
 DOR 11.34 6.15 20.90 
HRT-MRA + 
GDx 
Sensitivity % 89.5 82.7 94.3 
 Specificity % 62.8 59.0 66.5 
 
Positive Likelihood 
Ratio 
2.41 2.14 2.70 
 
Negative 
Likelihood Ratio 
0.17 0.10 0.28 
 DOR 14.43 7.95 26.17 
HRT-MRA + 
OCT 
Sensitivity % 91.7 85.7 95.8 
 Specificity % 53.8 50.0 57.5 
 
Positive Likelihood 
Ratio 
1.98 1.80 2.18 
 
Negative 
Likelihood Ratio 
0.15 0.09 0.27 
 DOR 12.90 6.84 24.34 
 
Discussion 
The diagnostic performance of four imaging tests (HRT-MRA, HRT-GPS, GDx and 
OCT) for the detection of glaucoma was compared for the GATE population of 
referrals to a glaucoma clinic in secondary care. The sensitivity and specificity of the 
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four imaging tests for the default diagnosis analysis and sensitivity analyses (see table 
15 for details) are summarised in Figure 11 and 12 respectively.  
 
 
Figure 11  Summary of the sensitivity of imaging tests across all diagnosis 
analyses 
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Figure 12  Summary of the specificity of imaging tests across all diagnosis 
analyses 
 
All four imaging tests had some value in terms of ruling in and ruling out the presence 
of glaucoma. However, the diagnostic performance of the imaging tests differed in the 
ability to correctly diagnose glaucoma (sensitivity) and non-glaucoma cases 
(specificity). HRT-MRA had the highest sensitivity across analyses, except when the 
reference standard diagnosis was moderate and severe glaucoma only, when HRT-
GPS was higher, but at a cost of lower specificity compared to other tests. In contrast 
GDx had consistently the best specificity though the lowest sensitivity. HRT-GPS 
results were typically similar to HRT-MRA as might be anticipated given that their 
analysis is based on the same imaging machine. Sensitivity for OCT was generally of 
a similar magnitude to its specificity.  When the reference standard definition of 
disease excluded mild glaucoma, OCT provided higher diagnostic performance than 
the HRT-GPS and HRT-MRA with GDx providing the best specificity. The choice of 
which imaging test is to be preferred reflects the inherent trade off regarding 
diagnostic testing where the desire not to miss glaucoma when present must be 
balanced again the desire to correctly identify those who are without disease. 
74 
 
The non-diagnostic outcomes tended to favour OCT. OCT had the lowest number of 
low quality imaging results, with GDx having the highest. Average time taken to 
conduct the tests was lowest for OCT with the other tests taking a similar length of 
time. Less dilation was required for OCT followed by GDx than the HRT tests. 
Considering the time taken and need for dilation, patient preference tended to favour 
OCT followed by GDx although almost half of participants did not have a preference.  
 
GATE was a large prospective paired diagnostic study and provided diagnostic tests 
in this desired setting. This is reflected in the precision in which the sensitivity and 
specificity were calculated with differences between every pair of tests identified for 
one if not both the sensitivity and specificity. McNemar’s test was used to compare 
the sensitivity and specificity of the tests. Following the rationale of others in 
effectiveness studies, the paired comparisons were not adjusted for multi-
comparisons. Even if such a correction were to have been applied such was the 
strength of evidence there would still be evidence of differences in the diagnostic 
performance of the different imaging tests.  
 
A number of sensitivity analyses were carried out to assess the robustness of the 
findings of the default analysis. Varying the test definition of an abnormal imaging 
result by including the borderline category was carried out; this had the anticipated 
impact of improving the detection of glaucoma, though at the expense of more non-
glaucoma cases being falsely classified to have glaucoma. This resulted in very high 
detection of glaucoma for HRT-MRA, HRT-GPS and OCT but with low to moderate 
diagnosis of non-glaucoma cases. GDx provided moderate performance for both 
detecting glaucoma and correctly diagnosing non-glaucoma cases. Additionally, the 
impact of also seeking to diagnose glaucoma suspects (based upon optic disc and/or 
visual field findings as described in Chapter 2) was assessed both with and without 
classifying borderline imaging findings as abnormal. When the test definition of 
abnormal incorporated the borderline category, the net impact was a slight increase in 
sensitivity for GDx, HRT-GPS and HRT-MRA, with OCT slightly reduced compared 
to the default analysis, suggesting that the OCT test deals less well with glaucoma 
suspect cases. The diagnostic performance upon the best eye as opposed to the worse 
eye gave similar results though with generally a lower sensitivity and slightly higher 
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specificity. HRT-GPS diagnostic performance for this data was remarkably similar to 
when the worse eye was used.  
 
Finally, the impact of using a combination of tests was assessed. Given the findings of 
the default diagnosis analysis and associated sensitivity analyses, this was restricted to 
an assessment of whether using another imaging test in addition to HRT-MRA 
appeared to be beneficial. While the additional use of another test led to improved 
detection of glaucoma, the improvement was marginal and smaller than the loss in 
terms of the handling of non-diseased cases. While the use of two tests in combination 
did have some benefit in terms of reducing the number of no result cases, the change 
in diagnostic performance coupled with the additional practical and cost implications 
in terms of training and staff time and an additional requirement of equipment (for 
two of the three combinations) suggest that the use of a single test is to be preferred.  
 
A number of assumptions underpinned the analysis and interpretation of the results. 
Most importantly the reference standard was assumed to be perfect though it is widely 
recognised that diagnosis of glaucoma is difficult and uncertainty exists even amongst 
specialists. While consensus was sought through structured training, some assessor 
differences may have remained between the sites. Additionally, the diagnosis and 
clinical management of patients with suspected glaucoma is uncertain; in particular 
the risk of conversion of such individuals is not known. Nevertheless, the findings 
provide evidence reflective of current clinical practice in NHS glaucoma clinics.  
A number of areas for further research are clear. Further investigation of varying the 
results of the imaging tests beyond the standard options could be undertaken as the 
recommended classification may not the one best suited to the population which 
GATE recruited from. The definition and clinical management of glaucoma suspects 
is also an area in which further research is needed, in particular quantifying the 
proportion which will convert or will be discharged from clinical care over 
subsequent years. Finally, the diagnosis value of using an imaging test explicitly in a 
triage scenario with the additional use of an IOP measurement and visual acuity to 
form a composite triage test requires evaluation.
76 
 
Chapter 5  Triage analysis results 
 
Overview 
The chapter reports the results of the triage analyses which aimed to assess the 
diagnostic performance of the four imaging tests in a triage setting. The specific 
diagnostic performance analyses covered in this chapter are the default triage analysis 
along with eight sensitivity analyses (triage sensitivity analyses 1-8 – see Table 29) 
for a list with definitions. A further set of three analyses specifically to inform the 
economic model are in Appendix 7. The default triage analysis was defined as one 
where the reference standard was the person level clinical decision (“not discharged” 
or “discharged”). The test was defined as categorising a patient as requiring to be 
referred on (“For referral”) if any of the elements of the composite triage test 
(Imaging, IOP and/or visual acuity) were themselves “abnormal”: imaging outside 
normal limits on the overall classification of the respective imaging test (see Chapter 
2), IOP>21mmHg or visual acuity of 6/12 or poorer under the default triage analysis. 
 
Cases where the imaging test did not produce an overall classification or where 
quality was poor were also defined as imaging test being abnormal and therefore “For 
referral”. The eight sensitivity analyses assessed the impact of varying assumptions 
made in the default triage analysis relating to the definition of a positive test result, 
modifying or removing the IOP and/or visual acuity components of the triage test, and 
how cases where the test did not produce an overall classification were handled in the 
analysis.  
 
The analyses in this chapter pertain to the 943 participants remaining in the study (see 
Chapter 4). The reference standard was available for 933 cases. For all analyses, a 
STARD diagram shows the flow of participants. The subset of participants who 
received all four tests and were considered in the statistical analyses are separated out 
into three groups according to whether each triage test result was “abnormal”, 
“normal”, or “no result” (the triage test result was not available whether because the 
test was inconclusive or the result was missing). For each of these three groups the 
group status according to the reference standard (“discharged” or “not discharged”) 
for each participant is given or alternatively the reference standard was stated to be 
77 
 
missing or inconclusive. The final categorisations of the triage test result by reference 
standard status provides the four possible combinations (true and false positive, false 
and true negative) from which the diagnostic performance was assessed.  Sensitivity, 
specificity, likelihood ratios and DOR are provided with associated 95% CIs for each 
analysis. 
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Table 29  Triage analyses 
Analysis Reference standard 
definition 
Test abnormal Handling of no result 
categories 
Figure no. Table no. 
Default triage Analysis Not discharged Imaging (outside normal 
limits) or IOP>21mmHg 
or VA6/12 or poorer 
A-D for referral  
E excluded 
13 30, 31 
Triage sensitivity analysis 1 Not discharged Imaging (outside normal 
limits or borderline) or 
IOP>21mmHg or 
VA6/12 or poorer 
A-D for referral  
E excluded 
14 32 
Triage sensitivity analysis 2 Not discharged Imaging (outside normal 
limits) or IOP>21mmHg 
or VA6/12 or poorer 
A use imaging classification 
B for referral 
C-E excluded 
15 33 
Triage sensitivity analysis 3 Not discharged Imaging (outside normal 
limits or borderline) or 
IOP>21mmHg or 
VA6/12 or poorer 
A use imaging classification 
B for referral 
C-E excluded 
16 34 
Triage sensitivity analysis 4 Not discharged Imaging (outside normal 
limits) or IOP>21mmHg 
(Referred IOP) or 
VA6/12 or poorer 
A-D for referral 
E excluded 
17 35 
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Analysis Reference standard 
definition 
Test abnormal Handling of no result 
categories 
Figure no. Table no. 
Triage sensitivity analysis 5 Not discharged Imaging (outside normal 
limits) or VA6/12 or 
poorer 
A-D for referral 
E excluded 
18 36 
Triage Sensitivity analysis 6 
 
Not discharged Imaging (outside normal 
limits) 
or IOP>21mmHg 
A-D for referral 
E excluded 
19 37 
Triage sensitivity analysis 7 
 
Not discharged Imaging (outside normal 
limits) or IOP>26mmHg 
or VA6/12 or poorer 
A-D for referral 
E excluded 
20 38 
Triage sensitivity analysis 8 
 
Not discharged Imaging (outside normal 
limits) or IOP>21mmHg 
or VA6/18 or poorer 
A-D for referral 
E excluded 
21 39 
No result categories  
A: test performed and imaging report produced but quality is lower than manufacturer quality cut-off 
B: test performed and imaging report produced but no overall classification generated by machine 
C: test performed but there was a clear imaging artefact on the report 
D: test attempted but no imaging could be acquired from the patient’s eyes – no report generated 
E: missing imaging (due to study related or data collection issues)  
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Default triage analysis 
The results for the default triage analysis are presented in two sections: 
• diagnostic performance of the triage tests, and 
• paired comparisons of triage tests. 
 
Diagnostic performance of the triage tests 
For the default triage analysis, the triage test is classified as abnormal if (a) the 
imaging test result is classified as ‘outside normal limits’ OR (b) IOP>21mmHg OR 
(c) visual acuity is 6/12 or poorer. Imaging test results which did not provide an 
overall classification were included as abnormal. The corresponding reference 
standard definition is a clinical decision not to discharge the patient. 
 
The flow of study participants according to the default triage analysis is shown in 
Figure 13 with respective numbers of referral, not for referral and no result cases by 
triage test, and the corresponding reference standard finding shown. Of the 933 
participants for whom all four tests were performed, 576 were not discharged and 357 
were discharged. The discharge status was missing for 10 participants. The diagnostic 
performance for the four tests is given in Table 30. Results showed a trade-off 
between detection of patients who need to be referred and discharging those who do 
not need to be referred: HRT-GPS had the highest sensitivity (86.0%, 95% CI 
(82.8,88.7)) but lowest specificity (39.1%, 95% CI (34.0,44.5)), GDx had the lowest 
sensitivity (64.7%, 95% CI (60.7,68.7)) but the highest specificity (53.6%, 95% CI 
(48.2,58.9)), and the other two tests provided intermediate results (HRT-MRA values 
were very similar to the HRT-GPS results, and OCT had lower sensitivity 75.4%, 
95% CI (71.9,78.9)) but higher specificity values than HRT-GPS and HRT-MRA). 
Likelihood ratios (and 95% CI) showed evidence of both being able to rule in and out 
the presence of glaucoma for all 4 triage tests (CIs did not contain 1.0). DORs ranged 
from 2.12 for GDx and OCT to 3.94 for HRT-GPS.  
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Completed composite index test (imaging+IOP+VA)
n=943
For referral
IOP+VA+MRA(HRT) n=711
IOP+VA+GPS (HRT) n=708
IOP+VA+GDx n=535
IOP+VA+OCT n=643
Not for referral
IOP+VA+MRA(HRT) n=202
IOP+VA+GPS (HRT) n= 221
IOP+VA+GDx n=394
IOP+VA+OCT n=290
No result
IOP+VA+MRA(HRT) n=30
IOP+VA+GPS (HRT) n= 14
IOP+VA+GDx n=14
IOP+VA+OCT n=10
No reference standard
IOP+VA+MRA n=5
IOP+VA+GPS n=5
IOP+VA+GDx n=4
IOP+VA+OCT n=5
No reference standard
IOP+VA+MRA n=4
IOP+VA+GPS n= 4
IOP+VA+GDx n=6
IOP+VA+OCT n=5
No reference standard
IOP+VA+MRA n= 1
IOP+VA+GPS n=1
IOP+VA+GDx n=0
IOP+VA+OCT n=0
Reference standard
IOP+VA+MRA n=29
IOP+VA+GPS  n=13
IOP+VA+GDx n=14
IOP+VA+OCT n=10
Reference standard
IOP+VA+MRA n=706
IOP+VA+GPS n=703
IOP+VA+GDx n=531
IOP+VA+OCT n=638
Reference standard
IOP+VA+MRA n=198
IOP+VA+GPS  n=217
IOP+VA+GDx n=388
IOP+VA+OCT n=285
NOT DISCHARGED 
(TP)
IOP+VA+MRA n=481
IOP+VA+GPS  n=490
IOP+VA+GDx n=369
IOP+VA+OCT n=429
NOT DISCHARGED 
(FN)
IOP+VA+MRA n=81
IOP+VA+GPS  n=80
IOP+VA+GDx n=201
IOP+VA+OCT n=140
DISCHARGED 
(FP)
IOP+VA+MRA n=225
IOP+VA+GPS  n=213
IOP+VA+GDx n=162
IOP+VA+OCT n=209
NOT DISCHARGED
IOP+VA+ MRA n=14
IOP+VA+GPS  n=6
IOP+VA+GDx n=6
IOP+VA+OCT n=7
DISCHARGED 
(TN)
IOP+VA+MRA n=117
IOP+VA+GPS  n=137
IOP+VA+GDx n=187
IOP+VA+OCT n=145
DISCHARGED
IOP+VA+MRA n=15
IOP+VA+GPS  n=7
IOP+VA+GDx n=8
IOP+VA+OCT n=3
Reference standard definition: not discharged
For referral: imaging (outside normal limits) or IOP 
>21mmHg or VA 6/12 or poorer
Handling of no result categories: A-D For referral
E excluded
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• withdrawn = 1
Available for index test
n= 955
Imaging not performed for all four index tests
n= 12
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Figure 13  Flow diagram: default triage analysis  
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Table 30  Diagnostic performance: default triage analysis 
 
  
Test Parameter Value 95% CI 
Lower  Upper  
HRT-MRA Sensitivity - %  85.6 82.4 88.4 
 Specificity - %  34.2 29.20 39.5 
 Positive Likelihood Ratio 1.3 1.20 1.41 
 Negative Likelihood Ratio 0.4 0.33 0.54 
 DOR 3.09 2.23 4.27 
HRT-GPS Sensitivity - %  86.0 82.8 88.7 
 Specificity - %  39.1 34.0 44.5 
 Positive Likelihood Ratio 1.41 1.29 1.55 
 Negative Likelihood Ratio 0.36 0.28 0.46 
 DOR 3.94 2.86 5.42 
GDx Sensitivity - %  64.7 60.7 68.7 
 Specificity - %  53.6 48.2 58.9 
 Positive Likelihood Ratio 1.39 1.23 1.59 
 Negative Likelihood Ratio 0.66 0.57 0.76 
 DOR 2.12 1.62 2.78 
OCT Sensitivity - %  75.4 71.6 78.9 
 Specificity - %  41.0 35.8 46.3 
 Positive Likelihood Ratio 1.28 1.16 1.41 
 Negative Likelihood Ratio 0.60 0.50 0.73 
 DOR 2.13 1.60 2.83 
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Paired comparisons of imaging tests 
Table 31 shows the paired difference (with 95% CI) and corresponding McNemar’s 
tests p-value for comparisons between pairs of tests. There was evidence that the 
sensitivity of all tests differed from each other except for HRT-GPS versus HRT-
MRA.  
 
HRT-GPS, HRT-MRA and GDx had the highest and lowest sensitivity respectively. 
Differences varied from 0.2% (HRT-GPS versus HRT-MRA) to 19.7 %. (HRT-GPS 
versus GDx). Similarly there was evidence that specificities for all the tests varied 
from each other (according to McNemar’s test) except HRT-GPS versus OCT. 
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Table 31  Paired comparisons of sensitivity and specificity between the triage 
tests 
Tests 
Compared 
Parameter  
 
Test  Value - % (95% CI) p-value 
(McNemar’s) 
HRT-GPS vs   Sensitivity HRT-GPS 85.8 (82.9 to 88.7)  
GDx  GDx 64.5 (60.6 to 68.5)  
  Difference 21.3 (17.7 to 24.9) <.0001 
 Specificity HRT-GPS 39.6 (34.4 to 44.7)  
  GDx 53.8 (48.5 to 59.0)  
  Difference -14.2 (-19.0 to -9.2) <.0001 
GDx vs   Sensitivity GDx 64.8 (60.9 to 68.8)  
OCT  OCT 75.1 (71.6 to 78.7)  
  Difference -10.3 (-13.5 to -7.0) <.0001 
 Specificity GDx 53.4 (48.2 to 58.7)  
  OCT 41.1 (35.9 to 46.3)  
  Difference 12.4 (7.9 to 16.7) <.0001 
GDx vs   Sensitivity GDx 64.9 (61.0 to 68.9)  
HRT-MRA  HRT-MRA 85.4 (82.5 to 88.4)  
  Difference -20.5 (-24.3 to -16.7) <.0001 
 Specificity GDx 53.3 (47.9 to 58.6)  
  HRT-MRA 34.3 (29.3 to 39.4)  
  Difference 18.9 (13.8 to 23.9) <.0001 
HRT-GPS vs   Sensitivity HRT-GPS 85.7 (82.8 to 88.6)  
HRT-MRA  HRT-MRA 85.5 (82.6 to 88.4)  
  Difference 0.2 (-2.4 to 2.8) 0.8907 
 Specificity HRT-GPS 39.3 (34.1 to 44.5)  
  HRT-MRA 34.3 (29.3 to 39.3)  
  Difference 5.0 (0.3 to 9.6) <.0001 
HRT-MRA vs   Sensitivity HRT-MRA 85.6 (82.7 to 88.5)  
OCT  OCT 75.2 (71.6 to 78.8)  
  Difference 10.4 (7.1 to 13.8) <.0001 
 Specificity HRT-MRA 34.2 (29.2 to 39.2)  
  OCT 40.9 (35.7 to 46.1)  
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Tests 
Compared 
Parameter  
 
Test  Value - % (95% CI) p-value 
(McNemar’s) 
  Difference -6.7 (-12.2 to -1.2) 0.0171 
HRT-GPS vs   Sensitivity HRT-GPS 86.1 (83.2 to 88.9)  
OCT  OCT 75.3 (71.8 to 78.9)  
  Difference 10.8 (7.4 to 14.2) <.0001 
 Specificity HRT-GPS 39.1 (34.0 to 44.3)  
  OCT 41.1 (36.0 to 46.3)  
  Difference -2.0 (-7.4 to 3.5) 0.4726 
 
Triage sensitivity analysis 1 
Triage sensitivity analysis 1 differed from the default triage analysis in that a 
borderline finding on the imaging test was also classified as an abnormal result.  
For triage sensitivity analysis1, the triage test is classified as abnormal if (a) the 
imaging test result is classified as ‘outside normal limits’ or ‘borderline’ OR (b) 
IOP>21mmHg OR (c) visual acuity is 6/12 or poorer. Imaging test results which did 
not provide an overall classification were included as abnormal. The corresponding 
reference standard definition is a clinical decision not to discharge the patient. 
The flow of study participants according to triage sensitivity analysis 1 is shown in 
Figure 14 with respective numbers of referral, not for referral and no result cases by 
triage test, and the corresponding reference standard finding shown. Of the 933 
participants for whom all four tests were performed, 576 were not discharged and 357 
were discharged. The discharge status was missing for 10 participants. The diagnostic 
performance for the four tests is given in Table 32. Results generally showed a trade-
off between detection of patients who need to be referred and discharging those who 
do not need to be referred: HRT-GPS had the highest sensitivity (94.0%, 95% CI 
(91.8,95.8)) but second lowest specificity (24.9%, 95% CI (20.4,29.7)), GDx had the 
lowest sensitivity (74.9%, 95% CI (71.1, 78.4))  but the highest specificity, and the 
other two tests provided intermediate results (HRT-MRA values were very similar 
though marginally inferior to the HRT-GPS results, and OCT had lower sensitivity 
(84.2%, 95% CI (80.9,87.1)) but slightly higher specificity than HRT-GPS and HRT-
MRA). Likelihood ratios (and 95% CI) showed evidence of both being able to rule in 
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and out the presence of glaucoma for all 4 triage tests (CIs did not contain 1.0). DORs 
ranged from 2.04 for OCT to 5.21 for HRT-GPS.  
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Completed composite index test (imaging+IOP+VA)
n=943
For referral
IOP+VA+MRA(HRT) n=788
IOP+VA+GPS (HRT) n=805
IOP+VA+GDx n=624
IOP+VA+OCT n=741
Not for referral
IOP+VA+MRA(HRT) n=125
IOP+VA+GPS (HRT) n= 124
IOP+VA+GDx n=305
IOP+VA+OCT n=192
No result
IOP+VA+MRA(HRT) n=30
IOP+VA+GPS (HRT) n= 14
IOP+VA+GDx n=14
IOP+VA+OCT n=10
No reference standard
IOP+VA+MRA n=7
IOP+VA+GPS n=6
IOP+VA+GDx n =5
IOP+VA+OCT n=6
No reference standard
IOP+VA+MRA n=2
IOP+VA+GPS n =3
IOP+VA+GDx n =5
IOP+VA+OCT n=4
No reference standard
IOP+VA+MRA n=1
IOP+VA+GPS n=1
IOP+VA+GDx n=0
IOP+VA+n=0
Reference standard
IOP+VA+MRA n=29
IOP+VA+GPS n=13
IOP+VA+GDx n=14
IOP+VA+OCT n=10
Reference standard
IOP+VA+MRA n=781
IOP+VA+GPS  n=799
IOP+VA+GDx n=619
IOP+VA+OCT n=735
Reference standard
IOP+VA+MRA n=123
IOP+VA+GPS n=121
IOP+VA+GDx n=300
IOP+VA+OCT n=188
NOT DISCHARGED
(TP)
IOP+VA+MRA n=521
IOP+VA+GPS n=536
IOP+VA+GDx n=427
IOP+VA+OCT n=479
NOT DISCHARGED
(FN)
IOP+VA+MRA n=41
IOP+VA+GPS  n=34
IOP+VA+GDx n=143
IOP+VA+OCT n=90
DISCHARGED
(FP)
IOP+VA+MRA n=260
IOP+VA+GPS n=263
IOP+VA+GDx n=192
IOP+VA+OCT n=256
NOT DISCHARGED
IOP+VA+ MRA n=14
IOP+VA+GPS n=6
IOP+VA+GDx n=6
IOP+VA+OCT n=7
DISCHARGED
(TN)
IOP+VA+MRA n=82
IOP+VA+GPS n=87
IOP+VA+GDx n=157
IOP+VA+OCT n=98
DISCHARGED
IOP+VA+MRA n=15
IOP+VA+GPS n=7
IOP+VA+GDx n=8
IOP+VA+OCT n=3
Reference standard definition:  not discharged
For referral: imaging (outside normal limits or 
borderline) or IOP >21mmHg or VA 6/12 or poorer
Handling of no result categories: A-D For referral
E excluded
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• withdrawn = 1
Available for index test
n= 955
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Imaging not performed for all four index tests
n= 12
Figure 14  Flow diagram: triage sensitivity analysis 1 
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Table 32  Diagnostic performance: triage sensitivity analysis 1  
Test Parameter Value 95% CI 
Lower  Upper  
HRT-MRA Sensitivity - %  92.7 90.2 94.7 
 Specificity - %  24.0 19.5 28.9 
 Positive Likelihood Ratio 1.2 1.14 1.30 
 Negative Likelihood Ratio 0.30 0.21 0.43 
 DOR 4.01 2.68 6.00 
HRT-GPS Sensitivity - %  94.0 91.8 95.8 
 Specificity - %  24.9 20.4 29.7 
 Positive Likelihood Ratio 1.25 1.17 1.33 
 Negative Likelihood Ratio 0.24 0.17 0.35 
 DOR 5.21 3.42 7.96 
GDx Sensitivity - %  74.9 71.1 78.4 
 Specificity - %  45.0 39.7 50.4 
 Positive Likelihood Ratio 1.36 1.22 1.51 
 Negative Likelihood Ratio 0.56 0.46 0.67 
 DOR 2.44 1.84 3.24 
OCT Sensitivity - %  84.2 80.9 87.1 
 Specificity - %  27.7 23.1 32.7 
 Positive Likelihood Ratio 1.16 1.08 1.51 
 Negative Likelihood Ratio 0.57 0.44 0.74 
 DOR 2.04 1.47 2.82 
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Triage sensitivity analysis 2 
Triage sensitivity analysis 2 has the same reference standard and definition of 
abnormal test result as the default analysis but did not include all ‘no result’ cases (see 
Table 33).  
 
For triage sensitivity analysis 2, the triage test is classified as abnormal if (a) the 
imaging test result is classified as ‘outside normal limits’ OR (b) IOP>21mmHg OR 
(c) visual acuity is 6/12 or poorer. Poor quality imaging test results were included, and 
those where an image was acquired but no classification generated were included as 
abnormal.  All other missing imaging results were excluded.  The corresponding 
reference standard definition is a clinical decision not to discharge the patient. 
The flow of study participants according to triage sensitivity analysis 2 is shown in 
Figure 15 with respective numbers of referral, not for referral and no result cases by 
triage test, and the corresponding reference standard finding shown. Of the 933 
participants for whom all four tests were performed, 481 were not discharged and 562 
were discharged. The discharge status was missing for 10 participants. The diagnostic 
performance for the four tests is given in Table 33. Results generally showed a trade-
off between detection of patients who need to be referred and discharging those who 
do not need to be referred: HRT-GPS had the highest sensitivity (84.6%, 95% CI 
(81.6,87.5)) but the second lowest specificity (39.7%, 95% CI (34.6,45.1)), GDx had 
the lowest sensitivity (61.1%, 95% CI (59.9,65.1)) but the highest specificity (59.0%, 
95% CI (53.7,64.2)), and the other two tests providing intermediate results (HRT-
MRA values were very similar though slightly inferior to the HRT-GPS results, and 
OCT had the second lowest sensitivity (75.0%, 95% CI (71.3,78.5)) but the second 
highest specificity (42.1%, 95% CI (36.9,47.4)) values). Likelihood ratios (and 95% 
CI) showed evidence of both being able to rule in and out the presence of glaucoma 
for all 4 triage tests (CIs did not contain 1.0). DORs ranged from 2.19 for GDx to 3.61 
for OCT.  
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For referral
IOP+VA+MRA(HRT) n=702
IOP+VA+GPS (HRT) n=698
IOP+VA+GDx n=495
IOP+VA+OCT n=637
Not for referral
IOP+VA+MRA(HRT) n=211
IOP+VA+GPS (HRT) n= 231
IOP+VA+GDx n=434
IOP+VA+OCT n=296
No result
IOP+VA+MRA(HRT) n=30
IOP+VA+GPS (HRT) n= 14
IOP+VA+GDx n=14
IOP+VA+OCT n=10
No reference standard
IOP+VA+MRA n=4
IOP+VA+GPS n=5
IOP+VA+GDx n=4
IOP+VA+OCT n=5
No reference standard
IOP+VA+MRA n=5
IOP+VA+GPS n= 4
IOP+VA+GDx n=6
IOP+VA+OCT n=5
No reference standard
IOP+VA+MRA n= 1
IOP+VA+GPS n=1
IOP+VA+GDx n=0
IOP+VA+OCT n=0
Reference standard
IOP+VA+MRA n=29
IOP+VA+GPS n=13
IOP+VA+GDx n=14
IOP+VA+OCT n=10
Reference standard
IOP+VA+MRA n=698
IOP+VA+GPS n=693
IOP+VA+GDx n=491
IOP+VA+OCT n=632
Reference standard
IOP+VA+MRA n=206
IOP+VA+GPS  n=227
IOP+VA+GDx n=428
IOP+VA+OCT n=291
NOT DISCHARGED
(TP)
IOP+VA+MRA n=474
IOP+VA+GPS n=482
IOP+VA+GDx n=348
IOP+VA+OCT n=427
NOT DISCHARGED
(FN)
IOP+VA+MRA n=88
IOP+VA+GPS n=88
IOP+VA+GDx n=222
IOP+VA+OCT n=142
DISCHARGED
(FP)
IOP+VA+MRA n=224
IOP+VA+GPS n=211
IOP+VA+GDx n=143
IOP+VA+OCT n=205
NOT DISCHARGED
IOP+VA+ MRA n=14
IOP+VA+GPS n=6
IOP+VA+GDx n=6
IOP+VA+OCT n=7
DISCHARGED
(TN)
IOP+VA+MRA n=118
IOP+VA+GPS  n=139
IOP+VA+GDx n=206
IOP+VA+OCT n=149
Reference standard definition:  not discharged
For referral:  imaging (outside normal limits) or IOP 
>21mmHg or VA 6/12 or poorer
Handling of no result categories: A classification used
B For referral
C-E excluded
Completed composite index test (imaging+IOP+VA)
n=943
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• withdrawn = 1
Available for index test
n= 955
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
DISCHARGED
IOP+VA+MRA n=15
IOP+VA+GPS n=7
IOP+VA+GDx n=8
IOP+VA+OCT n=3
Imaging not performed for all four index tests
n= 12
Figure 15  Flow diagram: triage sensitivity analysis 2 
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Table 33  Diagnostic performance: triage sensitivity analysis 2  
Test Parameter Value 95% CI 
Lower  Upper  
HRT-MRA Sensitivity - %  84.3 81.1 87.2 
 Specificity - %  34.5 29.5 39.8 
 Positive Likelihood Ratio 1.29 1.18 1.40 
 Negative Likelihood Ratio 0.45 0.36 0.58 
 DOR 2.84 2.06 3.90 
HRT-GPS Sensitivity - %  84.6 81.4 87.5 
 Specificity - %  39.7 34.6 45.1 
 Positive Likelihood Ratio 1.40 1.28 1.54 
 Negative Likelihood Ratio 0.39 0.31 0.49 
 DOR 3.61 2.64 4.93 
GDx Sensitivity - %  61.1 56.9 65.1 
 Specificity - %  59.0 53.7 64.2 
 Positive Likelihood Ratio 1.49 1.29 1.72 
 Negative Likelihood Ratio 0.66 0.58 0.76 
 DOR 2.26 1.72 2.96 
OCT Sensitivity - %  75.0 71.3 78.5 
 Specificity - %  42.1 36.9 47.4 
 Positive Likelihood Ratio 1.30 1.17 1.43 
 Negative Likelihood Ratio 0.59 0.49 0.72 
 DOR 2.19 1.65 2.90 
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Triage sensitivity analysis 3 
Triage sensitivity analysis 3 was the same as triage sensitivity analysis 2 except that 
‘borderline’ test results were also classified as abnormal.   
 
For triage sensitivity analysis 3, the triage test is classified as abnormal if (a) the 
imaging test result is classified as ‘outside normal limits’ or ‘borderline’ OR (b) 
IOP>21mmHg OR (c) visual acuity is 6/12 or poorer. Poor quality imaging test results 
were included, and those where an image was acquired but no classification generated 
were included as abnormal.  All other missing imaging results were excluded.  The 
corresponding reference standard definition is a clinical decision not to discharge the 
patient. 
 
The flow of study participants according to triage sensitivity analysis 3 is shown in 
Figure 16 with respective numbers of referral, not for referral and no result cases by 
triage test, and the corresponding reference standard finding shown. Of the 933 
participants for whom all four tests were performed, 481 were not discharged and 562 
were discharged. The discharge status was missing for 10 participants. The diagnostic 
performance for the four tests is given in Table 34. Results generally showed a trade-
off between detection of patients who need to be referred and discharging those who 
do not need to be referred: HRT-GPS had the highest sensitivity (93.3%, 95% CI 
(91.0,95.2)) but second lowest specificity (24.9%, 95% CI (20.4,29.7)), GDx had the 
lowest sensitivity (72.3%, 95% CI (68.4,75.9)) but the highest specificity (49.0%, 
95% CI (43.6,54.4)), and the other two tests providing intermediate results (HRT-
MRA values were very similar to the HRT-GPS results though slightly inferior, and 
OCT had the second lowest sensitivity (84.2%, 95% CI (80.9,87.1)) but the second 
highest specificity). Likelihood ratios (and 95% CI) showed evidence of both being 
able to rule in and out the presence of glaucoma for all 4 triage tests (CIs did not 
contain 1.0). DORs ranged from 2.12 for OCT to 4.63 for HRT-GPS. 
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For referral
IOP+VA+MRA(HRT) n=786
IOP+VA+GPS (HRT) n=801
IOP+VA+GDx n=595
IOP+VA+OCT n=738
Not for referral
IOP+VA+MRA(HRT) n=127
IOP+VA+GPS (HRT) n= 128
IOP+VA+GDx n=334
IOP+VA+OCT n=195
No result
IOP+VA+MRA(HRT) n=30
IOP+VA+GPS (HRT) n= 14
IOP+VA+GDx n=14
IOP+VA+OCT n=10
No reference standard
IOP+VA+MRA n=7
IOP+VA+GPS n=6
IOP+VA+GDx n =5
IOP+VA+OCT n=6
No reference standard
IOP+VA+MRA n=2
IOP+VA+GPS n =3
IOP+VA+GDx n =5
IOP+VA+OCT n=4
No reference standard
IOP+VA+MRA n=1
IOP+VA+GPS n=1
IOP+VA+GDx n=0
IOP+VA+OCT n=0
Reference standard
IOP+VA+MRA n=29
IOP+VA+GPS n=13
IOP+VA+GDx n=14
IOP+VA+OCT n=10
Reference standard
IOP+VA+MRA n=779
IOP+VA+GPS  n=795
IOP+VA+GDx n=590
IOP+VA+OCT n=732
Reference standard
IOP+VA+MRA n=125
IOP+VA+GPS  n=125
IOP+VA+GDx n=329
IOP+VA+OCT n=191
NOT DISCHARGED
(TP)
IOP+VA+MRA n=519
IOP+VA+GPS n=532
IOP+VA+GDx n=412
IOP+VA+OCT n=479
NOT DISCHARGED
(FN)
IOP+VA+MRA n=43
IOP+VA+GPS n=38
IOP+VA+GDx n=158
IOP+VA+OCT n=90
DISCHARGED
(FP)
IOP+VA+MRA n=260
IOP+VA+GPS n=263
IOP+VA+GDx n=178
IOP+VA+OCT n=253
NOT DISCHARGED
IOP+VA+ MRA n=14
IOP+VA+GPS n=6
IOP+VA+GDx n=6
IOP+VA+OCT n=7
DISCHARGED
(TN)
IOP+VA+MRA n=82
IOP+VA+GPS n=87
IOP+VA+GDx n=171
IOP+VA+OCT n=101
DISCHARGED
IOP+VA+MRA n=15
IOP+VA+GPS n=7
IOP+VA+GDx n=8
IOP+VA+OCT n=3
Reference standard definition:  not discharged
For referral:  imaging (outside normal limits or 
borderline or IOP >21mmHg or VA 6/12 or poorer
Handling of no result categories: A classification used
B For referral
C-E excluded
Completed composite index test (imaging+IOP+VA)
n=943
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• withdrawn = 1
Available for index test
n= 955
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Imaging not performed for all four index tests
n= 12
Figure 16  Flow diagram: triage sensitivity analysis 3 
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Table 34  Diagnostic performance: triage sensitivity analysis 3  
Test Parameter Value 95% CI 
Lower  Upper  
HRT-MRA Sensitivity - %  92.3 89.8 94.4 
 Specificity - %  24.0 19.5 28.9 
 Positive Likelihood Ratio 1.21 1.14 1.03 
 Negative Likelihood Ratio 0.32 0.23 0.45 
 DOR 3.81 2.56 5.67 
HRT-GPS Sensitivity - %  93.3 91.0 95.2 
 Specificity - %  24.9 20.4 29.7 
 Positive Likelihood Ratio 1.24 1.16 1.32 
 Negative Likelihood Ratio 0.27 0.19 0.38 
 DOR 4.63 3.08 6.97 
GDx Sensitivity - %  72.3 68.4 75.9 
 Specificity - %  49.0 43.6 54.4 
 Positive Likelihood Ratio 1.42 1.26 1.59 
 Negative Likelihood Ratio 0.57 0.48 0.67 
 DOR 2.51 1.90 3.31 
OCT Sensitivity - %  84.2 80.9 87.1 
 Specificity - %  28.5 23.9 33.5 
 Positive Likelihood Ratio 1.18 1.09 1.27 
 Negative Likelihood Ratio 0.55 0.43 0.71 
 DOR 2.12 1.54 2.93 
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Triage sensitivity analysis 4 
Triage sensitivity analysis 4 differed from the default triage analysis in that referral 
IOP >21mmHg rather than clinician IOP > 21mmHg was used to identify abnormal 
tests.  The triage test is classified as abnormal if (a) the imaging test result is classified 
as ‘outside normal limits’ OR (b) Referral IOP>21mmHg OR (c) visual acuity is 6/12 
or poorer. Imaging test results which did not provide an overall classification were 
included as abnormal. The corresponding reference standard definition is a clinical 
decision not to discharge the patient. 
 
The flow of study participants according to triage sensitivity analysis 4 is shown in 
Figure 17 with respective numbers of referral, not for referral and no result cases by 
triage test, and the corresponding reference standard finding shown. Of the 933 
participants for whom all four tests were performed, 481 were not discharged and 562 
were discharged. The discharge status was missing for 10 participants. The diagnostic 
performance for the four tests is given in Table 35. Results generally showed a trade-
off between detection of patients who need to be referred and discharging those who 
do not need to be referred: HRT-GPS had the highest sensitivity (86.5%, 95% CI 
(83.4,89.2)) but second lowest specificity (24.0%, 95% CI (19.6,28.8)), GDx had the 
lowest sensitivity (67.2%, 95% CI (63.2,71.0)) but the highest specificity (35.8%, 
95% CI (30.8,41.1)), and the other two tests providing intermediate results (HRT-
MRA values were very similar to the HRT-GPS results though slightly inferior, and 
OCT had the second lowest sensitivity (76.8%, 95% CI (73.1,80.2)) but the second 
highest specificity (27.7%, 95% CI (23.1,32.7)). Likelihood ratios (and 95% CI) 
showed evidence of both being able to rule in and out the presence of glaucoma for all 
4 triage tests (CIs did not contain 1.0). DORs ranged from 1.14 for GDx to 2.02 for 
HRT-GPS.  
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For referral
IOP+VA+MRA(HRT) n=767
IOP+VA+GPS (HRT) n=766
IOP+VA+GDx n=615
IOP+VA+OCT n=702
Not for referral
IOP+VA+MRA(HRT) n=146
IOP+VA+GPS (HRT) n= 163
IOP+VA+GDx n=314
IOP+VA+OCT n=231
No result
IOP+VA+MRA(HRT) n=30
IOP+VA+GPS (HRT) n= 14
IOP+VA+GDx n=14
IOP+VA+OCT n=10
No reference standard
IOP+VA+MRA n=7
IOP+VA+GPS n=7
IOP+VA+GDx n=8
IOP+VA+OCT n=9
No reference standard
IOP+VA+MRA n=2
IOP+VA+GPS n= 2
IOP+VA+GDx n=2
IOP+VA+OCT n=1
No reference standard
IOP+VA+MRA n= 1
IOP+VA+GPS n=1
IOP+VA+GDx n=0
IOP+VA+OCT n=0
Reference standard
IOP+VA+MRA n=29
IOP+VA+GPS n=13
IOP+VA+GDx n=14
IOP+VA+OCT n=10
Reference standard
IOP+VA+MRA n=760
IOP+VA+GPS n=759
IOP+VA+GDx n=607
IOP+VA+OCT n=693
Reference standard
IOP+VA+MRA n=144
IOP+VA+GPS n=161
IOP+VA+GDx n=312
IOP+VA+OCT n=230
NOT DISCHARGED 
(TP)
IOP+VA+MRA n=486
IOP+VA+GPS  n=493
IOP+VA+GDx n=383
IOP+VA+OCT n=437
NOT DISCHARGED
(FN)
IOP+VA+MRA n=76
IOP+VA+GPS n=77
IOP+VA+GDx n=187
IOP+VA+OCT n=132
DISCHARGED
(FP)
IOP+VA+MRA n=274
IOP+VA+GPS n=266
IOP+VA+GDx n=224
IOP+VA+OCT n=256
NOT DISCHARGED
IOP+VA+ MRA n=14
IOP+VA+GPS n=6
IOP+VA+GDx n=6
IOP+VA+OCT n=7
DISCHARGED
(TN)
IOP+VA+MRA n=68
IOP+VA+GPS n=84
IOP+VA+GDx n=125
IOP+VA+OCT n=98
DISCHARGED
IOP+VA+MRA n=15
IOP+VA+GPS  n=7
IOP+VA+GDx n=8
IOP+VA+OCT n=3
Reference standard definition:  not discharged
For referral:  imaging (outside normal limits) or 
referral IOP >21mmHg or VA 6/12 or poorer
Handling of no result categories: A-D For referral
E excluded
Completed composite index test (imaging+referral IOP+VA)
n=943  
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• withdrawn = 1
Available for index test
n= 955
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Imaging not performed for all four index tests
n= 12
Figure 17  Flow diagram: triage sensitivity analysis 4 
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Table 35  Diagnostic performance: triage sensitivity analysis 4 
Test Parameter Value 95% CI 
Lower  Upper  
HRT-MRA Sensitivity - %  86.5 83.4 89.2 
 Specificity - %  19.9 15.8 24.5 
 Positive Likelihood Ratio 1.08 1.01 1.15 
 Negative Likelihood Ratio 0.68 0.50 0.92 
 DOR 1.59 1.11 2.27 
HRT-GPS Sensitivity - %  86.5 83.4 89.2 
 Specificity - %  24.0 19.6 28.8 
 Positive Likelihood Ratio 1.14 1.06 1.22 
 Negative Likelihood Ratio 0.56 0.43 0.74 
 DOR 2.02 1.43 2.85 
GDx Sensitivity - %  67.2 63.2 71.0 
 Specificity - %  35.8 30.8 41.1 
 Positive Likelihood Ratio 1.05 0.95 1.15 
 Negative Likelihood Ratio 0.924 0.76 1.10 
 DOR 1.1 0.86 1.51 
OCT Sensitivity - %  76.8 73.1 80.2 
 Specificity - %  27.7 23.1 32.7 
 Positive Likelihood Ratio 1.06 0.98 1.15 
 Negative Likelihood Ratio 0.84 0.67 1.05 
 DOR 1.27 0.94 1.72 
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Triage sensitivity analysis 5 
Triage sensitivity analysis 5 differed from the default triage analysis in that the IOP 
component was removed from the composite triage test.  The triage test is classified 
as abnormal if the imaging test result is classified as ‘outside normal limits’ OR visual 
acuity is 6/12 or poorer. Imaging test results which did not provide an overall 
classification were included as abnormal. The corresponding reference standard 
definition is a clinical decision not to discharge the patient. 
 
The flow of study participants according to triage sensitivity analysis 5 is shown in 
Figure 18 with respective numbers of referral, not for referral and no result cases by 
triage test, and the corresponding reference standard finding shown. Of the 933 
participants for whom all four tests were performed, 481 were not discharged and 562 
were discharged. The discharge status was missing for 10 participants. The diagnostic 
performance for the four tests is given in Table 36. Results generally showed a trade-
off between detection of patients who need to be referred and discharging those who 
do not need to be referred: HRT-MRA had the highest sensitivity (68.9%, 95% CI 
(64.9,72.7)) but the lowest specificity (52.3%, 95% CI (463.9, 57.7)), GDx had the 
lowest sensitivity (32.8%, 95% CI (29.0,36.8)) but the highest specificity (81.1%, 
95% CI (76.6,85.1)), and the other two tests providing intermediate results (HRT-GPS 
values were very similar to the HRT-MRA results, and OCT had the second lowest 
sensitivity but the second highest specificity). Likelihood ratios (and 95% CI) showed 
evidence of both being able to rule in and out the presence of glaucoma for all 4 triage 
tests (CIs did not contain 1.0). DORs ranged from 1.80 for OCT to 2.91 for HRT-
GPS.  
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For referral
VA+MRA(HRT) n=555
VA+GPS (HRT) n=546
VA+GDx n=257
VA+OCT n=426
Not for referral
VA+MRA(HRT) n=358
VA+GPS (HRT) n= 383
VA+GDx n=672
VA+OCT n=507
No result
VA+MRA(HRT) n=30
VA+GPS (HRT) n= 14
VA+GDx n=14
VA+OCT n=10
No reference standard
VA+MRA n=5
VA+GPS n=5
VA+GDx n=4
VA+OCT n=5
No reference standard
VA+MRA n=4
VA+GPS n= 4
VA+GDx n=6
VA+OCT n=5
No reference standard
VA+MRA n= 1
VA+GPS n=1
VA+GDx n=0
VA+OCT n=0
Reference standard
VA+MRA n=29
VA+GPS  n=13
VA+GDx n=14
VA+OCT n=10
Reference standard
VA+MRA n=550
VA+GPS n=541
VA+GDx n=253
VA+OCT n=421
Reference standard
VA+MRA n=354
VA+GPS n=379
VA+GDx n=666
VA+OCT n=502
NOT DISCHARGED
(TP)
VA+MRA n=387
VA+GPS  n=391
VA+GDx n=187
VA+OCT n=291
NOT DISCHARGED
(FN)
VA+MRA n=175
VA+GPS n=179
VA+GDx n=383
VA+OCT n=278
DISCHARGED
(FP)
VA+MRA n=163
VA+GPS n=150
VA+GDx n=66
VA+OCT n=130
NOT DISCHARGED
VA+ MRA  n=14
VA+GPS n=6
VA+GDx n=6
VA+OCT n=7
DISCHARGED
(TN)
VA+MRA n=179
VA+GPS n=200
VA+GDx n=283
VA+OCT n=224
DISCHARGED
VA+MRA n=15
VA+GPS n=7
VA+GDx n=8
VA+OCT n=3
Reference standard definition:  not discharged
For referral:  imaging (outside normal limits) or VA 
6/12 or poorer
Handling of no result categories: A-D For referral 
E excluded
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• withdrawn = 1
Available for index test
n= 955
Completed composite index test (imaging+VA)
n=943
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Imaging not performed for all four index tests
n= 12
Figure 18  Flow diagram: triage sensitivity analysis 5 
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Table 36  Diagnostic performance: triage sensitivity analysis 5  
Test Parameter Value 95% CI 
Lower  Upper  
HRT-MRA Sensitivity - %  68.9 64.9 72.7 
 Specificity - %  52.3 46.9 57.7 
 Positive Likelihood Ratio 1.44 1.28 1.64 
 Negative Likelihood Ratio 0.59 0.51 0.70 
 DOR 2.43 1.84 3.20 
HRT-GPS Sensitivity - %  68.6 64.6 72.4 
 Specificity - %  57.1 51.8 62.4 
 Positive Likelihood Ratio 1.60 1.40 1.83 
 Negative Likelihood Ratio 0.55 0.47 0.64 
 DOR 2.91 2.21 3.84 
GDx Sensitivity - %  32.8 29.0 36.8 
 Specificity - %  81.1 76.6 85.1 
 Positive Likelihood Ratio 1.73 1.36 2.22 
 Negative Likelihood Ratio 0.83 0.77 0.89 
 DOR 2.09 1.52 2.88 
OCT Sensitivity - %  51.1 47.0 55.3 
 Specificity - %  63.3 58.0 68.3 
 Positive Likelihood Ratio 1.39 1.19 1.63 
 Negative Likelihood Ratio 0.77 0.69 0.87 
 DOR 1.80 1.37 2.37 
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Triage sensitivity analysis 6 
Triage sensitivity analysis 6 differed from the default triage analysis in that the visual 
acuity component was removed from the composite triage test.  The triage test is 
classified as abnormal if the imaging test result is classified as ‘outside normal limits’ 
OR IOP >21mmHg. Imaging test results which did not provide an overall 
classification were included as abnormal. The corresponding reference standard 
definition is a clinical decision not to discharge the patient. 
 
The flow of study participants according to triage sensitivity analysis 6 is shown in 
Figure 19 with respective numbers of referral, not for referral and no result cases by 
triage test, and the corresponding reference standard finding shown. Of the 933 
participants for whom all four tests were performed, 481 were not discharged and 562 
were discharged. The discharge status was missing for 10 participants. The diagnostic 
performance for the four tests is given in Table 37. Results generally showed a trade-
off between detection of patients who need to be referred and discharging those who 
do not need to be referred: HRT-MRA had the highest sensitivity (84.9%, 95% CI 
(81.9,87.7)) but second lowest specificity (37.4%, 95% CI (32.3,42.8)), GDx had the 
lowest sensitivity (60.5%, 95% CI (56.4,64.6)) but the highest specificity(57.6%, 95% 
CI (52.2,62.8)), and the other two tests provided intermediate results (HRT-GPS 
values were very similar to the HRT-MRA results, and OCT had the second lowest 
sensitivity but the second highest specificity). Likelihood ratios (and 95% CI) showed 
evidence of both being able to rule in and out the presence of glaucoma for all 4 triage 
tests (CIs did not contain 1.0). DORs ranged from 2.03 for OCT to 3.97 for HRT-
GPS.  
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For referral
IOP+MRA(HRT) n=696
IOP+GPS (HRT) n=689
IOP+GDx n=497
IOP+OCT n=608
Not for referral
IOP+MRA(HRT) n=217
IOP+GPS (HRT) n= 240
IOP+GDx n=432
IOP+OCT n = 325
No result
IOP+MRA(HRT) n=30
IOP+GPS (HRT) n= 14
IOP+GDx n=14
IOP+OCT n=10
No reference standard
IOP+MRA n=5
IOP+GPS n=4
IOP+GDx n=4
IOP+OCT n=5
No reference standard
IOP+MRA n=4
IOP+GPS n= 5
IOP+GDx n=6
IOP+OCT n=5
No reference standard
IOP+MRA n= 1
IOP+GPS n=1
IOP+GDx n=0
IOP+OCT n=0
Reference standard
IOP+MRA n=29
IOP+GPS  n=13
IOP+GDx n=14
IOP+OCT n=10
Reference standard
IOP+MRA n=691
IOP+GPS  n=685
IOP+GDx n=493
IOP+OCT n=605
Reference standard
IOP+MRA n=213
IOP+GPS  n=235
IOP+GDx n=426
IOP+OCT n=320
NOT DISCHARGED
(TP)
IOP+MRA n=477
IOP+GPS n=482
IOP+GDx n=345
IOP+OCT n=407
NOT DISCHARGED
(FN)
IOP+MRA n=85
IOP+GPS n=88
IOP+GDx n=225
IOP+OCT n=162
DISCHARGED
(FP)
IOP+MRA n=214
IOP+GPS n=203
IOP+GDx n=148
IOP+OCT n=196
NOT DISCHARGED
IOP+ MRA n=14
IOP+GPS n=6
IOP+GDx n=6
IOP+OCT n=7
DISCHARGED
(TN)
IOP+MRA n=128
IOP+GPS n=147
IOP+GDx n=201
IOP+OCT n=158
DISCHARGED
IOP+MRA n=15
IOP+GPS n=7
IOP+GDx n=8
IOP+OCT n=3
Reference standard definition:  not discharged
For referral: imaging (outside normal limits) or IOP 
>21mmHg 
Handling of no result categories: A-D For referral
E excluded
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• withdrawn = 1
Available for index test
n= 955
Completed composite index test (imaging+IOP)  
n=943
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Imaging not performed for all four index tests
n= 12
Figure 19  Flow diagram: triage sensitivity analysis 6 
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Table 37  Diagnostic performance: triage sensitivity analysis 6  
Test Parameter Value 95% CI 
Lower  Upper  
HRT-MRA Sensitivity - %  84.9 81.6 87.7 
 Specificity - %  37.4 32.3 42.8 
 Positive Likelihood Ratio 1.36 1.24 1.48 
 Negative Likelihood Ratio 0.40 0.32 0.48 
 DOR 3.36 2.44 4.61 
HRT-GPS Sensitivity - %  84.6 81.3 87.4 
 Specificity - %  42.0 36.8 47.4 
 Positive Likelihood Ratio 1.46 1.32 1.60 
 Negative Likelihood Ratio 0.37 0.29 0.46 
 DOR 3.97 2.91 5.41 
GDx Sensitivity - %  60.5 56.4 64.6 
 Specificity - %  57.6 52.2 62.8 
 Positive Likelihood Ratio 1.43 1.24 1.64 
 Negative Likelihood Ratio 0.69 0.60 0.79 
 DOR 2.08 1.59 2.73 
OCT Sensitivity - %  71.5 67.6 75.2 
 Specificity - %  44.6 39.4 50.0 
 Positive Likelihood Ratio 1.29 1.16 1.44 
 Negative Likelihood Ratio 0.64 0.54 0.76 
 DOR 2.03 1.53 2.67 
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Triage sensitivity analysis 7 
Triage sensitivity analysis 7 differed from the default triage analysis in that a higher 
IOP threshold of 26mmHg rather than 21mmHg was used to identify abnormal tests.  
The triage test is classified as abnormal if (a) the imaging test result is classified as 
‘outside normal limits’ OR (b) IOP>26mmHg OR (c) visual acuity is 6/12 or poorer. 
Imaging test results which did not provide an overall classification were included as 
abnormal. The corresponding reference standard definition is a clinical decision not to 
discharge the patient. 
 
The flow of study participants according to triage sensitivity analysis 7 is shown in 
Figure 20 with respective numbers of referral, not for referral and no result cases by 
triage test, and the corresponding reference standard finding shown. Of the 933 
participants for whom all four tests were performed, 481 were not discharged and 562 
were discharged. The discharge status was missing for 10 participants. The diagnostic 
performance for the four tests is given in Table 38. Results generally showed a trade-
off between detection of patients who need to be referred and discharging those who 
do not need to be referred: HRT-MRA had the highest sensitivity (77.2%, 95% CI 
(73.5,80.6)) but second lowest specificity (51.8%, 95% CI (46.3,57.2)), GDx had the 
lowest sensitivity (47.9%, 95% CI (43.7,52.1) but the highest specificity (79.1%, 95% 
CI (74.4,81.2)), and the other two tests provided intermediate results (HRT-GPS 
values were very similar to the HRT-MRA results, and OCT had very similar 
sensitivity and specificity). Likelihood ratios (and 95% CI) showed evidence of both 
being able to rule in and out the presence of glaucoma for all 4 triage tests (CIs did 
not contain 1.0). DORs ranged from 2.61 for OCT to 4.03 for HRT-GPS.  
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For referral
IOP+VA+MRA(HRT) n=604
IOP+VA+GPS (HRT) n=590
IOP+VA+GDx n=350
IOP+VA+OCT n=491
Not for referral
IOP+VA+MRA(HRT) n=309
IOP+VA+GPS (HRT) n= 339
IOP+VA+GDx n=579
IOP+VA+OCT n=442
No result
IOP+VA+MRA(HRT) n=30
IOP+VA+GPS (HRT) n= 14
IOP+VA+GDx n=14
IOP+VA+OCT n=10
No reference standard
IOP+VA+MRA n=5
IOP+VA+GPS n=5
IOP+VA+GDx n=4
IOP+VA+OCT n=5
No reference standard
IOP+VA+MRA n=4
IOP+VA+GPS n= 4
IOP+VA+GDx n=6
IOP+VA+OCT n=5
No reference standard
IOP+VA+MRA n= 1
IOP+VA+GPS n=1
IOP+VA+GDx n=0
IOP+VA+OCT n=0
Reference standard
IOP+VA+MRA n=29
IOP+VA+GPS n=13
IOP+VA+GDx n=14
IOP+VA+OCT n=10
Reference standard
IOP+VA+MRA n=599
IOP+VA+GPS n=585
IOP+VA+GDx n=346
IOP+VA+OCT n=486
Reference standard
IOP+VA+MRA n=305
IOP+VA+GPS n=335
IOP+VA+GDx n=573
IOP+VA+OCT n=437
NOT DISCHARGED
(TP)
IOP+VA+MRA n=434
IOP+VA+GPS n=432
IOP+VA+GDx n=273
IOP+VA+OCT n=351
NOT DISCHARGED
(FN)
IOP+VA+MRA n=128
IOP+VA+GPS n=138
IOP+VA+GDx n=297
IOP+VA+OCT n=218
DISCHARGED
(FP)
IOP+VA+MRA n=165
IOP+VA+GPS  n=153
IOP+VA+GDx n=73
IOP+VA+OCT n=135
NOT DISCHARGED
IOP+VA+ MRA n=14
IOP+VA+GPS n=6
IOP+VA+GDx n=6
IOP+VA+OCT n=7
DISCHARGED
(TN)
IOP+VA+MRA n=177
IOP+VA+GPS  n=197
IOP+VA+GDx n=276
IOP+VA+OCT n=219
DISCHARGED
IOP+VA+MRA n=15
IOP+VA+GPS n=7
IOP+VA+GDx n=8
IOP+VA+OCT n=3
Reference standard definition:  not discharged
For referral:  imaging (outside normal limits) or IOP 
>26mmHg or VA 6/12 or poorer
Handling of no result categories: A-D For referral
E excluded
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• withdrawn = 1
Available for index test
n= 955
Completed composite index test (imaging+IOP+VA)
n=943
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Imaging not performed for all four index tests
n= 12
Figure 20  Flow diagram: triage sensitivity analysis 7 
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Table 38  Diagnostic performance: triage sensitivity analysis 7 
Test Parameter Value 95% CI 
Lower  Upper  
HRT-MRA Sensitivity - %  77.2 73.5 80.6 
 Specificity - %  51.8 46.3 57.2 
 Positive Likelihood Ratio 1.60 1.42 1.80 
 Negative Likelihood Ratio 0.44 0.37 0.53 
 DOR 3.64 2.72 4.86 
HRT-GPS Sensitivity - %  75.8 72.1 79.3 
 Specificity - %  56.3 50.9 61.6 
 Positive Likelihood Ratio 1.73 1.53 1.97 
 Negative Likelihood Ratio 0.43 0.36 0.51 
 DOR 4.03 3.03 5.36 
GDx Sensitivity - %  47.9 43.7 52.1 
 Specificity - %  79.1 74.4 81.2 
 Positive Likelihood Ratio 2.29 1.84 2.86 
 Negative Likelihood Ratio 0.66 0.60 0.72 
 DOR 3.48 1.99 3.43 
OCT Sensitivity - %  61.7 57.6 65.7 
 Specificity - %  61.9 56.6 66.9 
 Positive Likelihood Ratio 1.62 1.40 1.87 
 Negative Likelihood Ratio 0.62 0.54 0.71 
 DOR 2.61 1.99 3.43 
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Triage sensitivity analysis 8 
Triage sensitivity analysis 8 differed from the default triage analysis in that a higher 
visual acuity threshold of VA 6/18 or poorer was used to identify abnormal tests.  The 
triage test is classified as abnormal if (a) the imaging test result is classified as 
‘outside normal limits’ OR (b) IOP>21mmHg OR (c) visual acuity is 6/18 or poorer. 
Imaging test results which did not provide an overall classification were included as 
abnormal. The corresponding reference standard definition is a clinical decision not to 
discharge the patient. 
 
The flow of study participants according to triage sensitivity analysis 8 is shown in 
Figure 21 with respective numbers of referral, not for referral and no result cases by 
triage test, and the corresponding reference standard finding shown. Of the 933 
participants for whom all four tests were performed, 481 were not discharged and 562 
were discharged. The discharge status was missing for 10 participants. The diagnostic 
performance for the four tests is given in Table 39. Results showed a trade-off 
between detection of patients who need to be referred and discharging those who do 
not need to be referred: HRT-MRA had the highest sensitivity (85.1%, 95% CI 
(81.8,87.9) but lowest specificity (35.1%, 95% CI (31.8,40.4)), GDx had the lowest 
sensitivity (61.9%, 95% CI (57.8,65.9)) but the highest specificity (55.6%, 95% CI 
(50.2,60.9)), and the other two tests provided intermediate results (HRT-GPS values 
were very similar to the HRT-MRA results, and OCT had the second lowest 
sensitivity (72.9%, 95% CI (69.1,76.5)) but the second highest specificity (42.9%, 
95% CI (37.7,48.3)). Likelihood ratios (and 95% CI) showed evidence of both being 
able to rule in and out the presence of glaucoma for all 4 triage tests (CIs did not 
contain 1.0). DORs ranged from 2.03 for OCT to 3.80 for HRT-GPS.  
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For referral
IOP+VA+MRA(HRT) n=705
IOP+VA+GPS (HRT) n=697
IOP+VA+GDx n=512
IOP+VA+OCT n=622
Not for referral
IOP+VA+MRA(HRT) n=208
IOP+VA+GPS (HRT) n= 232
IOP+VA+GDx n=417
IOP+VA+OCT n=311
No result
IOP+VA+MRA(HRT) n=30
IOP+VA+GPS (HRT) n= 14
IOP+VA+GDx n=14
IOP+VA+OCT n=10
No reference standard
IOP+VA+MRA n=5
IOP+VA+GPS n=4
IOP+VA+GDx n=4
IOP+VA+OCT n=5
No reference standard
IOP+VA+MRA n=4
IOP+VA+GPS n= 5
IOP+VA+GDx n=6
IOP+VA+OCT n=5
No reference standard
IOP+VA+MRA n= 1
IOP+VA+GPS n=1
IOP+VA+GDx n=0
IOP+VA+OCT n=0
Reference standard
IOP+VA+MRA n=29
IOP+VA+GPS n=13
IOP+VA+GDx n=14
IOP+VA+OCT n=10
Reference standard
IOP+VA+MRA n=700
IOP+VA+GPS n=693
IOP+VA+GDx n=508
IOP+VA+OCT n=617
Reference standard
IOP+VA+MRA n=204
IOP+VA+GPS n=227
IOP+VA+GDx n=411
IOP+VA+OCT n=306
NOT DISCHARGED
(TP)
IOP+VA+MRA n=478
IOP+VA+GPS  n=484
IOP+VA+GDx n=353
IOP+VA+OCT n=415
NOT DISCHARGED
(FN)
IOP+VA+MRA n=84
IOP+VA+GPS n=86
IOP+VA+GDx n=217
IOP+VA+OCT n=154
DISCHARGED
(FP)
IOP+VA+MRA n=222
IOP+VA+GPS n=209
IOP+VA+GDx n=155
IOP+VA+OCT n=202
NOT DISCHARGED
IOP+VA+ MRA n=14
IOP+VA+GPS n=6
IOP+VA+GDx n=6
IOP+VA+OCT n=7
DISCHARGED
(TN)
IOP+VA+MRA n=120
IOP+VA+GPS n=141
IOP+VA+GDx n=194
IOP+VA+OCT n=152
DISCHARGED
IOP+VA+MRA n=15
IOP+VA+GPS n=7
IOP+VA+GDx n=8
IOP+VA+OCT n=3
Reference standard definition:  not discharged
For referral: imaging (outside normal limits) or IOP 
>21mmHg or VA 6/18 or poorer
Handling of no result categories: A-D For referral 
E excluded
Eligible patients
n= 2088
Consented
n= 966
Not consented
n= 1122
Excluded  n= 11
• Ineligible =  10
• withdrawn = 1
Available for index test
n= 955
Completed composite index test (imaging+IOP+VA)
n=943
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Inconclusive
reference standard
n=0
Imaging not performed for all four index tests
n= 12
Figure 21  Flow diagram: triage sensitivity analysis 8 
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Table 39  Diagnostic performance: triage sensitivity analysis 8 
Test Parameter Value 95% CI 
Lower  Upper  
HRT-MRA Sensitivity - %  85.1 81.8 87.9 
 Specificity - %  35.1 30.0 40.4 
 Positive Likelihood Ratio 1.31 1.20 1.43 
 Negative Likelihood Ratio 0.43 0.33 0.54 
 DOR 3.08 2.23 4.24 
HRT-GPS Sensitivity - %  84.9 81.7 87.8 
 Specificity - %  40.3 35.1 45.6 
 Positive Likelihood Ratio 1.42 1.30 1.56 
 Negative Likelihood Ratio 0.37 0.30 0.47 
 DOR 3.80 2.78 5.19 
GDx Sensitivity - %  61.9 57.8 65.9 
 Specificity - %  55.6 50.2 60.9 
 Positive Likelihood Ratio 1.39 1.22 1.59 
 Negative Likelihood Ratio 0.68 0.60 0.79 
 DOR 2.04 1.55 2.67 
OCT Sensitivity - %  72.9 69.1 76.5 
 Specificity - %  42.9 37.7 48.3 
 Positive Likelihood Ratio 1.28 1.15 1.42 
 Negative Likelihood Ratio 0.63 0.53 0.76 
 DOR 2.03 1.53 2.68 
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Discussion 
Four composite triage (imaging, IOP measurement and visual acuity assessment) tests 
were compared with regards to their diagnostic performance for determining who 
should be referred for further assessment or discharged using the GATE population of 
referrals to a glaucoma clinic in secondary care.  
 
The sensitivity and specificity of the four triage tests incorporating each of the 
imaging technologies along with IOP and VA for the default triage analysis and 
sensitivity analyses (see Table 29 for details) are summarised in Figure 22 and 23 
respectively.  
 
 
Figure 22 Summary of the sensitivity of the composite test across all triage 
analyses 
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Figure 23 Summary of the specificity of the composite test across all triage 
analyses 
 
All four triage tests had value in terms of ruling in and ruling out the need for referral 
on to a consultant ophthalmologist. The diagnostic performance of the triage tests 
differed with substantial differences in the ability to correctly detect those who need 
to be referred and those who do not. HRT-GPS and HRT-MRA had consistently the 
highest sensitivities across analyses but at a cost of lower specificity compared to 
other tests. HRT-GPS had the slightly higher specificity. In contrast GDx consistently 
has the best specificity though the lowest sensitivity. HRT-GPS results were typically 
similar to HRT-MRA as might be anticipated given they use the same machine. OCT 
generally had similar levels of sensitivity and specificity. The choice of which triage 
test is to be preferred reflects the inherent trade off regarding diagnostic testing where 
the desire to refer onwards when referral is needed must be balanced again the desire 
to discharge those who do not need a further assessment. A formal assessment of this 
trade-off and the consequences in terms of health outcome and costs is covered in 
Chapters 6 and 7. 
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The triage was formed from three components, an imaging test as evaluated in 
Chapter 4, a measurement of IOP and visual acuity measurement. The elements were 
combined in an additive manner where an individual was referred if any one of the 
three components met the respective referral criteria. A number of sensitivity analyses 
were carried out to assess the robustness of the findings of this default triage analysis. 
Varying the imaging test definition of a positive result by including the borderline 
category of imaging test result was carried out; this had the anticipated impact of 
improving the detection of glaucoma though at the cost of more non-glaucoma cases 
being falsely identified as having glaucoma. This resulted in very high detection of 
glaucoma for HRT-MRA, HRT-GPS and high sensitivities for GDx and OCT but the 
consequence of lower specificities (GDx  had a higher specificity value than the other 
three triage tests). Additionally, the impact of using the classification from the 
imaging test when the quality criterion was not met was assessed. The impact was at 
most a small reduction in sensitivity with an increase in specificity (only GDx had 
more than a nominal change in values). The added value of the IOP and visual acuity 
components was assessed by dropping one of the respective components, varying the 
cut-off used to define abnormality, and for the IOP component, using the referral IOP 
measurement in place of the ophthalmologist’s. Removal of the IOP component had a 
noticeable impact upon the diagnostic performance with exclusion leading to a 
reduction in sensitivity though a gain in specificity. Modifying the IOP cut-off value 
changed the balance in terms of sensitivity and specificity as anticipated. When the 
referral IOP was used in place of the ophthalmologist’s IOP the specificity was 
reduced. Such an impact is unsurprisingly given the known variability in IOP 
measurements41 and the use of an absolute cut-off will lead to a regression to the 
mean effect when another measurement is taken (in this case by a different observer). 
Removing the visual acuity component had very little impact upon the diagnostic 
accuracy with a slight reduction in the sensitivity and corresponding increase in 
specificity. This impact may have been limited by the method of data collection 
(referral letter quotation) as opposed to complete data capture of a new visual acuity 
measurement). 
 
A number of assumptions underpinned the analysis and interpretation of these results 
in addition to those highlighted previously for diagnoses analyses. The reference 
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standard here was the clinical decision to discharge or not which will vary to some 
degree between individual clinicians and centres according to policies and practices 
(perhaps most noteworthy for individuals with suspected glaucoma). Components of 
the triage test were combined in an additive manner which reflects an implicit desire 
to favour sensitivity over specificity. No other options were assessed though arguably 
this approach reflects clinical practice. The use of the ophthalmologist’s measurement 
does not reflect the reality of how a triage system would be implemented where, if a 
measurement was taken in hospital eye services, it would be by another individual 
(e.g. technician). Using the referral IOP did have a substantial impact though most if 
not all of this impact might be attributed to the inevitable variability between 
measurements taken at different times by different observers and the impact of 
regression to the mean. The finding does suggest there is value in taking a 
measurement upon referral to hospital eye services.
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Chapter 6  Economic evaluation methods 
 
The objective of this chapter is to present the economic evaluation of four automated 
optic nerve and retinal nerve fibre layer imaging tests (HRT-MRA, HRT-GPS, GDx 
and OCT ), hereafter referred to as imaging technologies. These were evaluated in the 
GATE study as triage diagnostic stations in hospital eye services (secondary care), 
compared with current practice, for patients referred to hospital eye services for 
possible glaucoma. The triage diagnostic station included an imaging test, a visual 
acuity test, and an intraocular pressure measurement.   
 
The model 
The cost-effectiveness of the different imaging technologies and their subsequent care 
management pathways was assessed using a multi-state Markov model. As glaucoma 
is a chronic condition, which progresses slowly over time, the model reflects the 
timing of both diagnostic testing and disease progression. This approach allowed 
modelling of the logical and temporal sequence of events (e.g. diagnosis or 
monitoring visits) following the initial diagnostic strategy. 
 
Typically, Markov models have states (e.g. Markov states) in which individuals stay 
for a period of time called a ‘cycle’. The cycle must be a period relevant to the 
condition considered (e.g. 6 months, 1 year). At the end of each cycle, individuals can 
remain in the state in which they started the cycle or move to a different state. The 
probabilities of moving from one state to another are called transition probabilities. In 
each state, the model will assign costs and benefits for each individual according to 
different interventions and/or time spent in the state. In these models, there must be at 
least one absorbing state, typically death, from which the individual will not be able to 
leave. The sum of the cost in each year and the product of the utilities in each year 
were summed over fifty years of the simulated patient cohort to compute total cost 
and quality adjusted life year (QALY) for that cohort.  
 
The purpose of this model was to compare and contrast different imaging 
technologies (used as part of a wider triage station) for the identification of patients 
who should be referred for a clinician led diagnostic examination. We can thus 
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compare and contrast these with standard care where all patients receive a clinician 
led diagnosis based on clinical examination and visual field (VF) assessment 
(automated perimetry). The model was constructed such that different sensitivities and 
specificities of each diagnostic strategy would determine if glaucoma was correctly 
identified or not, the health state patients would move to and the associated 
progression of any underlying glaucoma. The consequences could then be considered 
in terms of the monetary costs (of testing and subsequent management of the patient’s 
condition) to the NHS and in terms of the effects on quality of life (by assigning 
utility weights). Combining these data with information of the probabilities of events 
occurring over time enabled cost, patient outcomes and quality adjusted life years 
(QALYs) to be estimated for a hypothetical cohort of patients undergoing each triage 
strategy. 
 
The results of the model are presented in Chapter 7 and are presented as incremental 
cost per QALYs and incorporate: (i) costs (of testing) and diagnostic outcomes, (ii) 
costs (of testing and subsequent management) and (iii) QALYs.  
 
 
Figure 24  Schematic diagram of model states and possible transitions 
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Figure 24 shows the possible health states in ovals, while the arrows show the 
possible directions in which individuals can move at the end of each cycle, depending 
on the transition probabilities. The states considered in the model were those thought 
to reflect possible paths for normal, ‘at risk of glaucoma’ and glaucoma individuals of 
different stages (see below). Each state, other than normal and death, is divided into 
two categories. The treated states on the right hand side of Figure 24 represent those 
individuals whose condition is identified and being treated and the untreated states on 
the left hand side represent those individuals whose condition is not yet identified and 
thus they are not receiving treatment. The treatment health states refer to treated 
disease at each stage of glaucoma. The modality of treatment, either IOP-lowering eye 
drops, laser or surgery or any combination thereof, is not specified for a glaucoma 
related treatment state. A treatment state refers to any modality or combination 
treatment for each stage of glaucoma severity. There are three treatment states for the 
three stages of manifest glaucoma and a treatment state for sight impairment. The ‘at 
risk of glaucoma’ treatment state includes those individuals who are glaucoma 
suspects and those who have OHT and PAC. Among the “at risk of glaucoma” group 
we have assumed that all patients with OHT will be treated in the same way and 
incorporates annual outpatient appointments for observation with all OHT individuals 
receiving continuous Latanoprost (eye drops, once a day).     
 
According to the individuals’ underlying condition, each individual will start in the 
model in a normal state, an untreated ‘at risk of glaucoma’ state or an untreated 
glaucoma disease state (mild, moderate, severe or sight impaired). Each individual 
will then enter a diagnosis process that will differ according to the compared 
strategies where their diagnosis will be made (i.e. for current practice in the form of 
consultant led diagnosis and care or a triage station including one of the imaging 
technologies under consideration, see above). The sensitivity and specificity of each 
diagnostic strategy determines the Markov state an individual will move to. In 
particular, it will determine if an individual enters a treated or untreated disease state 
and the possible transitions associated with these. In general, as time passes, the 
normal or ‘at risk of glaucoma’ individuals could develop glaucoma, while those with 
glaucoma could progress onto a more severe disease state until they eventually 
become visually impaired. 
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Glaucoma is not reversible and this is reflected in the model (see Figure 24). 
However, individuals can return to a normal state after a number of model cycles 
within the ‘at risk of glaucoma’ Markov state. The absorbing state in the model is 
death. Any individual can move into this state from any other state in the model.   
 
The model allows for a cohort of the population, some with glaucoma, to pass through 
different diagnostic strategies. The intuitive idea behind the model is to identify the 
strategy that leads to the largest proportion of individuals with glaucoma correctly 
diagnosed and being in treatment to reduce disease progression and visual loss.   
 
Definition of health states used in the model 
Glaucoma states were defined in terms of severity of disease namely mild, moderate 
and severe glaucoma and sight impaired. The agreed glaucoma severity definitions 
used for the GATE study data collection was used for the economic model (see Table 
40). Furthermore, an additional disease state defined as ‘at risk of glaucoma’ was 
included in the model to represent those individuals who do not have manifest 
glaucoma but have a higher risk of developing glaucoma (glaucoma suspects, those 
with OHT and those with primary angle closure). 
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Table 40  Definition of health states for the economic evaluation  
“At risk of glaucoma” health state: glaucoma suspect, ocular hypertension, or primary angle-closure  
Glaucoma Suspect Either the optic disc, or visual field, or both, have some features that are suggestive of glaucoma but may also 
represent a variation of normality (with or without high IOP) 
Ocular Hypertension    Both the visual field and optic nerve appear normal in the presence of elevated pressure > 21 mmHg 
Primary angle-closure  Closed anterior chamber angle (appositionally or synechial) in at least 270°, and at least one of the following two: 
IOP > 21 mmHg and/or presence of peripheral anterior synechiae.  Both visual field and optic nerve appear normal 
“Glaucoma”: different health states according to mean deviation index (MD) of the visual field test 
“Mild glaucoma” Evidence of glaucomatous optic neuropathy and a characteristic visual field loss. MD better than or equal to -6 dB 
“Moderate glaucoma” Evidence of glaucomatous optic neuropathy and a characteristic visual field loss. MD between -6.01dB and -12 dB 
“Severe glaucoma” Evidence of glaucomatous optic neuropathy and a characteristic visual field loss. MD worse than or equal to -12.01 
dB 
“Sight impaired” health state:  sight impaired and severely sight impaired 
Sight impaired 
 
Poor visual acuity (3/60 to 6/60) with full field of vision; or slightly reduced visual acuity (up to 6/24) and reduced 
field of vision or blurriness/ cloudiness in central vision; or relatively good visual acuity (up to 6/18) but 
significantly reduced field of vision 
Severely sight impaired Very poor visual acuity (less than 3/60) with full field of vision; or poor visual acuity (between 3/60 and 6/60) and 
severely reduced field of vision; or slightly reduced visual acuity (6/60 or better) and significantly reduced field of 
vision 
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Description of the healthcare diagnostic strategies and management pathways 
considered within the model 
The care pathways modelled within the Markov model following diagnosis were 
developed in consultation with the study team and the independent steering committee 
members. The main study team for this element of the work included two 
ophthalmologists (AA-B, JB), and three health economists (RH, PM, JG), and a 
health services researcher (KB). Over a number of meetings, the group mapped out 
the sequence of events for patients potentially eligible for treatment or monitoring 
following the diagnostic strategies under consideration. Additional information came 
from our previous models in this area, notably our model comparing alternative 
screening strategies for open angle glaucoma19 reviewed guidelines and expert 
opinion. These care pathways were then presented to the steering committee and 
revised to reflect the comments received. 
 
Current practice care pathway 
Patients enter the model as a cohort who have been identified with signs of e.g. 
possible glaucoma or OHT by a community optometrist or GP and have been referred 
to secondary care. Within hospital eye services, all individuals will see a nurse that 
will perform a visual acuity (VA) examination and a technician that will perform a 
visual field (VF) test. All individuals will then see a clinician (typically an 
ophthalmologist) who will measure IOP (using GAT), will look at the VF results and 
perform a fundus examination to examine the optic disc and the posterior retina. 
Figure 25 shows the care pathway. 
 
 
Figure 25  Care pathway: current practice 
 
120 
 
Considering all the clinical information the clinician will decide on a diagnosis as 
described in Chapter 2 (Methods). For the purpose of the model these diagnoses have 
been grouped into five health states described further in Table 40: Mild Glaucoma; 
Moderate Glaucoma; Severe Glaucoma; At risk of glaucoma; Normal. Furthermore, 
the ‘at risk of glaucoma’ health state includes those with a diagnosis of OHT or 
glaucoma suspect or PAC.   
 
Individuals who are diagnosed by the clinician to be in the normal health state are 
discharged from secondary care. Individuals diagnosed with glaucoma remain in 
secondary care under treatment and enter the relevant glaucoma treated health state.  
Individuals diagnosed as ‘at risk of glaucoma’ also remain in secondary care and enter 
into the ‘at risk of glaucoma’ treatment state.  The subset of ‘at risk of glaucoma’ 
patients with OHT are all assumed to be on treatment.  
 
Triage care pathway  
As described in Chapter 2, the triage pathway used IOP, imaging and visual acuity 
(VA) to identify patients who could be discharged from secondary care if all tests 
were normal.  IOP and VA are routinely collected in primary and/or secondary care 
and used to inform the clinical decision-making process as to whether to discharge a 
patient or not. At HES the individuals will be seen by a nurse that will perform VA 
examination and IOP measurement. They will also be seen by a technician who will 
perform the index (imaging) test (HRT-MRA, HRT-GPS, GDx or OCT depending on 
triage strategy). Figure 26 shows the care pathway for the triage strategies. 
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Figure 26  Care pathway: triage strategies 
 
Results of these three examinations are combined into a composite triage test result as 
follows. If any of the VA or IOP or imaging test results are abnormal then the 
composite test is assumed to be positive or abnormal. Only if all three (VA, IOP and 
imaging test) are normal is the composite test result negative or normal. Individuals 
with normal (negative) composite triage test results are discharged from secondary 
care. Individuals with abnormal (positive) test results are referred to the clinician to 
make a diagnosis. Definitions of abnormal (positive) test results for the elements of 
the composite test are as follows: IOP>21mmHg, VA 6/12 or worse, imaging 
technology classification abnormal or borderline. 
 
Individuals who have been discharged with normal (negative) composite triage test 
results can either be truly normal (true negative) or can be incorrectly diagnosed as 
normal when they do in fact have disease (false negative). Individuals with an 
abnormal (positive) composite triage test result are then referred to the clinician who 
will make a definitive diagnosis. Perfect information by the clinician is assumed in the 
model, therefore, individuals will be correctly identified as glaucoma (e.g. mild, 
moderate, severe or visually impaired), at risk of glaucoma or without any of these 
conditions (e.g. normal). Normal individuals are discharged while all others are kept 
under monitoring or observation. The perfect information assumption is explored in 
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sensitivity analysis with the possibility of misdiagnoses by the clinician (e.g. false 
positive and false negative results). 
 
Model strategies 
Five diagnostic strategies are explicitly considered in the model (Table 41). The 
comparator in the model reflects the current practice. In this strategy, all patients 
referred to secondary care for possible glaucoma see a clinician for diagnosis of their 
condition.   
 
Four diagnostic imaging technologies (HRT-MRA, HRT -GPS, GDx, OCT) used as 
part of a composite triage test which includes an assessment of IOP and VA are 
evaluated within the model. The diagnostic strategies and associated care pathways 
used in the economic model are summarised in Table 41. 
 
123 
 
Table 41  Diagnostic strategies and associated care pathways 
Strategy Triage stage  
(composite test) 
Diagnosis stage  
(clinician) 
Treatment Note 
Current Practice 
/ Standard Care 
N/A VA by nurse and VF by 
technician. Then IOP 
measured (GAT) and fundus 
exam conducted by a 
clinician who will make 
diagnosis decision (together 
with VF and VA 
information). 
Treatment/monitoring 
according to NICE 
guidelines.27 
All glaucoma patients treated 
according to severity.  
Assume all OHT treated with 
Latanoprost.   
Glaucoma suspects monitored 
only. 
  
Triage 1:  
HRT-MRA 
HRT-MRA test by 
technician; IOP and VA 
by nurse.  
If all 3 tests negative 
discharge. 
If any of HRT-MRA or 
IOP or VA test positive 
refer on to diagnosis 
stage (clinician exam).  
VF test by technician, IOP 
measured (GAT) and fundus 
exam conducted by a 
clinician who will make 
diagnosis decision (together 
with VF and VA 
information). 
Treatment/monitoring 
according to NICE 
guidelines.27 
All glaucoma patients treated 
according to severity.  
Assume all OHT treated with 
Latanoprost.   
Glaucoma suspects monitored 
only. 
• MRA positive: ‘outside 
normal limits’ or 
‘borderline’ classification 
• IOP positive: >21mmHg 
• VA positive: 6/12 or 
poorer 
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Strategy Triage stage  
(composite test) 
Diagnosis stage  
(clinician) 
Treatment Note 
Triage 2:  
HRT-GPS 
HRT-GPS test by 
technician; IOP and VA 
by nurse.  
If all 3 tests negative 
discharge. 
If any of HRT-GPS or 
IOP or VA test positive 
refer on to diagnosis 
stage (clinician exam).  
VF test by technician; IOP 
measured (GAT) and fundus 
exam conducted by   a 
clinician who will make 
diagnosis decision (together 
with VF and VA 
information). 
Treatment/monitoring 
according to NICE 
guidelines.27 
All glaucoma patients treated 
according to severity.  
Assume all OHT treated with 
Latanoprost.   
Glaucoma suspects monitored 
only. 
• GPS positive: ‘outside 
normal limits’ or 
‘borderline’ classification 
• IOP positive: >21mmHg 
• VA positive: 6/12 or 
poorer 
Triage 3:  
GDx 
GDx test by technician; 
IOP and VA by nurse.  
If all 3 tests negative 
discharge. 
If any of GDx or IOP or 
VA test positive refer on 
to diagnosis stage 
(clinician exam).  
VF test by technician; IOP 
measured (GAT) and fundus 
exam conducted by a 
clinician who will make 
diagnosis decision (together 
with VF and VA 
information). 
Treatment/monitoring 
according to NICE 
guidelines.27 
All glaucoma patients treated 
according to severity.  
Assume all OHT treated with 
Latanoprost.   
Glaucoma suspects monitored 
only. 
• GDx positive: NFI>35 
• IOP positive: >21mmHg 
• VA positive: 6/12 or 
poorer 
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Strategy Triage stage  
(composite test) 
Diagnosis stage  
(clinician) 
Treatment Note 
Triage 4:  
OCT 
OCT test by technician; 
IOP and VA by nurse.  
If all 3 tests negative 
discharge. 
If any of OCT or IOP or 
VA test positive refer on 
to diagnosis stage 
(clinician exam).  
VF test by technician; IOP 
measured (GAT) and fundus 
exam conducted by a 
clinician who will make 
diagnosis decision (together 
with VF and VA 
information). 
Treatment/monitoring 
according to NICE 
guidelines.27 
All glaucoma patients treated 
according to severity.  
Assume all OHT treated with 
Latanoprost.   
Glaucoma suspects monitored 
only. 
• OCT positive: ‘outside 
normal limits’ or 
‘borderline’ classification 
• IOP positive: >21mmHg 
• VA positive: 6/12 or 
poorer 
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Estimation of parameters used within the model 
This section summarises the parameter values used in the economic evaluation model. 
 
Data regarding the cohort in terms of prevalence, incidence and progression are 
reported first, followed by diagnostic triage test performance data, with subsequent 
sections regarding data on cost and utilities reported respectively. 
 
Cohort data: prevalence, incidence and progression data 
Table 42 shows data on prevalence, incidence and progression of glaucoma used in 
the model.  
 
Table 42  Cohort data: prevalence, incidence and progression 
Probability  Value Source 
Cohort start age 40 Base-case assumption 
Prevalence of glaucoma  0.17 GATE study  
Proportion of normal  0.412 GATE study  
Prevalence of ‘at risk of glaucoma’ 0.418 GATE study  
Proportion of glaucoma mild 0.523 GATE study  
Proportion of glaucoma moderate 0.302 GATE study  
Proportion of glaucoma severe 0.174 GATE study  
Incidence of glaucoma   
50 years old  0.0003 Burr 200719 
60 years old 0.0008 Burr 200719 
70 years old 0.00181 Burr 200719 
80 years old 0.00414 Burr 200719 
Progression to glaucoma mild from ‘at risk 
of glaucoma’ 
0.002 Expert opinion  
Progression to glaucoma moderate 0.129 Burr 201442 
Progression to glaucoma severe 0.048 Burr 201442 
Progression to sight impaired 0.042 Burr 201442 
Reduction in risk of progression from any 
medical treatment for glaucoma  
0.65 Burr 201442 
Mortality  various (see Appendix 8 for interim life table) 
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Prevalence data and proportion of glaucoma subjects by severity of disease was based 
upon the GATE study population (see Chapter 3). Incidence data and progression data 
as well as relative rate of progression between treated and untreated individuals were 
obtained from previous models of glaucoma management and surveillance.19,41,42 The 
annual probability of having an eye test was informed by Burr19 who used data on eye 
test, gender and age from the British Household Panel Survey43 to estimate the annual 
probabilities of having an eye test by a community optometrist for different age 
groups. We utilised the average of 2 probabilities estimated in the report: 0.248 per 
year for those in the 40 to 59 year old range and 0.3769 per year for those in the 60 to 
75 year old age range to give 0.312 visits per year.  
 
Test performance data 
Table 43 shows data on the test performances of each of the triage strategies that 
incorporated the different diagnostic technologies plus IOP and VA measurement and 
the current practice strategy in the form of clinician diagnosis. Although the imaging 
technology is used to define the strategy, all performance measures are calculated 
based on a composite test result which combines imaging, IOP and VA test results 
(see Appendix 7). 
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Table 43  Accuracy parameters of the triage test used in the model (see Appendix 
7)  
Probability  Value Source 
Sensitivity for all glaucoma individuals 
HRT-MRA 0.99 GATE Study  
HRT-GPS 0.99 GATE Study  
GDx 0.88 GATE Study  
OCT 0.97 GATE study  
Sensitivity for all ‘at risk of glaucoma’ individuals 
HRT-MRA 0.97 GATE Study  
HRT-GPS 0.97 GATE Study  
GDx 0.77 GATE Study  
OCT 0.87 GATE Study  
Specificity for all normal individuals 
HRT-MRA 0.30 GATE Study  
HRT-GPS 0.28 GATE Study  
GDx 0.51 GATE Study  
OCT 0.35 GATE Study  
Sensitivity and specificity of current practice (diagnosis by an ophthalmologist) for all 
individuals (glaucoma, ‘at risk of glaucoma’ and normal)  
Sensitivity  1 Assumption  
Specificity  1 Assumption  
 
For current clinical practice, diagnosis by a clinician was assumed to be 100% 
sensitive and specific. The remaining composite test performances for detecting 
glaucoma, ‘at risk of glaucoma’ and normal individuals was informed by statistical 
analysis of the GATE study specifically carried out to inform the economic model. 
Triage accuracy data for the four triage strategies (e.g. sensitivity and specificity) 
were calculated for glaucoma, ‘at risk of glaucoma’, and normal groups (see Appendix 
7). 
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Estimation of costs used within the model 
All costs were estimated based on resource-use inputs and unit costs for the 2012-
2013 financial year and are reported in UK pound sterling. With the exception of 
treatment costs, which were taken from the literature, costs included in the model 
were estimated using a micro costing exercise or using NHS reference costs. The data 
used in this exercise were then subsequently checked by the steering committee 
members. Specific costs to the NHS relevant to the diagnostic strategies, subsequent 
treatment pathways, and events included diagnostic imaging, staff time, treatment, 
equipment and capital costs. With the exception of capital costs which were sourced 
from specific commercial providers, most unit costs were sourced from NHS 
reference costs,23 Unit costs of health and social care44 and Agenda for Change.45  
Where costs were not reported in 2012-13 values, they were inflated by the Hospital 
and Community Health Sector (HCHS) inflation index.44  
 
All capital costs for each of the diagnostic imaging technologies were costed using 
current market prices obtained from various commercial providers to the NHS (see 
explanations below). These initial outlay costs were annuitised over the useful 
working lifespan of the piece of equipment (assumed to be 10 years for all equipment) 
applying an annual discount factor of 3.5%46  to account for the opportunity cost of 
the investment over time.   
 
The equivalent annual cost of each piece of equipment was divided through by its 
estimated maximum number of uses per annum (from NHS providing units and expert 
opinion) to give cost per use estimates.   
 
Tables 44, 45 and 46 show the cost estimates used in the model for diagnosis by 
current practice, diagnosis by the triage strategies and treatment costs respectively.  
 
Costs of diagnosis pathway: current practice 
The costs of the current practice diagnostic pathway are presented in Table 44. At 
hospital eye services, all individuals see a nurse that will perform a VA examination 
and a technician who will perform a VF test. It was assumed that the VA test would 
take 10 minutes of a Grade 5 (midpoint scale) nurse’s time and the VF test would take 
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15 minutes of a grade 3 (midpoint scale) technician’s time. The unit costs for these 
were taken from Agenda for Change45 and inflated to 2012-13 prices. All individuals 
will then see a clinician and the cost of this was based on the NHS reference cost 
(HRG WF01B) of a first consultant led ophthalmology outpatient appointment.  
 
Table 44  Costs of current practice diagnosis used in the model 
Costs  Value (£) Source 
Nurse led VA test 2.45 Agenda for Change 45 
Technician VF test  2.72 Agenda for Change45 
Ophthalmology first outpatient 
appointment.  
106 NHS Reference Costs23 
 
Costs of diagnosis pathway: triage strategies 
The costs of the GATE triage diagnostic strategies are specified in Table 45. All 
individuals will see a nurse who will perform a VA and an IOP test. It was assumed 
that this would take 10 minutes of a Grade 5 (midpoint scale) nurses’ time. All 
patients would then go on to have one of the four index tests (diagnostic 
technologies). We assumed that these imaging tests would be performed by a band 3 
technician (midpoint scale) and would take 15 minutes of staff time. As stated 
previously, the unit costs of staff time were calculated from Agenda for Change45  and 
inflated to 2012-13 values.   
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Table 45  Costs of triage strategies used in the model 
Costs  Value (£)  Source 
Triage appointment costs   
Nurse led VA & IOP test 2.45 Agenda for Change45 
Technician led Index test (e.g. OCT, GDx or 
HRT)  
2.72 Agenda for Change45 
Capital cost  OCT diagnostic technology 1.32 Micro costed 
Capital cost of HRTIII (GPS & MRA) and 
GDx diagnostic technologies  
0.79  Micro costed 
Appointment costs for those triaged and referred to the clinician 
Technician VF test  2.72 Agenda for Change45 
Ophthalmology first outpatient appointment  106 NHS Reference Costs23 
 
UK capital costs for the OCT Spectralis and HRT III diagnostic imaging technologies 
and associated installation and maintenance costs were obtained from Heidelberg 
Engineering Ltd (http://www.HeidelbergEngineering.co.uk) (personal 
communication, Tosh Vadhia, Regional Business Manager – South, August 2013).  
These initial outlay costs were annuitised over the useful working lifespan of the piece 
of equipment (assumed to be 10 years for all equipment) applying an annual discount 
factor of 3.5%46  to account for the opportunity cost of the investment over time. The 
equivalent annual cost of each piece of equipment was divided through by its 
estimated maximum number of uses per annum (from NHS providing units and expert 
opinion) to give cost per use estimates. The expected number of uses per annum were 
based on a 253 working days per year with each use taking a fifteen minute slot over a 
seven and a half hour working day. This assumption was based on information 
provided by Moorfields Eye Hospital NHS Foundation Trust (personal 
communication, Edward White, Chief Ophthalmology Technician, September 2013).  
During the course of the study, we were unable to obtain data on capital cost of the 
GDx diagnostic technology. As such, we assumed that due to the competitive nature 
of the pricing from suppliers to the NHS, this technology had the same capital, 
installation and associated maintenance contract costs as the HRT III machine.  
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In each triage diagnostic strategy, patients who were diagnosed with a positive 
composite test result were referred for a first consultant led ophthalmology outpatient 
appointment, the cost of which was based on NHS reference costs (HRG WF01B). 
This outpatient visit would also involve VF testing by a technician (costs as for the 
standard care strategy detailed above). Thereafter, those who were identified by the 
ophthalmologist as being normal were then assumed to be discharged from secondary 
care. 
 
Costs of treatment 
Table 46 shows costs of treatment which are separated into two distinct categories: 
those related to glaucoma related states (mild, moderate, severe and sight impaired) 
and those for the ‘at risk of glaucoma’ state.   
 
Table 46  Annual cost of treatment 
Costs  Value (£)  Source 
Glaucoma related treatment costs 
Glaucoma mild treatment 499.80 Burr 200719 
Glaucoma moderate treatment 562.87 Burr 200719 
Glaucoma severe treatment  447.44 Burr 200719 
Sight impaired annual cost  796.11 Burr 200719 
At risk of glaucoma state treatment costs 
Multi professional follow up 
ophthalmology outpatient appointment 
87.00 NHS reference 
costs23 
Latanoprost  23.64 British National 
Formulary47  
 
Costs of treating the glaucoma related states (mild, moderate, severe, sight impaired) 
were taken from a related study19  and inflated to 2013-14 prices. The authors used 
costs estimates based on Traverso and colleagues48 which is a Europe-based study and 
includes data for the UK by severity of glaucoma. Treatment costs related to the ‘at 
risk of glaucoma’ state (i.e. individuals who are glaucoma suspects or diagnosed with 
OHT) were based on a number of assumptions and expert opinion and were micro 
costed to get an average annual cost per patient. It was assumed that all individuals in 
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the ‘at risk of glaucoma’ state would be given an annual multi professional follow up 
ophthalmology outpatient appointment, the cost of which was taken from NHS 
reference costs (WF02A).23 Furthermore, it was assumed that all OHT individuals 
would be treated (based on advice from our expert advisory group) with Latanoprost 
for the rest of their lives or until their condition progressed with annual costs of 
£23.64.47 
 
Estimation of utilities used within the model 
QALYs are calculated by weighting life-years with utility values, to reflect 
individuals’ preferences for the health related quality of life that they experience. 
There are various methods and tools that can be used to elicit utility values. NICE 
recommends, in their methods guide,46 the use of the EQ-5D.  
 
Previous research by members of the study team used the EQ-5D to value quality of 
life states for those with mild, moderate or severe glaucoma and sight impaired and 
these data were used in the model to value time in these health states. The EQ-5D-3L 
data were obtained from responses from 640 participants with ocular hypertension and 
glaucoma sampled from a secondary glaucoma service.41 Similar to the study by Burr 
and colleagues in 2012 who suggested that the degree of visual impairment for mild 
glaucoma is minimal, it was assumed that the score for those individuals in the ‘at risk 
of glaucoma’ state would be the same as the score for those with mild glaucoma. 
Table 47 shows the utility weights used in the model.   
 
Table 47  Utility weights used in the model 
Health state  Utility weight Source/note 
Normal  1 Assumption 
Glaucoma mild 0.8371 Burr 201241 
Glaucoma moderate 0.7919 Burr 201241 
Glaucoma severe  0.7156 Burr 201241 
Sight impaired 0.5367 Burr 201241 
At risk of glaucoma 0.8371 Assumed equal to 
glaucoma mild individuals 
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Validation of the model 
Our model was developed from that successfully used by Burr.19  Developing the 
model from a pre-existing model meant that much of the structure had been 
previously validated.  However, this approach also meant that there is no scope to 
make methodological changes to the way the previous model was 
implemented.  Therefore, the Markov model was developed in TreeAge 2013 using 
the same core structures and transition probabilities as Burr 2007.19 TreeAge is a 
frequently used tool for the type of model used in the economic evaluation and allows 
the documentation of our model and simplifies its’ use by other researchers.  
 
To validate the model structure where changes were made to that of Burr, a simple 
Markov model was developed in R in order to make comparisons with the model 
developed in TreeAge. 
 
Base-case analysis  
The base-case analysis was run for a cohort of 40 year-old males. Although the choice 
of this start age was arbitrary, it was felt that it covered the range over which 
diagnostic strategies for glaucoma might be considered, and would cover most of 
prevalent cases of glaucoma, which is an age-related disease. Gender-specific 
variables were not available for any of the model parameters except for mortality, and 
a decision was made to use male mortality rates in the base-case analysis, consistent 
with good modelling practice, as they are a conservative assumption for this enhanced 
case detection study. The model was run for a range of possible prevalence values and 
for a 50 year time horizon. Cycle length was set at 1 year. Costs are presented in 
2012-13 UK pound sterling and effectiveness in quality adjusted life years (QALYs). 
A discount rate of 3.5% for costs and benefits was used following guidelines for 
technology assessment by the National Institute for Health and Clinical Excellence 
(NICE).46 Results are presented in incremental cost effectiveness ratios (ICERs). This 
measure is a ratio of the difference in costs divided by the difference in the 
effectiveness between two alternative strategies. These data can be interpreted as how 
much society would have to pay for an extra unit of effectiveness. Central to the 
assessment of cost-effectiveness is the value that society would put on gaining an 
additional QALY.  NICE states that “Below a most plausible ICER of £20,000 per 
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QALY, judgements about the acceptability of a technology as an effective use of NHS 
resources are based primarily on the cost-effectiveness estimate. Above a most 
plausible ICER of £20,000 per QALY, judgements about the acceptability of the 
technology as an effective use of NHS resources are more likely to make more 
explicit reference to factors including: 
• the degree of uncertainty surrounding the calculation of ICERs 
• the innovative nature of the technology 
• the particular features of the condition and population receiving the technology 
• where appropriate, the wider societal costs and benefits. 
 
Above an ICER of £30,000 per QALY, the case for supporting the technology on 
these factors has to be increasingly strong.46 In the absence of a more definitive 
statement this report focuses on a willingness to pay of £30,000 for a QALY. 
 
Sensitivity analysis 
We addressed uncertainty by conducting deterministic (e.g. one way) sensitivity 
analyses. In consultation with the independent advisory group, the following 
deterministic sensitivity analyses were considered: 
 
1. The base-case analysis assumed that the annual probability of having an eye test is 
31.2%. All patients who are discharged by the diagnosing clinician, or discharged 
by the triage station for the triage strategies, would therefore be expected to be 
picked up in the community and return to the secondary care triage station 
approximately every 3 years.  In this analysis, based on clinical opinion, the 
impact of changing this probability and thus the diagnostic screening interval 
within a range of 1 to 10 years inclusive was explored.  
2. In the base case, the diagnostic triage strategies were micro-costed and included 
staff time and capital costs of the diagnostic technologies. However, due to the 
relatively large cost differential of these triage strategies compared to current 
practice, it was deemed appropriate to explore the effects on cost-effectiveness of 
introducing an NHS reference cost for a non-consultant led first outpatient 
appointment (£85) to the costs of the triage strategies. This was further varied 
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from £10 to £85 in £5 intervals to explore if this changed either the diagnostic 
strategies that were deemed cost-effective or the magnitude of effect. 
3. The base case analysis included a cohort of men with an age of 40 years to be 
modelled for 50 years. The impact of modelling older cohorts of men was 
explored by varying the start age from 45 to 70 years old in 10 year intervals. 
4. The base case analysis was conducted on the basis that all glaucoma patients and 
those at risk of glaucoma (including glaucoma suspects, OHT and PAC) would be 
monitored and treated depending on their definitive diagnosis. It was discussed 
and agreed in a meeting between the study team and the independent steering 
committee that there was a need to explore the effects of a hypothetical secondary 
care service where those patients diagnosed as “at risk” would be discharged from 
the service thus potentially reducing the diagnostic, monitoring and or treatment 
costs.  
5. The base case analysis assumed that clinicians were 100% sensitive and specific 
in their diagnosis of patients. The sensitivity and specificity was varied between 
0.85 and 1 respectively to explore the impact for patients’ not always being seen 
in secondary care by an ophthalmologist with glaucoma expertise and thus having 
100% diagnostic accuracy. 
6. A threshold analysis was conducted in order to explore the impact of increasing 
the costs of the triage strategies and discharging those patients that are given a 
diagnosis of “at risk” of glaucoma. 
7. The base case analysis incorporated point estimates for the sensitivities and 
specificities of each of the imaging technologies that were estimated from the 
GATE study. We varied sensitivity and specificity of each triage strategy to create 
a best case diagnostic scenario ( + 10% sensitivity and + 5% specificity) and a 
worse case diagnostic scenario (-10% sensitivity and -5% specificity) for each of 
the imaging technologies as shown in Table 48 to explore the impact on the 
incremental cost effectiveness ratios.  These values were decided upon by the 
research study team on the basis of variations in the confidence intervals in the 
base case analysis. 
8. The base case analysis assumed the prevalence of glaucoma in the referred 
population which was estimated from the GATE study.  However, no referral 
refinement schemes were in place during the GATE study. Other measures to 
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improve the accuracy of glaucoma referrals are constantly being explored, with a 
reduction in false positive rates.  The impact of adding an imaging based 
composite triage system to a referred population with lower false positives rates 
was explored by decreasing the proportion of normal in the cohort from 0.412 to 
0.212 and increasing the glaucoma prevalence from 0.17 to 0.27 and the “at risk” 
group from 0.418 to 0.518. 
9. The base case analysis assumed that the utility weights for the “at risk” health 
state were the same as mild glaucoma in the absence of literature addressing this 
issue.  We explored the impact of a utility weight for the “at risk” health state 
being the same as normals.  
 
Table 48  Alternative best case and worst case sensitivity and specificity values 
used to explore uncertainties in point estimates  
 
‘Glaucoma’ 
sensitivity 
‘At risk’ 
sensitivity 
‘Normal’ 
specificity  
HRT-MRA:    
Base Case 0.99 0.97 0.3 
Best case 1 1 0.35 
Worst case 0.89 0.87 0.25 
HRT-GPS:    
Base case 0.99 0.97 0.28 
Best case 1 1 0.33 
Worst case 0.89 0.87 0.23 
GDx:    
Base case 0.88 0.77 0.51 
Best case 0.98 0.87 0.56 
Worst case 0.78 0.67 0.46 
OCT:    
Base case 0.97 0.87 0.35 
Best case 1 0.97 0.4 
Worst case 0.87 0.77 0.3 
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Chapter 7  Economic evaluation results 
 
This chapter reports the results of the cost-utility analysis for four alternative triage 
strategies that incorporate each of the imaging tests evaluated in the GATE study 
(combined with IOP and visual acuity data) to identify appropriate referrals to 
hospital eye services, compared to current practice where all referrals receive 
assessment and diagnosis by a clinician in hospital eye services. Expected cost and 
expected QALYs, as well as incremental cost-effectiveness ratios (ICERs), are 
presented for the base case analysis and for sensitivity analyses conducted to explore 
uncertainties. Unless stated, ICERs are reported against the next least costly non-
dominated strategy. 
  
Base case analysis  
The base case analysis was conducted for a male cohort with a starting age of 40 years 
old who were assumed to have an eye test approximately once every three years, and 
clinicians in hospital eye services were assumed to have perfect diagnostic ability. 
Table 49 shows the cost-effectiveness results for the base case analysis. All triage 
strategies were less costly than the current practice strategy but the triage strategies 
resulted in fewer expected QALYs than the current practice strategy where a perfect 
diagnosis by the clinician was assumed. Triage with GDx was the strategy with lowest 
expected cost, followed by triage with OCT, HRT-MRA and HRT-GPS, respectively. 
Triage with OCT was extended dominated (i.e. a combination of triage with GDx or 
HRT-MRA could, in theory, produce more QALYs at lower expected costs compared 
with triage only with OCT alone). Triage with HRT-GPS strategy was dominated by 
HRT-MRA (i.e. HRT-GPS was more costly but did not produce more QALYs 
compared with HRT-MRA). This is further illustrated in Figure 27. 
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Table 49  Incremental cost effectiveness ratios: base case 
Intervention  Cost(£) QALYs ICER 
GDx 2791 19.7701  
OCT 2917 19.7746 Ext Dominateda 
HRT-MRA 2952 19.7771 22904 
HRT-GPS 2961 19.7771 Dominatedb 
Current practice 3084 19.778 156985 
a Extended dominated: a combination of a less costly and less effective intervention, 
and a more costly and more effective intervention would be more efficient. 
b An intervention is more costly but equally as effective than an intervention 
 
Incremental cost effectiveness ratios (ICERs) were calculated for all non-dominated 
strategies. The ICER reported for current practice (£156,985) represents the 
comparison between HRT-MRA and current practice strategies. It should be noted 
that the interpretation of this ICER is slightly different from the usual case. In moving 
from current practice to HRT-MRA, savings would be expected but at the expense of 
lost QALYs.  ..  
 
The usual willingness to pay (WTP) threshold value for an additional QALY has been 
stated around £30,000 for the UK.46 However, it is not clear what decision rule should 
be applied when resources are saved in exchange for fewer QALYs. One possible 
interpretation is that of a similar threshold (e.g. £30,000 saved at the expense of a 
QALY) and this has been adopted in this chapter. Therefore, with this interpretation, 
adopting a triage with HRT-MRA strategy would be worthwhile (e.g. resources would 
be freed and could be used elsewhere in the health care system to obtain QALYs at 
the threshold value of £30,000 per QALY).   
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Figure 27  Base case cost effectiveness analysis results 
 
As stated above, results show that GDx is the least costly, least effective strategy and 
OCT is extendedly dominated by GDx and HRT-MRA. This means that if it was 
possible to provide a mix of GDx and HRT-MRA, then a combination of provision of 
these two strategies would be dominant. Therefore, in economic evaluation we can 
disregard OCT from further consideration. In considering if it is worthwhile providing 
HRT-MRA in preference to GDx, we refer to incremental cost effectiveness ratio.  
Relative to GDx, the incremental cost effectiveness ratio of HRT-MRA is £22,904 
and is below the typical £30,000 value considered to be cost-effective in the UK.46 In 
other words, moving from a triage strategy with HRT-MRA to GDx would save only 
£22,904 but at the expense of a QALY. Given the £30,000 threshold, any saved 
resources would not be sufficient to allow the QALY lost to be regained elsewhere.  
 
Sensitivity analyses 
A number of sensitivity analyses were performed as described in the methods (see 
Chapter 6). 
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Changes to the annual probability of having an eye test 
The base case analysis assumed that the annual probability of having an eye test by a 
community optometrist is 31.2%. All patients who are discharged by the diagnosing 
clinician, or by the triage station for the triage strategies (false negatives), would 
therefore be expected to be picked up in the community and subsequently referred 
back to the triage station at hospital eye services approximately every 3 years. We 
assumed that the community optometrist would identify a potential abnormality and 
subsequently refer the patient back to hospital eye services. In this sensitivity analysis, 
the impact of changing the annual probability of attending a community optometrist 
was explored. The annual probability was varied from 10% to 100% inclusive 
corresponding to a return period decreasing from 10 years to 1 year respectively. Note 
that as the annual probability increases, the time to return to community optometrist 
decreases. As shown in Table 50, as the annual probability increases, both costs and 
QALYs increase but the savings realised (at the expense of a QALY)decrease. For 
instance, for HRT-MRA changing from a 20% probability (once every 5 years) to 
10% (once every 10 years), savings (at the expense of a QALY) decreased from 
£106,392 to £71,187. This is driven by a reduction in costs of the current practice 
strategy and since glaucoma progresses relatively slowly, there is only a small 
reduction in QALY for missed cases. Therefore, any reduction in total QALYs is 
more than offset by a reduction in costs.  
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Table 50  Incremental cost-effectiveness ratios for the 40 year old cohort by 
varying annual probabilities of having a community optometrist eye test  
Probability Strategy Cost(£) QALYs ICER 
10% GDx 1853 19.7253  
OCT 1960 19.7295 25407 
HRT-MRA 1989 19.7313 15503 
HRT-GPS 1992 19.7313 Dominateda 
Current practice 2038 19.7320 71187 
 
20% GDx 2451 19.7527  
OCT 2564 19.7165 Dominateda 
HRT-MRA 2596 19.7596 20876 
HRT-GPS 2602 19.7596 Dominateda 
Current practice  2684 19.7604 106392 
 
30% GDx 2763 19.7686  
OCT 2886 19.7731 27427 
HRT-MRA 2921 19.7756 13738 
HRT-GPS 2930 19.7756 Dominateda 
Current practice 3048 19.7765 150869 
 
40% GDx 2972 19.7794  
OCT 3111 19.7837 32321 
HRT-MRA 3149 19.7862 15635 
HRT-GPS 3162 19.7862 Dominateda 
Current practice  3317 19.7870 208159 
 
50% GDx 3134 19.7873  
OCT 3292 19.7913 39267 
HRT-MRA 3335 19.7936 18788 
HRT-GPS 3350 19.7936 Dominateda 
Current practice  3543 19.7943 282447 
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Probability Strategy Cost(£) QALYs ICER 
60% GDx 3271 19.7932  
OCT 3449 19.7969 48375 
HRT-MRA 3497 19.7990 23231 
HRT-GPS 3516 19.7990 Dominateda 
Current practice 3746 19.7996 377466 
70% GDx 3393 19.7978  
OCT 3593 19.8012 59823 
HRT-MRA 3647 19.8030 29027 
HRT-GPS 3668 19.8030 Dominateda 
Current practice 3937 19.8036 495605 
80% GDx 3505 19.8015  
OCT 3728 19.8045 73741 
HRT-MRA 3788 19.8061 36177 
HRT-GPS 3813 19.8061 Dominateda 
Current practice 4119 19.8067 637178 
90% GDx 3611 19.8044  
OCT 3858 19.8071 90141 
HRT-MRA 3924 19.8086 44594 
HRT-GPS 3952 19.8086 Dominateda 
Current practice  4297 19.8091 800615 
100% GDx 3713 19.8067  
OCT 3983 19.8092 108907 
HRT-MRA 4057 19.8106 54140 
HRT-GPS 4088 19.8106 Dominateda 
 Current practice  4471 19.8110 983958 
 
HRT-GPS is always dominated regardless of the annual probability of having an eye 
test as this strategy is always more expensive and less effective than HRT-MRA. 
Moreover, when a higher proportion of the cohort comes back every year it is less 
clear which triage strategy should be adopted. The extreme case is for the cohort to 
come back every year (100% annual probability) where adopting a triage strategy 
with HRT-MRA would represent savings of £983,958, but moving from HRT-MRA 
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to OCT and from OCT to GDx would account for savings of £54,140 and £108,907 
respectively but at the expense of a QALY. Therefore, at a WTP threshold value of 
£30,000 per QALY, GDx based triage should be adopted. It should be noted that this 
is an extreme case example.  
 
Changes in the costs of the triage strategies 
The costs of the triage strategies included in the base case analysis were estimated on 
the basis of a bottom up approach to costing and were therefore micro-costed. Due to 
the relatively large cost differential between the triage strategies and current practice 
and that NHS secondary care providers charge for a non-consultant led outpatient 
appointment, the effects of introducing an NHS reference cost for a non-consultant led 
first outpatient appointment (£85) was explored.23 The results are presented in Table 
51. 
 
Table 51  Incremental cost effectiveness ratios for an increase to the unit costs of 
the triage strategies 
Intervention Cost(£) QALYs ICER 
Current practice 3084 19.778  
GDx 3217 19.7701 Dominateda 
OCT 3339 19.7746 Dominateda 
HRT-MRA 3372 19.7771 Dominateda 
HRT-GPS 3381 19.7771 Dominateda 
a An intervention is more costly but less effective than an intervention that is more 
effective. 
 
These data suggest that increasing the cost of the triage strategies by the inclusion of 
an NHS reference cost, renders them all dominated by current practice. On the basis 
of this result, a threshold analysis was performed to explore the maximum NHS 
reference cost which could be applied to the triage strategies for them to become un-
dominated compared to current practice. The additional cost was varied from £10 to 
£85 in £3 intervals. The results are presented in Appendix 9 and suggest that as the 
cost of the triage strategies increases, the incremental cost per QALY of current 
practice decreases. Once the reference cost of the triage strategies reaches £61, all 
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triage strategies are dominated by current practice.  The incremental cost effectiveness 
ratios of current practice relative to GDx or OCT are below the value typically 
considered to be cost effective in the UK46 and HRT-GPS is always dominated.  
Triage (with HRT-MRA) is cost-effective if the NHS reference cost tariff lies below 
£22, given a WTP threshold of £30,000 per QALY. 
 
Changes to the start age of the cohort 
The base case analysis included a cohort of men with an age of 40 years to be 
modelled for 50 years. The impact of modelling older cohorts of men was explored by 
varying the start age from 40 to 70 years old in 10 year intervals for the same 50 years 
time horizon. The results are shown in Table 52. 
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Table 52  Incremental cost effectiveness ratios for changes in the age of the 
cohort at referral 
Start age (years) Intervention Cost(£) QALYs ICER 
40 
 
 
 
 
GDx 2791 19.7701 0 
OCT 2917 19.7746 27904 
HRT-MRA 2952 19.7771 13896 
HRT-GPS 2961 19.7771 Dominateda 
Current practice 3084 19.7780 156985 
50 
 
 
 
 
GDx 2390 17.2356 0 
OCT 2503 17.2392 30995 
HRT-MRA 2535 17.2412 16016 
HRT-GPS 2544 17.2412 Dominateda 
Current practice 2647 17.2419 165616 
60 
 
 
 
 
GDx 1886 13.9949 0 
OCT 1983 13.9975 36940 
HRT-MRA 2011 13.9989 20152 
HRT-GPS 2018 13.9989 Dominateda 
Current practice 2098 13.9994 180864 
70 GDx 1318 10.3259 0 
 OCT 1395 10.3274 49717 
 HRT-MRA 1419 10.3283 29376 
 HRT-GPS 1423 10.3283 Dominateda 
 Current practice 1478 10.3285 211668 
a An intervention is more costly but equally as effective than an intervention that is 
less costly. 
 
As the starting age of the cohort increases, the incremental cost per QALYs of all 
interventions increases. Incrementally, as the cohort ages, both costs and QALYs  are 
decreasing but decreases in costs are outweighed by  
decreases in QALYs. This can be explained by the fact that treating younger 
populations yields larger health gains.   
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Changes to the patients treated: not treating patients at risk 
The base case analysis was conducted on the basis that all glaucoma patients and 
those “at risk of glaucoma” (including glaucoma suspects, OHT and PAC) would be 
monitored and treated depending on their definitive diagnosis. Due to the potential 
overload of hospital eye services, it was agreed there was a need to explore the effects 
of a hypothetical hospital eye service where those patients diagnosed as “at risk of 
glaucoma” would be discharged from the service thus potentially reducing the 
diagnostic, monitoring and or treatment costs. This analysis was conducted for all 
diagnostic strategies. The results are presented in Table 53. 
 
Table 53  Incremental cost effectiveness for treating glaucoma patients only and 
discharging those “at risk” 
Intervention Cost (£) QALYs ICER 
GDx 2673 19.7392  
OCT 2794 19.741 68362 
HRT-MRA 2824 19.7414 83590 
HRT-GPS 2833 19.7414 Dominateda 
Current practice 2954 19.7415 752248 
a An intervention is more costly but equally as effective than an intervention that is 
less costly. 
 
Compared to base case, all strategies have lower expected costs and lower expected 
QALYs. This is explained by the lower proportion of individuals that are under 
treatment. Also, the incremental cost effectiveness ratios for all interventions have 
increased; in moving from current practice to HRT-MRA, HRT-MRA to OCT and 
OCT to GDx, savings are £752,248, £83,590 and £68, 362respectively but at the 
expense of a QALY.   
 
The higher ICERs are due to less people “at risk of glaucoma” being referred to 
hospital eye services for re-diagnosis and further savings from the triage strategies are 
expected compared with base case analysis. In other words, there is not much benefit 
from referral to the clinician for the “at risk of glaucoma” group as the decision would 
always be to discharge them and wait until conversion to glaucoma in order to start 
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treatment. Given the value of all incremental cost effectiveness ratios, all the triage  
strategies except thedominated HRT-GPS can be considered cost effective given the 
typical thresholds used for decision making in the UK.46 
 
Changes to the sensitivity and specificity of the clinician 
The base case analysis assumed that clinicians were 100% sensitive and specific in 
their diagnosis of patients. In this sensitivity analysis, the sensitivity and specificity of 
clinicians was varied between 0.85 and 1 incrementally for all cohorts to explore the 
impact for patients of not always being seen in hospital eye services by a consultant 
ophthalmologist with glaucoma expertise, and thus having the possibility of reduced 
diagnostic accuracy. In the triage strategies, the diagnostic performance of the 
diagnosing clinician was not altered: for those referred (i.e. with a positive result of 
the triage testing) the clinician diagnosis was assumed to be perfect. The results are 
presented in Tables 54 and 55. 
  
149 
 
Table 54  Incremental cost effectiveness ratios for changes in sensitivity of 
clinicians 
Sensitivity Intervention Cost (£) QALYs ICER 
0.85 
 
GDx 2791 19.7701  
OCT 2917 19.7746 27904 
HRT-MRA 2952 19.7771 13896 
HRT-GPS 2961 19.7771 Dominateda 
Current practice 3025 19.7754 Dominateda 
0.90 
 
GDx 2791 19.7701  
OCT 2917 19.7746 27904 
HRT-MRA 2952 19.7771 13896 
HRT-GPS 2961 19.7771 Dominateda 
Current practice 3046 19.7763 Dominateda 
0.95 
 
GDx 2791 19.7701  
OCT 2917 19.7746 27904 
HRT-MRA 2952 19.7771 13896 
HRT-GPS 2961 19.7771 Dominateda 
Current practice 3066 19.7772 2068661 
a An intervention is more costly and either equally or less effective than an 
intervention that is less costly 
 
As the sensitivity of the clinician decreases from 1 to 0.95, the incremental cost per 
QALY of moving from HRT-MRA to current practice increases from £156,985 to 
£2,068,661. The incremental effect in terms of QALYs lost decreases as fewer 
patients are being correctly diagnosed. Similarly, incremental costs decrease; this is 
due to fewer patients being seen by a clinician which is only partially offset by cost 
increases due to more people being referred back for diagnostic testing with more 
expensive treatments. The incremental cost effective ratio decreases and is very 
sensitive to the performance of the clinician as the QALYs lost outweigh the cost 
gains. Once the sensitivity drops below 0.95, current practice along with HRT-GPS 
becomes dominated by HRT-MRA which is cheaper and either more or equally 
effective. This is because the cost savings realised by not being seen by a clinician are 
outweighed by the higher sensitivity of the alternative triage strategy (HRT-MRA). 
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The ICER of moving to any of the other triage strategies are below the values that are 
deemed acceptable in the UK to be cost effective (£30,000).46 
 
Table 55  Incremental cost effectiveness ratios for changes in specificity of 
clinicians  
Specificity  Intervention Cost(£) QALYs ICER 
0.85 
 
GDx 3029 19.7706  
OCT 3227 19.7752 42496 
HRT-MRA 3283 19.7778 22333 
HRT-GPS 3302 19.7778 1028309 
Current practice 3542 19.7789 221312 
0.9 
 
GDx 2952 19.7704  
OCT 3126 19.7750 37961 
HRT-MRA 3176 19.7776 19709 
HRT-GPS 3191 19.7776 1278469 
Current practice 3395 19.7786 201885 
0.95 
 
GDx 2872 19.7703  
OCT 3023 19.7748 33106 
HRT-MRA 3065 19.7773 16902 
HRT-GPS 3078 19.7774 2027006 
Current practice 3243 19.7783 177341 
 
As the specificity of the clinician decreases from 1 to 0.85, the incremental cost per 
QALY of moving from current practice to another triage strategy increases from 
£156, 985 to £221,312. The incremental effect in terms of QALYs lost increases as 
more patients, although being incorrectly diagnosed, who would go on eventually to 
develop glaucoma or be at risk are already being monitored/treated. Incrementally, 
costs are also increasing due to more patients seeing a clinician and being 
subsequently monitored / treated. The costs are sensitive to clinicians’ specificity as 
the cost increases are outweighed by the QALY gains. The values of incremental cost 
effectiveness ratios for current practice and HRT-GPS are above the acceptable 
threshold in the UK. That is, the savings, but with the loss of a QALY, of moving 
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from current practice to HRT-GPS and from this strategy to HRT-MRA exceed the 
WTP for a QALY and therefore a movement to HRT-MRA would be worthwhile.    
 
Changes in the costs of the triage strategies and not treating patients “at risk” 
A threshold analysis was conducted in order to explore the impact of increasing the 
costs of the triage strategies and discharging those patients that are given a diagnosis 
of “at risk” of glaucoma. Full results are presented in Appendix 9.  
 
Adding an NHS reference cost of £85 to the cost of the triage station has the impact of 
current practice dominating all strategies. This prevails until the unit cost of triage 
station falls below £64 when both current practice and GDx become un-dominated. 
Reducing the reference cost to around £46, GDx becomes cost effective compared to 
current practice. OCT also becomes un-dominated when the unit cost of the triage 
strategy falls to £34. Adding a lower reference cost to the triage station makes the 
triage strategies with lower expected cost worthwhile. This is reflected in the values 
of the ICERs that, compared with the usual threshold value for cost effectiveness in 
the UK,46 would render higher expected cost strategies to be not cost effective and 
therefore would make a triage with GDx worthwhile. 
 
Changes to the diagnostic performance of the imaging technologies 
The base case analysis incorporated point estimates for the sensitivities and 
specificities of each of the imaging technologies that were estimated from the GATE 
study. We explored the impact of changing these to a best case diagnostic scenario 
and a worst case diagnostic scenario for each of the imaging technologies (see 
Chapter 6) on the incremental cost effectiveness ratios. These figures were based on 
the confidence intervals of diagnostic performance measures used in the base case 
analysis and the results are presented in Table 56.  
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Table 56  Incremental cost effectiveness ratios for exploring triage performance best and worst case scenarios  
Strategy Cost QALYs ICER Strategy Cost QALYs ICER 
GDx best case GDx worst case 
GDx 2778 19.7717  GDx 2696 19.7683  
OCT 2917 19.7746 Ext Dominateda OCT 2917 19.7746 Ext. Dominateda 
HRT-MRA 2952 19.7771 31863 HRT-MRA 2952 19.7771 28988 
HRT-GPS 2961 19.7771 Ext Dominateda HRT-GPS 2961 19.7771 Ext Dominateda 
Current practice 3084 19.778 156985 Current practice 3084 19.778 156985 
OCT best case OCT worst case 
GDx 2791 19.7701  GDx 2791 19.7701  
OCT 2928 19.7751 Ext Dominateda OCT 2925 19.7746 Ext Dominateda 
HRT-MRA 2952 19.7771 26326 HRT-MRA 2952 19.7771 26326 
HRT-GPS 2961 19.7771 Ext Dominateda HRT-GPS 2961 19.7771 Ext Dominateda 
Current practice 3084 19.778 156985 Current practice 3084 19.778 156985 
HRT-GPS best case HRT-GPS worst case 
GDx 2791 19.7701  GDx 2791 19.7701  
OCT 2917 19.7746 Ext. Dominateda OCT 2917 19.7746 Ext. Dominateda 
HRT-MRA 2952 19.7771 26326 HRT-GPS 2921 19.7755 Ext Dominateda 
HRT-GPS 2965 19.7773 89632 HRT-MRA 2952 19.7771 26326 
Current practice 3084 19.778 172479 Current practice 3084 19.778 156985 
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HRT-MRA best case HRT-MRA worst case 
GDx 2791 19.7701  GDx 2791 19.7701  
OCT 2917 19.7746 Ext. Dominateda HRT-MRA 2905 19.7755 25658 
HRT-MRA 2955 19.7773 26275 OCT 2917 19.7746 Dominatedb 
HRT-GPS 2961 19.7771 Dominatedb HRT-GPS 2961 19.7771 34269 
Current practice 3084 19.778 186408 Current practice 3084 19.778 145579 
a Extended dominated: a combination of a less costly and less effective intervention and a more costly and more effective intervention 
would be more efficient. 
b An intervention is more costly but equally as  effective than an intervention that is less costly. 
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The results show that in all scenarios, current practice always has the highest un-
dominated ICER as it is always more costly and effective than any of the triage 
strategies. Furthermore, the order of the strategies, according to ascending cost, do not 
change, with GDx, even under a best case scenario, always having the lowest 
expected cost and the fewest expected QALYs.  
 
When considering the performance of OCT in a best case scenario, it does not form 
part of the efficiency frontier and would never be considered as a triage strategy as it 
is always dominated by other strategies.  The worst case scenario for OCT does not 
affect the ICER as OCT was not on the base case efficiency frontier. 
 
Compared with base case analysis, when the best case diagnostic scenarios are applied 
to HRT-MRA and HRT-GPS technologies in turn, the particular triage technology  
either replaces the other as the dominant option or reinforces its position as the 
dominant technology. The results of the sensitivity analysis investigating the best case 
scenarios show that the choice of strategies, in order of willingness to pay, is sensitive 
to the relative performance of HRT-MRA and HRT-GPS.  Given the assumptions in 
the model about consultant performance, no strategy displaces it as the most effective 
treatment. 
 
When the worst case diagnostic scenarios are applied to all the imaging technologies 
in turn, with the exception of GDx and OCT which was dominated already, they all 
become dominated and are not cost effective. This can be explained by the lower cost 
of the GDx imaging technology. However, HRT-MRA was always un-dominated 
except in the worst case diagnostic scenario when it was replaced by HRT-GPS. This 
can be explained by the similarities in the diagnostic performance and confidence 
intervals of these two imaging technologies. Identical to the base case results, with the 
exception of reducing the diagnostic ability of HRT-MRA as stated above, GDx, 
HRT-MRA and current practice are all dominant strategies and have increasing 
incremental cost effectiveness ratios relative to each other.   
 
In summary, in terms of GDx and current practice having the lowest and highest 
ICERs respectively, the base case results are not sensitive to changes in the diagnostic 
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accuracy of the imaging technologies. Similar to the base case analysis, current 
practice is not deemed cost effective in any scenario.46 However, the results are 
sensitive to improvements in the diagnostic accuracy in all the imaging technologies. 
The corresponding ICERs rise and the best case triage strategy becomes cost 
effective.  When the diagnostic accuracy of the imaging technologies are reduced, 
HRT-MRA remains the winning strategy. The exception to this is the worst case 
scenario for HRT-MRA where HRT-GPS becomes cost effective. This can be 
explained by the similarities in the diagnostic accuracy of these two technologies.    
 
Changes to the prevalence of glaucoma and “at risk” groups in the referred 
population 
The base case analysis assumed the prevalence of disease in the referred population 
was as found for the GATE study.  We explored the impact of a more enriched 
referred population (with higher proportion of glaucoma and “at risk” patients and a 
lower proportion of normal) if the existing triage system was used alongside a referral 
refinement scheme to filter out normal cases before referral to secondary care.  The 
results are reported in Table 57 and show higher expected costs and lower expected 
QALYs for all strategies compared with the base case analysis. This was anticipated 
as there are a higher proportion of glaucoma and “at risk of glaucoma” individuals 
entering the model compared with base case analysis. In addition, and also compared 
with base case analysis, triage strategies are less appealing (e.g. ICER for Current 
Practice compared with HRT-MRA of £156,985 for base case and £99,227 in Table 
57); however, the ICER of £99,227 is still above the usual cost-effectiveness 
threshold.   
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Table 57 Incremental cost effectiveness ratios of increasing the prevalence of 
glaucoma and “at risk” groups in the referred population 
Intervention Cost (£) QALYs ICER 
GDx 3991 19.1070  
OCT 4123 19.1131 Ext Dominateda 
HRT-MRA 4158 19.1163 18152 
HRT-GPS 4166 19.1163 Ext Dominateda 
Current practice 4266 19.1174 99227 
a Extended dominated: a combination of a less costly and less effective intervention 
and a more costly and more effective intervention would be more efficient. 
 
Changes to the quality of life for the “at risk” health state 
The base case analysis assumed a quality of life for the “at risk” health state equal to 
the mild glaucoma health state (QoL=0.8371).  We explored the impact of assuming 
that the “at risk health state” would have a quality of life equal to the normal health 
state (QoL=1).   As expected, Table 58 shows no changes in expected costs as well as 
higher values for expected QALYs for all strategies in the model. Moreover, there is 
no major impact in cost-effectiveness results with lower ICERs but close to the values 
observed for the base case analysis. Hence, base case results are robust to this 
sensitivity analysis. 
 
Table 58 Incremental cost effectiveness ratios of changing the quality of life for 
the “at risk” health state  
Intervention Cost (£) QALYs ICER 
GDx 2791 20.1788  
OCT 2917 20.1836 Ext Dominateda 
HRT-MRA 2952 20.1864 21107 
HRT-GPS 2961 20.1864 Abs Dominatedb 
Current practice 3084 20.1873 142873 
aExtended dominated: a combination of a less costly and less effective intervention 
and a more costly and more effective intervention would be more efficient. 
 b An intervention is more costly but equally as  effective than an intervention that is 
less costly. 
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Summary and discussion  
This chapter reported the results of a cost utility analysis of alternative composite 
triage strategies using alternative diagnostic imaging technologies compared with 
current practice for patients referred to hospital eye services for possible glaucoma.   
The base case results suggest that HRT-MRA is the most cost effective strategy.  
Given that current practice represents standard care in the UK, large savings in costs 
(£156,985) could be made but at the expense of a QALY. Furthermore, the 
incremental cost effectiveness ratio for current practice relative to HRT-MRA would 
exceed the value that is deemed to be cost effective in the UK. 
 
Another potential benefit is the release of clinicians’ time which could be used to 
deliver other interventions. 
Moreover, the sensitivity analysis results show triage strategies as a potential cost 
effective use of resources if the triage station cost does not reach  £30 per triage visit. 
However, sensitivity analysis results were inconclusive in signalling a unique cost 
effective triage strategy. HRT-GPS was often dominated by HRT-MRA but the 
expected QALYs that these two strategies produce were almost identical with the 
difference in total expected costs of around £10 which is not surprising since the 
results are obtained from the same imaging machine.  
 
Furthermore, on a cost effectiveness basis, GDx (or even OCT on a few occasions) 
could not be completely ruled out. GDx is highly specific and in a resource 
constrained health economy it could be an efficient use of resources. It should be 
noted, though, that clinically this strategy may not be acceptable to clinicians and/or 
patients due to its poor diagnostic performance (with low sensitivity). Determining a 
minimum level of diagnostic accuracy that is acceptable for clinical staff and patient 
was beyond the aims of this study and could be the subject of further research.  
 
The QALY outcomes of all strategies depend only on the sensitivities of the tests to 
identify glaucoma and those at risk of glaucoma. The sensitivities of the different 
triage strategies for glaucoma are very close to each other with the exception of GDx, 
but there is a greater difference between the strategies in their ability to identify 
people at risk of glaucoma. The consequences, in QALY terms, of missing a diagnosis 
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of glaucoma are greater than those that result from missing a diagnosis of being “at 
risk of glaucoma”. For these reasons the quality of life differences between triage 
strategies are small. The sensitivity of the triage strategies also means that the QALY 
differences between them and the base case scenario are small. This was to a certain 
extent anticipated for a study where triage strategies have similar diagnostic 
accuracies and a slow progression of disease. For example, this difference for the base 
case analysis between current practice and HRT-MRA triage strategy was 0.0008 
QALYs representing less than 8 hours in full health. This small difference might 
make easier to accept a triage strategy where QALY would be lost in exchange of 
potential savings.  
 
Furthermore, the incremental cost effectiveness of the triage strategies compared to 
current practice was very sensitive to costs included in the model. Unnecessary 
outpatient visits and associated treatment costs within current practice and, in 
particular, the costs of the actual triage strategies are model result drivers for the 
expected costs as well as the resulting incremental cost effectiveness ratios. The cost-
effectiveness of any triage strategy is heavily dependent on the unit cost of the triage 
station. As such, all these strategies were dominated by the current practice under the 
plausible assumption that an NHS provider of care would charge, for the triage 
station, an NHS reference cost tariff corresponding to an outpatient appointment. 
Indeed, current practice becomes dominant when the cost of an outpatient 
appointment increases to £61 and above.  
 
A key assumption used in the model was that clinicians are 100% accurate in their 
diagnostic ability. Relaxing this assumption further increased the incremental cost 
effectiveness ratios of current practice relative to other triage strategies above a level 
that would be deemed to be cost effective in the UK. 46 Even under extreme scenarios 
where the diagnostic accuracy of the triage strategies were reduced, current practice 
could not be deemed the most cost effective. Hence, in terms of diagnostic accuracy, 
no plausible scenarios rendered current practice to become the most cost effective. A 
probabilistic sensitivity analysis was therefore not warranted. Only when the costs of 
the triage strategies increased with an NHS reference cost did current practice become 
cost effective.  
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The strengths of this research are that an economic model has been developed and 
analysed using good modelling research practice.49,50 The cost-effectiveness of the 
different imaging technologies and their subsequent care management pathways were 
assessed using a multi-state Markov model. This modelling approach is highly 
relevant as glaucoma is a chronic condition, which progresses slowly over time, 
allowing the model to reflect both the timing of both diagnostic testing and disease 
progression following the initial diagnostic strategy. Furthermore, we believe this is 
the first economic evaluation of these interventions to be conducted in this context.   
 
There are limitations to this research. A key issue for the study is paucity of data 
regarding parameter inputs used in the model. As stated in the introduction (see 
Chapter 1), there is a lack of evidence regarding the diagnostic accuracy of imaging 
techniques in a triage setting and thus the parameter estimates regarding this have 
been based on the GATE study alone and not from multiple studies. Furthermore, the 
diagnostic accuracy of clinicians has been assumed to be perfect but explored in 
sensitivity analysis.    
 
Only very limited data on the costs of diagnosis and treatment were available, and 
although efforts were made to identify the best data applicable to the UK, these were 
sparse. The model estimates would be more robust if further data were to become 
available and as previously stated by colleagues,19 consideration should be given as to 
whether further primary research is needed. The model was very sensitive to the costs 
of the triage strategies and as stated above, adding additional costs to their unit costs 
renders triage not cost-effective compared to current practice.   
 
The quality and usefulness of the economic model is dependent not only on the 
quality of the data, but also on the way in which the data are used. The data 
requirements and the use of the data were determined by the structure adopted for the 
model. The development of the economic model was, as described in Chapter 6, based 
on discussions with a number of key stakeholders. It then underwent a prolonged 
period of refinement during which the care pathways were critically examined and 
refined. The model structure applies to a UK context, and may not be relevant to other 
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country settings, although other strategies could be developed and readily added to the 
model. 
 
As described in Chapter 6, the model structure was developed so that the assumptions 
made in the base case analysis could be explored in future work. For example, in the 
base case analysis it was assumed that the clinician would make a perfect diagnosis. 
The model structure has allowed for the possibility that this will not be the case and 
that the clinician might possibly initiate treatment when it is not required (a false 
positive) and fail to diagnose some cases of glaucoma(a false negative).  
 
The model is a simplification of the care pathways that may follow. For example, the 
model structure does not include all possible health states that may be relevant in 
context, such as misdiagnosis of those at risk of glaucoma as true positives. A second 
simplification made in the model was the relatively small number of stages used to 
reflect the progression of this chronic condition. While this assumption may fail to 
represent the subtleties of disease progression, it was believed the health states were 
sufficient in number to reflect the relevant issues needed for this economic evaluation.  
 
Estimates of the risk of progression between health states are based on data from one 
eye and do not necessarily represent the definition of the health states in the model, 
which is based on binocular visual field loss. The fellow eye may not have such 
advanced disease as the study eye and therefore the quality of life loss might be 
overestimated. While this is a limitation of the study, the alternative of using the 
better eye for the analysis would result in an under estimation of the risk of 
progressive binocular visual field loss. Furthermore, there were insufficient data to 
determine whether some of the parameter values varied between the stages of disease, 
for example the diagnostic performance of the diagnostic strategies. The model was, 
however, structured in such a way that should such data become available in the 
future, the model could be readily adapted and data incorporated. 
 
A further simplification in the model structure was that rather than modelling the full 
variety of treatments available for glaucoma it has been assumed that the effect of 
treatment can be represented by a single relative effect size for treatment compared 
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with no treatment. Also, when interpreting the results of the economic evaluation it 
should be borne in mind that the estimates of cost-effectiveness relate to a male 
cohort. Gender-specific data were not available for any of the parameter estimates 
except for annual all-cause mortality. 
 
Finally, there is no clear decision rule or willingness to accept threshold value to 
interpret cost-utility analysis results where savings are obtained at expense of QALY 
being lost. In this study a similar threshold value to the one often used as willingness 
to pay for a QALY gained was assumed (i.e. £30,000). While this is one value from 
many possible, in the great majority of the analysis the savings per QALY lost 
(ICERs) were well above this threshold. In other words, the adopted interpretation 
would be consistent with higher willingness to accept value should this become 
common practice.  
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Chapter 8  Discussion  
 
GATE was a large multi-centre study designed to evaluate the performance of a triage 
test for patients referred to hospital eye services with possible glaucoma. The triage 
test would include visual acuity and intraocular pressure measurements, and one of 
four imaging tests from three different instruments (the HRT-3 confocal scanning 
laser ophthalmoscope (HRT-GPS and HRT-MRA), GDx scanning laser polarimeter, 
and a spectral domain optical coherence tomograph, OCT (Spectralis)). There were 
two diagnostic evaluations that consisted of (1) an estimation of the ability of imaging 
technologies to diagnose glaucoma at an eye level, and (2) an assessment of the 
performance of a triage test. All instruments are currently available in the NHS. 
 
Regarding the diagnostic ability to detect and rule out glaucoma, all four imaging tests 
had some value but HRT-MRA had the highest sensitivity but lower specificity 
compared to other tests. In contrast GDx had the best specificity though the lowest 
sensitivity. HRT-GPS results were similar to HRT-MRA as might be anticipated 
given their analysis is based on imaging the same structure (i.e., the optic disc).   
Sensitivity for OCT was very similar magnitude to its specificity. OCT had the lowest 
percentage of low quality imaging results, with GDx having the highest, according to 
the image quality classification provided in the device software. Average time taken 
to conduct the tests was lowest for OCT. Patient preference tended to favour OCT 
followed by GDx although almost half of participants did not have a preference.  
 
A number of sensitivity analyses were carried out to assess the robustness of the 
findings of the default analysis. Varying the test definition of an abnormal imaging 
result by including the borderline category had the anticipated impact of improving 
the detection of glaucoma, though at the expense of more non-glaucoma cases being 
falsely classified to have glaucoma. The impact of combining two imaging tests 
improved detection of glaucoma, but the improvement was marginal and smaller than 
the loss of specificity.  
Regarding the triage analysis, four composite triage tests - which consisted of an 
imaging test, IOP measurement and visual acuity assessment - were compared with 
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regards to their performance for determining who should be referred onto a clinician 
for further assessment or discharged. All four triage tests had value in terms of ruling 
in and ruling out the need for referral to a clinician. The diagnostic performance of the 
triage tests differed substantially. HRT-GPS and HRT-MRA had consistently the 
highest sensitivities across analyses but at a cost of lower specificity compared to 
other tests. In contrast GDx consistently had the best specificity though the lowest 
sensitivity. OCT generally had similar levels of sensitivity and specificity. A number 
of sensitivity analyses were carried out that confirmed the robustness of the findings 
of this default triage analysis. 
The economic analysis suggested that a composite triage test, introduced into the care 
pathway for patients referred from community with possible glaucoma, appears to be 
cost-effective compared with current practice where all referred patients are seen by a 
clinician. Our findings are based on a relatively inexpensive composite triage test 
(£<30) including an imaging technology, IOP and visual acuity testing.    
Triage using HRT-MRA was the most cost effective strategy. Given that current 
practice in the model represented standard care in the UK, large savings in costs 
(£156,985) could be made for each QALY forgone. In the incremental cost 
effectiveness ratio current practice compared with HRT-MRA would largely exceed 
the value that is deemed to be cost effective in the UK. With the exception of GDx, 
the diagnostic accuracy of all the triage strategies and their unit costs are very similar. 
Using GDx in a triage test is the least costly and least effective diagnostic strategy but 
it was still cost effective compared with current practice for a number of analyses. 
 
A variety of sensitivity analyses were conducted. The incremental cost effectiveness 
ratio of the triage strategies compared to current practice was very sensitive to costs 
included in the model. With the exception of increasing the costs of the triage stations 
to NHS commissioners, within the uncertainty analysis, triage was always more cost-
effective than current practice.  Furthermore, the present analysis is inconclusive on 
the decision about a particular imaging test to be included in a triage station. Further 
research on acceptability of the alternative imaging tests is warranted. 
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There are emerging models of eye care  in the community that try to reduce the 
number of false positive referrals to hospital eye services.51-53 Their effectiveness, 
efficiency and acceptability needs to be evaluated in primary research before 
implementing change.  The GATE study provides  robust data on how such services 
might be reconfigured. 
 
Strengths and limitations 
A number of strengths can be highlighted. GATE was a large prospective paired 
diagnostic study and evaluated diagnostic tests in the desired setting. The benefit of 
the large sample size is reflected in the precision in which the sensitivity and 
specificity were calculated with differences between every pair of tests identified for 
one if not both the sensitivity and specificity. McNemar’s test was used to compare 
the sensitivity and specificity of the tests. Following the rationale of others in 
effectiveness studies, the paired comparisons were not adjusted for multi-
comparisons. Even if such a correction had been applied, such was the strength of 
evidence there would still be evidence of differences in the diagnostic performance of 
the different imaging tests.  
 
The population enrolled in GATE consisted of subjects without a known history of 
disease, which would reflect the potential clinical application of the triage test. Other 
reported studies evaluating the performance of diagnostic technologies have used 
patients already diagnosed with glaucoma, which has a risk of selection bias. This 
study recruited patients before diagnosis and the population tested had a broad 
spectrum of disease at presentation, from early through to severe glaucoma, and 
included a large percentage of healthy individuals. The healthy individuals from 
whom the test ‘specificity’ was determined were subjects referred from primary care 
with a possible glaucoma-related finding (either risk factor or suspected sign). Thus, 
the diagnostic performance reported here refers to a secondary care setting and may 
be different in an unselected population. 
 
An intentional aspect of the study’s design is the focus upon both the diagnostic 
performance of imaging tests for the identification of individuals with glaucoma, and 
the performance as a triage test where imaging tests would be used in conjunction 
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with other routine measurements (IOP and visual acuity). Both aspects are important 
for understanding the potential value of the imaging tests. We have also evaluated 
other important considerations for diagnostic technologies, such as interpretability, 
patient preference and time taken to perform the test.  
 
The reference standard was provided by different ophthalmologists with glaucoma 
expertise. The ophthalmologists had been trained in the study protocols and agreed to 
a common set of criteria to define glaucoma and normality. By using different 
ophthalmologists working at different units the results of the study are more likely to 
be generalisable than results from studies performed in a single unit. The participating 
units are likely to be representative of the NHS practice, including two district general 
hospitals and three academic units of different size: relatively small (Aberdeen), 
medium (Liverpool) and large (Moorfields).  
 
The economic model was developed and analysed using good modelling research 
practice.49,50 The cost-effectiveness of the different imaging technologies and their 
subsequent care management pathways were assessed using a multi-state Markov 
model. This modeling approach is highly relevant as glaucoma is a chronic condition, 
which progresses slowly over time, allowing the model to reflect both the timing of 
diagnostic testing and disease progression following the initial diagnostic strategy.  
 
Among the limitations, we recognise that diagnosing glaucoma during the very early 
stage of disease is challenging, and ideally a longitudinal follow-up would provide the 
best possible reference standard. This was proposed by Medeiros35 who used optic 
nerve head progression on stereophotographic examination as the criterion for 
glaucoma diagnosis, but we could not contemplate this possibility in GATE as years 
of follow-up would have been required. The reference standard was assumed to be 
perfect though it is widely recognised that diagnosis of glaucoma is difficult in early 
disease, and uncertainty exists even amongst specialists. While consensus was sought 
through structured training, some assessor differences may have remained between 
the sites. Adding CCT information for patients referred for high IOP could potentially 
add valuable information and help further refine the referral pathway of such patients.    
 
166 
 
There was lack of evidence base regarding some parameter inputs used in the 
economic model. Only very limited data on the costs of diagnosis and treatment were 
available, and although efforts were made to identify the best data applicable to the 
UK, these were sparse. Data with respect to health utilities was available but it is 
unclear whether EQ-5D is sensitive enough to detect clinically significant changes in 
glaucoma. The model is a simplification of the care pathways that may follow, with a 
relatively small number of stages used to reflect the progression of this chronic 
condition. Estimates of the risk of progression between health states were based on 
data from one eye, and do not necessarily represent the definition of the heath states in 
the model, which is based on binocular visual field loss. A further simplification in 
the model structure is that rather than modelling the full variety of treatments 
available for OAG it has been assumed that the effect of treatment can be represented 
by a single relative effect size for treatment compared with no treatment. 
 
Uncertainties 
• The diagnosis, natural history and risk of conversion to glaucoma of untreated 
or treated patients classified as glaucoma suspects is unknown. It is likely this 
is a very heterogeneous group, as reflected in the categories of glaucoma 
suspect defined in GATE. 
• The natural history and risk of conversion to glaucoma of untreated or treated 
patients with ocular hypertension undergoing standard care is unclear. 
Although there is evidence on the efficacy of treatment of OHT from large 
randomised controlled trials, the generalisability of their findings to routine 
clinical care in the NHS is ill defined.  
• It is unclear how often people attend community optometrists for regular eye 
exams. If they have glaucoma missed by the triage it is unknown how quickly 
it would be detected by the optometrist and at what severity of disease. In our 
model we hypothesised that all those with a false negative diagnosis at the 
triage stage would return to hospital eye services within three years.   
• The triage analysis used the IOP information provided by a consultant 
ophthalmologist. A triage system would rely on IOP measurements taken by a 
technician or a nurse, and it is uncertain whether such IOP measurements, 
possibly obtained with different tonometers, will be significantly different, and 
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what impact would it have in the performance of the triage test.  The 
diagnostic accuracy of clinicians is uncertain. Glaucoma is diagnosed 
clinically, relying on the experience of the examiner, and it is likely the 
relative performance of the imaging technologies may be underestimated if the 
reference standard comparator consists of experienced glaucoma experts, as 
were used in GATE. Glaucoma in the NHS is diagnosed by a variety of health 
care professionals, including optometrists, specialist nurses, senior 
ophthalmologists with variable glaucoma expertise, and trainees. 
• There are other OCT instruments in the market with glaucoma diagnostic 
capabilities and the results of this study using the Spectralis device may not be 
fully applicable to other OCT technologies.  
   
Chapter 9  Conclusions 
 
Implications for healthcare 
Automated imaging technologies can be effective tests to aid in the diagnosis of glaucoma 
among individuals referred from the community to hospital eye services with possible 
glaucoma. A model of care incorporating a triage composite test for diagnosing patients 
referred from the community appears to be cost-effective compared with current practice. 
Our findings are based on a relatively non-expensive composite triage test (£<30) including 
an imaging technology, IOP and visual acuity testing. The most efficient strategy would 
include HRT-MRA imaging. However, a triage test would be associated with reduced health, 
and the acceptability of this option among users and clinicians has not been evaluated.  
 
Recommendations for research 
• Acceptability to patients and health care providers of implementing an efficient triage 
glaucoma diagnostic system but with reduced health should be explored. A qualitative or 
mixed methods study, e.g. including a discrete choice experiment, incorporating also 
public perspectives, would be suitable.  
• Further data on the glaucoma disease progression under routine care, and specifically 
including patients classified as glaucoma suspects and ocular hypertension, associated 
utility, and cost of providing health care services and sight loss is needed. A long-term 
longitudinal cohort study would be ideal to address these issues.  
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• Further investigation of varying the thresholds for classification of the imaging tests 
beyond the standard options presented in the software could be undertaken as the 
standard classification may not be the one best suited to the population referred from the 
community to hospital eye services. Further analysis of GATE data or review of data 
from other relevant diagnostic studies would be able to answer this question.  
• The effectiveness of implementing a triage test incorporating imaging, an IOP 
measurement and visual acuity requires evaluation. A longitudinal diagnostic impact 
study is needed.  
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Versions of the study protocol 
Version 1, 28th July 2010 
Version 1.1, 31 January 2011 (minor typographical changes) 
Version 1.2, 17 April 2012 (extension of recruitment timescale)  
Version 1.3, 11April 2013 (extension of recruitment timescale) 
Version 1.4 (current) 4 July 2013 (updated list of grant holders and TSC members)  
           
Comparative study of new imaging technologies for the diagnosis of glaucoma: 
Protocol Approved by the Ethics Committee 
 
HTA 09/22/111.  
Applicants: Augusto Azuara-Blanco (CI), Jennifer Burr, , Rodolfo Hernández, 
Jonathan Cook, Kirsty McCormack, David Garway-Heath, Rupert Bourne, Mark 
Batterbury, Craig Ramsay. 
 
Other participants: Professor Colm O’Brien (Dublin, Study Steering Committee 
Chair), and Russell Young (patient representative), Anja Tuulonen (independent 
steering committee member), Anthony King (independent steering committee 
member) 
 
ACRONYMN:  GATE (Glaucoma Automated Tests Evaluation) 
 
INTRODUCTION 
Approximately 4000 people are registered either blind or partially sighted each year 
because of glaucoma in the UK.  Many more people have glaucoma not severe 
enough to be registered, but severe enough to reduce vision and quality of life.  
   
Diagnosis of glaucoma is challenging for health professionals and many people are 
incorrectly diagnosed as having glaucoma by community optometrists. In fact, only 
20-30% of those referred from optometric services have glaucoma and 45% of 
patients are discharged after their first visit.  Secondary care services are very busy 
(accounting for nearly 10% of all outpatient attendances to the NHS) and glaucoma is 
a major part of the workload of any eye unit. The referral of so many healthy subjects 
Appendix 1  GATE study protocol v1.4 
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(less than 1/3 of referrals) is a waste of resources and causes unnecessary worry and 
distress to the patient. New diagnostic tests are available and are easy to perform. 
They are based on imaging the posterior part (fundus) of the eye where glaucoma 
damage can be observed. However, how well such tests perform and which is the best 
test to use is uncertain. This project will evaluate the performance of three new such 
tests to prioritise patients referred for possible glaucoma.  
If one or more of the tests prove to be sufficiently accurate and easy to perform, the 
ophthalmologists would have more time and resources to treat patients with eye 
diseases. 
 
AIM To compare directly the diagnostic performance of three automated imaging 
technologies within patients referred to secondary care with possible glaucoma and to 
explore patient test preferences.  
 
METHODS 
 
Study design – A within patient multi-centre comparative study of the diagnostic 
performance of three automated imaging technologies for glaucoma diagnosis.  
 
The tests – 1) HRT-III: Confocal laser scanning imaging technology, employed by 
the Heidelberg Retina Tomograph exploits the principle of confocal laser scanning to 
allow quantitative structural information of the optic disc anatomy.  2) GDx-ECC: 
Scanning laser Polarimetry measures the retinal nerve fibre layer (RNFL) thickness. It 
is based on the birefringent properties of RNFL.  3) SD-OCT: Spectral Domain 
Optical Coherence Tomography is an optical imaging technique capable of providing 
high resolution, cross-sectional, imaging retina and quantifies the thickness of the 
RNFL.  The Heidelberg Spectralis will be used in this study.  
 
Inclusion and exclusion criteria 
Inclusion criteria:  Adult patients age 18 and over referred from community 
optometrists or General Practitioner to hospital eye services with glaucoma, or 
suspected glaucoma, including those with ocular hypertension, with or without 
associated ocular co-morbidity 
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Exclusion criteria: Patients referred to hospital eye services because of other ocular 
disease; children; patients who cannot give informed consent, patients already 
diagnosed with glaucoma in secondary care.  
 
Sample and recruitment 
Information about this study will be sent by post to eligible patients.  The research 
nurse will discuss the study with the patient when they come to the clinic and will 
then take them through the consent process. Patients who agree to participate and sign 
the consent form will be enrolled.  Of those patients who do not wish to participate, 
age and gender information will be collected.   
 
Procedure  
1. Each consented participant will undergo testing with the three technologies in both 
eyes.  Each test produces a diagnosis of glaucoma (yes/no) without observer input.  
The order of testing will be randomly selected for each participant using a sheet with 
the randomisation order.  
2. The research nurse will a) download the results to disks to be stored locally and 
sent to Aberdeen at the end of the project, ensuring all identifiers are removed, and b) 
print out the results of each test from the machines, remove the patient identifiers 
from the print out and write on the designated study number. 
3.  The participant will be asked to grade the tests in order of preference, using a 
standard form (see attached) 
4. The participants will be examined by an experienced glaucoma clinician who will 
perform a comprehensive examination including intraocular pressure (IOP) 
measurement and biomicroscopic slit lamp examination of the optic nerve (with pupil 
dilated) and visual field testing (with Humphrey SITA 24-2 strategy) and provide the 
reference standard masked to the results of the imaging technologies. The clinician 
will complete a clinical data collection form. 
5.  The research nurse will collate the results for each participant including a copy of 
the VF test, complete forms for each participant, upload the information into the 
webpage, and post to the coordinating centre in Aberdeen.  Information to be included 
in the webpage includes demographics (including non-participants), refraction (any 
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method), patient preference, need for pupil dilation, and visual field indices MD and 
VFI.  
 
Data handling - Confidentiality will be maintained for all participants.  All data 
collection sheets will have a unique study number and access to the data will be 
restricted to the study team.   
The study data will be stored securely for a minimum of 10 years after study 
completion by the co-ordinating office at the University of Aberdeen (in line with 
current MRC guidelines). 
 
Data analysis –  
Primary diagnostic performance outcomes: sensitivity, specificity of the three imaging 
technologies HRT III (GPS and MRA output), GDx-ECC, and OCT will be compared 
using McNemar’s test at the 5% significance level. Corresponding 95% confidence 
intervals for the paired difference will also be generated.  For the primary analysis, the 
cut-off values for a positive diagnosis will be the respective manufacturer’s 
recommended level.  However, possible threshold effects will also be investigated in 
the study by varying the respective cut-off.  The area under the ROC curve will also 
be formally compared between technologies. 
 
Secondary diagnostic performance outcomes: ROC curves (thresholds varied for test 
positivity), diagnostic odds ratio, likelihood ratio, proportion of indeterminate tests, 
patient preference for test. 
 
Primary and secondary diagnostic measures (area under ROC curve, likelihood ratios 
and diagnostic odds ratio) will be presented for each technology with appropriate 95% 
confidence intervals.  We shall also measure the proportion of tests that are 
indeterminate.  All analyses will follow a patient-based (referral eye) approach.  For 
referrals where bilateral disease is suspected, a study eye will be selected at random at 
the analysis stage.  Additionally, the level of diagnostic performance across the 
disease spectrum (as defined by the reference standard) will be explored.  
 
The overall diagnostic performance of combinations of these three technologies will 
also be evaluated, and their relative performance.  The diagnostic performance of the 
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tests (and corresponding combinations) will also be assessed according to the 
spectrum of glaucoma (mild, moderate, severe), as defined by the specialist 
ophthalmologist.  Additionally, the impact of introducing a measure of IOP into the 
triage test will be explored. 
 
A further analysis will consider the impact on diagnostic performance of using 
combinations of these technologies under three approaches: both positive, either 
positive or by generating a prognostic rule using multivariable logistic regression 
model.  Furthermore, the impact of using these technologies in tandem with a measure 
of IOP to identify suspected cases of glaucoma and/or ocular hypertension for 
referral, as might occur in a clinic setting, will also be examined.  For this analysis, 
disease will be defined as the presence of either condition.  The analysis would follow 
the above comparative approach. 
 
Economic outcomes: costs of providing the tests (initially retrieved from the four 
study sites), costs (of testing and subsequent management), QALYs, and incremental 
cost per QALY.  
 
Economic evaluation  
Modelling will be used to determine which test or combination of tests would be 
effective and cost-effective compared with current practice.  The results of the 
modelling will be diagnostic performance. We will develop a new economic model 
which will estimate the costs and outcomes of diagnosing glaucoma in secondary 
care. We will consider the use of the diagnostic tests used alone or in combination in 
secondary care. The model will compare the diagnostic performance of the tests and 
effect of longer term outcomes (e.g. Quality Adjusted Life Years – QALYs). The 
costs of current management alternative diagnostic pathways will depend upon the 
findings of the diagnostic performance analyses, the literature and advice from the 
project team. Costs and outcomes following diagnosis (both for those with true and 
false diagnoses) will be derived from an updated version of an existing economic 
model. The perspective of the economic analysis will be that of the NHS. The results 
of the model will be presented in terms of (i) costs (of testing) and diagnostic 
outcomes, (ii) costs (of testing and subsequent management), (iii) QALYs and 
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incremental cost per QALY. The results will be presented as point estimates and cost-
effectiveness acceptability curves (cost per QALY data). Deterministic sensitivity 
analysis will be combined with probabilistic sensitivity analysis to explore different 
types of uncertainty (e.g. impact of the scale of the service on cost-effectiveness). 
 
Sample size considerations 
The sample size calculation and analysis are based on standard McNemar diagnostic 
accuracy study methods.  The sensitivity and specificity of each of the automated tests 
will be compared.  A 5% significance level based upon a 2-sided test was used in the 
sample size calculations.  A study of 897 individuals would have 90% power to detect 
a difference in accuracy of 9% for the primary outcome of diagnosis of glaucoma.  
This is based upon conservative assumptions of a probability of disagreement of 0.18 
(maximum level possible), a glaucoma rate of 25% (as seen in similar populations) 
and a sensitivity of 86% as found in a systematic review for HRT II.  Given this 
sample size, there would also be 80% power for detecting a 6% difference in accuracy 
should the sensitivity be 93% (the current best estimate from meta analyses of high 
quality diagnostic studies).  For specificity, we would have over 90% power to detect 
a 5% difference.  Based upon current available evidence, a rate of 6% indeterminacy 
of tests results was assumed which increased the sample size to 954 in total.  A 
sample of this size would be of sufficient size for other measures of diagnostic 
performance (e.g. the sensitivity and specificity of individual technologies would be 
estimated to 95% confidence interval of width 10% and 5% respectively). 
 
Dissemination 
Participants will be offered a summary of the study findings once the study is 
complete.  Papers will be submitted for publication to peer reviewed journals and 
submitted for oral/poster presentation at both international and national conferences. 
 
We are also required to report these findings to the NIHR HTA who are funding this 
study.   
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Timelines 
 
Pre-funding 
Ethics 
 
Start date 
1 December 2010 
 
October 22 
First steering group meeting 
Month 1-3 
Study set-up, authorisations, protocol finalised 
Month 4-32 
Patient recruitment (from March 2011) 
Month 12 
Second steering group meeting 
Month 19 
Third steering group meeting 
Month 32 
Data cleaning and preliminary analysis 
Month 32 
Close down centre study processes 
Month 33-36 
Final analysis and reporting 
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Evaluation of novel imaging techniques for the detection of Glaucoma. 
 
Dear  
 
Invitation to take part in a research study 
 
I am currently undertaking a national study to evaluate the performance of three new automated 
eye tests for the diagnosis of glaucoma in conjunction with The Health Services Research Unit, 
University of Aberdeen.  As you are coming to the eye out patients department for an 
appointment I would like to invite you to take part. 
 
I have enclosed an information sheet about the study which will help you decide whether or not 
you would like to participate and would be most grateful if you could take a few minutes to read 
through the information. 
 
If you agree to take part then you will be given three automated eye tests during your 
appointment which should take no longer than one hour to complete before being seen by the 
ophthalmologist as per a normal clinic appointment. 
 
Although your involvement is very important to us we would like to stress that you are under no 
obligation to participate.  We will be happy to discuss any aspect of the study with you at the 
clinic when we see you and if you have any questions about the study we will be pleased to 
answer them then.  
 
Yours sincerely, 
 
 
Augusto Azuara-Blanco 
Consultant Ophthalmologist.
Appendix 2  Information for patients 
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Evaluation of novel imaging techniques for the detection of 
Glaucoma (GATE study). 
 
Information leaflet. 
 
You are being invited to take part in a research study.  Before you decide it is important for you 
to understand why the research is being done and what it will involve. Please take the time to 
read the following information carefully and discuss it with others if you wish.  Ask us anything 
that is not clear or if you would like more information.  Take time to decide whether you wish to 
take part. Thank you for reading this. 
 
What is the purpose of the Study? 
Glaucoma can reduce vision and quality of life but if diagnosed early it can be treated and 
reduction of vision prevented.  The main risk factor for a reduction in vision due to glaucoma is 
being diagnosed late and damage to the eyesight has already begun.  New promising diagnostic 
imaging tests are available and are easy to perform.  They use a laser to explore and analyse the 
structure of the optic nerve head and surrounding tissues in the back of the eye.  However, which 
test is the best to use is uncertain at present and this project will evaluate the performance of three 
new imaging tests.  If one of the tests proves to be accurate and easy to perform, it could be 
implemented in the community to reduce the risk of reduced vision from glaucoma. 
 
Why have I been chosen? 
As you are attending the eye out-patient clinic for an eye examination from an ophthalmologist 
we would like to invite you to take part. 
 
Do I have to take part? 
No. It is up to you to decide whether you take part. If you do decide to take part, you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to take 
part, you are still free to withdraw at any time and without giving a reason. 
GATE study patient information leaflet 
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What will happen if I take part? 
The study is carried out alongside your appointment in the local Eye Out-Patient Clinic. 
Depending on routine practice at your local clinic this may be one or two appointments. You will 
be given a visual fields test along with three imaging tests and finally a basic eye examination by 
an Ophthalmologist.  The addition of the imaging tests may extend your appointment time by 
approximately one hour. 
 
What do the imaging tests involve? 
There will be three imaging tests carried out by a research technician. The imaging tests are non-
invasive and do not usually require eye drops. During the test you will have to look at a fixation 
light for a short period whilst a series of images of the optic nerve head at the back of the eye are 
acquired. The imaging tests are rapid and take approximately 10 minutes to complete. In a small 
number of cases we may have to place some eye drops in your eyes to dilate your pupils.  This 
can make it easier to take the image.   
 
What are the possible disadvantages and risks of taking part in this study? 
Most people will not need their pupils dilated.  If we need to dilate your pupils it can sometimes 
cause some temporary blurring of vision and sensitivity to light.  This is, however, a routine 
procedure which would normally be performed as part of your eye examination 
 
Are there any benefits to taking part in the study? 
There will be no direct benefit to yourself in taking part in the study, however if any of the tests 
prove to be accurate and easy to perform, they could be implemented in the community. 
 
Will my taking part in this study be confidential? 
All information which is collected about you for the study will be kept strictly confidential.  
Information for all participants in the study will be kept for a minimum of ten years in line with 
current research governance arrangements and then destroyed.  Only researchers involved with 
the study will have access to your information 
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What happens to the results of the study? 
The results of the research will be published in relevant scientific journals and a report will be 
sent to the funder of the research, the NHS Health Technology Assessment programme.  We 
would also be happy to send you a short report when the study when the research is complete.  
You will not be identifiable in any publications from this research. 
 
How do I Complain? 
If you wish to complain or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal NHS complaints mechanisms 
are available to you. 
 
Who has reviewed the study? 
This study has been reviewed and approved by the North of Scotland Research Ethics 
Committee. 
 
Thank you very much for considering taking part in this research. 
 
Contact details for further information 
 
Central office:      Local contact details: 
GATE Study Office       
Health Services Research Unit     [Contact details]  
University of Aberdeen     [for local researchers] 
Health Sciences Building     [Affix sticker here] 
Foresterhill 
Aberdeen AB25 2ZD 
Tel: 01224 438196 
Fax: 01224 438165 
Email:gate@abdn.ac.uk
 188 
 
GATE study consent form 
 
 (Form to be on headed paper) 
 
Participant Study Number:  
 
CONSENT FORM 
 
 
Comparative study of new imaging technologies for the diagnosis of glaucoma: the GATE study 
 
 
       Please initial box 
 
 
1 I confirm that I have read and understand the information sheet dated ............................ 
 (version ............) for the above study.  I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
 
 
2 I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
 
 
3 I understand that relevant sections of my medical notes and data collected during the study, 
may be looked at by individuals from the University of Aberdeen, from regulatory 
authorities or from the NHS Trust/Health Board, where it is relevant to my taking part in 
this research.  I give permission for these individuals to have access to my records. 
 
 
  
4  I understand that my personal details collected during the study will be held in a secure 
central database, and may be subject to audit and monitoring by University of Aberdeen or 
NHS Trust/Health Board staff, without breaching data confidentiality 
 
 
5 I agree to take part in the above study.    
  
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________________________ ________________ ____________________ 
Name of Patient   Date Signature 
 
 
 
I confirm that I have explained to the person named above the nature and purpose of the GATE study and the 
procedures involved  
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date  Signature 
 
 
 
 
GATE study office, Health Services Research Unit, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD. 
Tel: 01224 438196, Fax 01224 438165, Email: gate@abdn.ac.uk 
 
Copies: Original to be returned to study office: 1 copy for patient; 1 copy to be filed with hospital notes 
 
 
 190 
 
Appendix 3  GATE study case report forms 
 
 
Study Number Patient Name Year of 
birth 
Gender 
M/F 
Info. sheet sent  Date info. 
sent 
Consented If not consented, state 
reason (A, B,  C or D ) 
Assigned Test 
Order 
 HRT   GDX OCT 
        Y  N   Y  N      
        Y  N   Y  N      
        Y  N   Y  N      
        Y  N   Y  N      
        Y  N   Y  N      
 Inclusion criteria   
 
• Adult patients (aged over 18 years old)  
• New referral from primary care to glaucoma clinic 
 
  
Clinic date 
 
 
…………..……………………………. 
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        Y  N   Y  N      
        Y  N   Y  N      
        Y  N   Y  N      
        Y  N   Y  N      
        Y  N   Y  N      
 
Reasons for not including  
A: Non attendance (DNA/CNA)  
B: Refusal – record reason if possible 
C: Missed 
D: Equipment not working (please record which machine is not working)  
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Participant Study No 
      
            
 
 
 
 
                  
 
 
 
 
 
 
 
 
 
 
 
          Research Officer Data Collection Form 
 
 
 
 
 
 
 
This study is funded by the NHS National Institute for Health Research 
Health Technology Assessment Programme   
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Research Officer Data Collection Form 
 
Participant Study number      
 
Date of Assessment D D / M M / Y Y Y Y 
 
 
CHI number (Scotland only) or 
NHS number 
          
 
Date of Birth D D / M M / Y Y Y Y 
 
Gender  Male  Female 
 
ETHNIC ORIGIN 
 
Please note the following are the main classification categories used by the Census 2001.  Please ask the patient how they would 
describe themselves. 
 
Black or Black British-Caribbean    
Black or Black British-African    
Other Black Background  Please specify  
    
Asian or Asian British-Indian    
Asian or Asian British-Pakistani    
Asian or Asian British-Bangladeshi    
Chinese     
Other Asian Background  Please specify  
Mixed – White and Black Caribbean    
Mixed – White and Black African    
SECTION A - PATIENT DETAILS 
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Mixed – White and Asian    
    
White     -       British    
Other   Please specify  
 
Has patient been fully consented? Yes  
 
 
 
Referral Eye (please tick only one) Right  Left  Both    
 
IOP on referral (mmHg) 
 
Method of assessment (please tick only one) 
 
Right 
  
Left 
  
 
NCT 
  
     
 
GAT 
  
     
 
Other 
  
Please specify 
 
 
Refraction 
 +/
- 
Sphere +/
- 
Cyl Axis 
Right eye     .   /     .   x      
 +/
- 
Sphere +/- Cyl Axis 
Left eye     .   /     .   x  
 
Best corrected visual acuity (Snellen) 
SECTION B – CLINICAL DATA 
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Right eye            Left eye 
     
 
 
 
Visual fields (Humphrey 24.2)  
SITA standard or SITA fast.  Record reliability information defined by the Humphrey 
   
Right Eye: Reliable  Unreliable  Not done    
Fixation 
losses 
False pos 
errors (%) 
False neg 
errors (%) 
  
+/- 
 
   MD 
(dB) 
 
    PSD (dB) 
 
    VFI (%) 
 /                      
 
 
 
Left Eye: Reliable  Unreliable  Not done    
 
Fixation 
losses 
False pos 
errors (%) 
False neg 
errors (%) 
  
+/- 
 
   MD 
(dB) 
 
    PSD (dB) 
 
    VFI (%) 
 /                      
 
  
Printout of Visual Fields for research site file attached to CRF. Yes  
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Test order   
The order that tests should be performed is found on the study website clinic log for this study number.  Please record 
the order in which the tests were performed (1=1st,2=2nd,3=3rd) 
 
   HRT     GDX     OCT  
HRT 
Start time (24hr clock) H H : M M   End time (24hr clock) H H : M M 
 
Were pupils dilated? Yes  No    
 
Right Eye: Completed  Not performed    Reason  
 
Left Eye: Completed  Not performed    Reason  
 
Raw data   Raw data        Hard copy  MRA right eye  
filename   saved to disk            report printed   MRA left eye  
      GPS  
GDX  
Start time (24hr clock) H H : M M   End time (24hr clock) H H : M M 
 
Were pupils dilated? Yes  No    
 
Right Eye: Completed  Not performed    Reason  
 
Left Eye: Completed  Not performed    Reason  
 
Raw data filename    Raw data saved to disk   Hard copy report printed    
OCT 
Start time (24hr clock) H H : M M   End time (24hr clock) H H : M M 
 
Were pupils dilated? Yes  No    
 
Right Eye: Completed  Not performed    Reason  
 
SECTION C – IMAGING DATA 
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Left Eye: Completed  Not performed    Reason  
 
Raw data filename    Raw data saved to disk   Hard copy report printed    
     (RNFL basic report OU)  
 
Has participant completed the GATE Participant Preference questionnaire? Yes  No  
If No, why?    
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Participant Study No 
      
            
 
 
 
 
 
 
 
 
 
 
        
 
 
       Participant Preference Questionnaire 
 
 
 
 
 
 
 
This study is funded by the NHS National Institute for Health Research 
Health Technology Assessment Programme 
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Participant Study No 
      
            
           
Date of examination   /   /                 
  
Now that you have had all three tests can you please give an order of preference 
from 1 for the most preferred test, to 3 for the least.   
If you have no preference please tick the last box.  
 
  
 
Optical Coherence Tomography  
 
 
 
 
    
  
 
Scanning laser polarimetry –  
GDx-VCC 
 
 
 
 
 
    
  
 
Heidelberg Retinal Tomography 
 
 
 
 
    
  
I have no preference  
  
 
Please note you may not have had your tests in the order above and may not remember which 
test is which.  If you are unsure then ask the research nurse for help.  
Participant Preference Questionnaire 
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DO NOT LOOK AT IMAGING RESULTS  
BEFORE COMPLETING THIS FORM 
 
 
Participant Study number      
 
Date of Assessment D D / M M / Y Y Y Y 
 
Clinician Name (Capitals)  
 
IOP (mmHg)     
Today Right  Left  
    
DIAGNOSIS 
(tick only one category in each column) 
Right Left    R L 
Glaucoma     Severity of glaucoma Mild   
Disc suspect     Moderate   
VF suspect     Severe   
VF+disc suspect        
OHT (normal disc and field)        
PAC (normal disc and field)       
PAC suspect (normal disc and field)       
No glaucoma-related findings       
Undetermined 
( ld t l t  t) 
  Please specify reason     
 
For glaucoma and suspects:  R L 
Please tick mechanism Open angle   
Angle closure   
Other   
 
Co-morbidity – tick all that apply Right Left  
AMD    
Cataract    
Neurological   Please specify 
Other    
        
CLINICIAN CRF CONFIDENTIAL 
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ACTION (please tick) 
Discharge?    Yes     No  
        
  If NO please complete – tick only one box in each column 
 
Clinical diagnosis definitions 
 
Glaucoma:  
Evidence of glaucomatous optic neuropathy* and a characteristic visual field loss**  
 
Glaucoma severity:  according to Humphrey SITA standard perimetry of a reliable VF ***:  
Mild: MD better than or equal to -6 dB;      
Moderate: MD between -6.01dB and -12 dB     
Severe: MD worse than or equal to -12.01 dB  
  
Mechanism:  
Open angle:  includes POAG, NTG,  
Angle closure:   includes evidence of glaucomatous optic neuropathy combined with a characteristic visual 
field loss, and a closed anterior chamber angle (appositionally or synechial) in at least 270°  
Other:  pigmentary glaucoma, pseudoexfoliation glaucoma or any other type of glaucoma  
 
Disc suspect:  appearance suggestive of glaucomatous optic neuropathy but may also represent a variation of 
normality, with normal visual fields (with or without high IOP).  
 
VF suspect:  visual field loss suggestive of glaucoma, but may also represent a variation of normality, with 
normal appearance of the optic disc (with or without high IOP) 
 
VF+disc suspect:  both the optic disc and visual field have some features that resemble glaucoma but may 
also represent a variation of normality (with or without high IOP) 
 
OHT:  when both the visual field and optic nerve appear normal in the presence of elevated pressure,  
 Right Left Comments 
Treat    
Monitor only    
Repeat  assessment required    
 202 
 
> 21 mmHg 
 
PAC:  Closed anterior chamber angle (appositionally or synechial) in at least 270°, and at least one of the 
following two: IOP > 21 mmHg and/or presence of peripheral anterior synechiae.  Both visual field and optic 
nerve appear normal 
 
PAC suspect:  Closed anterior chamber angle (appositionally without any synechiae) in at least 270°, with 
IOP < 21 mmHg.  Both visual field and optic nerve appear normal 
 
The decision to monitor/treat will be defined in accordance with the NICE guidelines 
 
*  Evidence of optic nerve damage from any of the following:  Optic disc or retinal nerve fibre layer structural 
abnormalities.  Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior 
or superior poles.  Documented, progressive thinning of the neuroretinal rim with an associated increase in 
cupping of the optic disc.  Diffuse or localised abnormalities of the peripapillary retinal nerve fibre layer, 
especially at the inferior or superior poles.  Disc rim or peripapillary retinal nerve fibre layer haemorrhages. 
Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue.  
 
**  Reliable visual field abnormality considered a valid representation of the subject's functional status. 
Visual field damage consistent with retinal nerve fibre layer damage (e.g. nasal step, arcuate field defect, or 
paracentral depression in clusters of test sites). Visual field loss in one hemifield that is different from the 
other hemifield, i.e. across the horizontal midline (in early/moderate cases). Absence of other known 
explanations.  
 
***A reliable visual fields is classified as: False positive error <15% and no evidence for learning effect or 
poor performance which could impact on MD value (clinical judgement).  In patients with unreliable visual 
field, the severity of glaucoma will be based upon clinical judgement. 
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Appendix 4  Example imaging report outputs from the four imaging tests 
 
HRT-MRA 
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HRT-GPS 
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GDx 
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OCT 
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Appendix 5  Imaging standard operating procedures for the GATE 
study 
 
 
STANDARD OPERATING PROCEDURES (SOP) 
Image acquisition and storage 
 
GATE: Glaucoma Automated Test Evaluation 
 
Comparative study of new imaging technologies  
for the diagnosis of glaucoma (HTA Reference Number: 09/22/111) 
 
Sites: 
 
1. Aberdeen Royal Infirmary 
2. Hinchingbrooke Hospital 
3. Moorfields Eye Hospital 
4. St. Paul’s Eye Unit, Liverpool 
5. Bedford Hospital Trust 
 
 
 
Instruments: HRT-III, GDx-PRO, Spectralis-OCT 
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Contact lens wear 
There is currently no consensus as to whether a patient should be imaged with or 
without contact lenses.  If a patient presents wearing contact lenses please follow local 
best practice. 
 
Imaging Test order 
Imaging should be performed in the random order allocated for each participant in the 
study. This can be found on the clinic log entry for that patient study ID on the GATE 
website. 
 
Pupil dilation for imaging 
Images should routinely be performed without dilation prior to clinician assessment 
and prior to visual field measurements.  If pupil dilation is required to obtain an adequate 
quality HRT or OCT image then the GDx scan should be attempted prior to dilation (if 
not already performed).  If an adequate quality GDx image is still not obtained prior to 
dilation the GDx scan should be repeated after pupil dilation. Whenever possible the 
random allocated test order should be used. 
 
General indications for pupil dilation are media opacities and/or small pupils.  However, 
the scan should always be attempted first to determine whether images are acceptable 
or if dilation is necessary. 
 
Criteria for dilating the pupil are as follows: 
• Unable to ‘lock-on’ to the pupil and save a scan 
• Acceptability of best saved image is below requirements stated in SOP for that 
imaging technique 
 
Acceptability criteria for each imaging technique are clearly detailed in the text for each 
technique below. Once an acceptable image has been obtained no further images 
should be acquired. 
 
Acceptable quality criteria for imaging (summary) 
HRT Mean standard deviation ≤30,  
Image quality score: Good, Very Good, or Excellent 
GDx Q≥8 
OCT Q>15 
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Heidelberg Retina Tomograph (HRT-III) 
 
Acquiring the image 
Before imaging a subject on the HRT you should record their refraction (focimetry or 
auto-refraction. The focimetry/autorefraction is useful to guide the setting of the scan 
focus before image acquisition, but is not required to be input in the software. 
 
Patients should not be imaged with their contact lenses in. 
 
1. Ensure that IOP measurements (and other contact exams like gonioscopy) are 
done after HRT imaging. 
2. Explain examination (method, time and requirements) to the patient. 
3. Disinfect chin- and forehead supporting-stand. 
4. Check optics for dirt or smudges, clean if required, with lint/oil-free lens paper 
moistened with a drop or two of photography quality lens cleaner. 
5. Enter new patient details:  
 
a)  Click on the new patient icon on the HEYEX tool bar to enter the subject’s 
details and the operator initials.  Enter the corneal curvature as an average of 
the two axes (i.e. 7.6 x 7.8 = 7.7) and enter the refractive error. 
 
The patient details need to be recorded as follows: 
o Last Name: ‘GATE’ 
o First Name: <site> e.g. ‘Aberdeen’ 
o Title: leave blank 
o Date of birth: enter patient date of birth 
o Sex: enter patient gender 
o Patient ID: enter < Participant study number> 
o Ancestry: enter the patient’s ethnicity 
6. Ensure that the table and the headrest are at the correct height for the subject.  
Adjust the chinrest height so that the patient’s eyes are at the same level as the 
red canthus marks on the headrest posts. When the subject’s details are entered 
the laser will activate and image acquisition can begin. As a starting point the 
focussing dial at the front of the HRT should be set to the subject’s refraction.   
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7. Check that the subject is comfortable, and the scanning head is correctly aligned 
using the black adjustment handles on the HRT.  The imaging distance between 
the HRT objective lens and the cornea is 1.5 cm; this can be judged by focussing 
the scanning beam on the iris (moving the scanning head towards or away from 
the eye). When the laser beam is focussed (sharp outline) on the iris, move the 
scanner sideways so the beam enters the pupil.  All of the red light emitted from 
the HRT should be going straight into the pupil with little or none visible on the 
iris. 
8. If cylinder correction exceeds ±0.75 diopter, place supplemental cylinder lens in 
front of the objective (image acquisition) lens.  Note that the HRT will display a 
flashing alert on the refractive error correction dialog box if cylinder correction is 
recommended:  
a. click on the check box to display the recommended cylinder lens strength to 
be used.  The lens should be oriented according to the axis provided by the 
autorefractometer.  
b. orientation of the cylinder may be adjusted manually during imaging in order 
to achieve the highest image quality on the screen (see point 9) 
9. The HRT has an internal fixation point, a yellowy/green light which, when fixated 
by subject, should bring the optic disk into view on the screen.  Once the scan is 
activated, the fixation point will appear on the subject’s left for the right eye and 
on their right for the left eye (i.e. always towards the nose).  Explain the fixation 
target (green light outside the red “carpet”).  Once the subject is fixating, check 
the alignment of the laser in the pupil and make small adjustments to the 
focusing to optimise the image quality. The operator may also manually adjust 
the cylinder lens axis, if present, to achieve the best image quality. 
a. Images that are dark, have vignetting of the image corners or are 
grainy can be improved by dilation.  If a good quality image 
cannot be obtained and dilation is required, delay the image 
acquisition until after clinical assessment as described in the flow 
chart in the GATE study procedures manual.   
b. In some cases where the internal fixation light cannot be seen by 
the patient, the external fixation device must be used.  To use 
this, the opposite eye fixates on the green light which is manually 
positioned by the operator to display the optic nerve head in the 
centre of the screen. 
10. Instruct the subject to blink as much as possible before you attempt to acquire a 
scan to avoid imaging a “dry eye” (drying of the corneal surface). The scan 
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duration is approx 6-8 seconds, during which time the subject should not blink 
and must maintain fixation. When ready, an image is acquired by pressing either 
the foot pedal or the grey button on the rear of the scan head. 
11. Optimise image quality if necessary (artificial tears, elevate upper eyelids, re-
adjust camera).  
a. Detector sensitivity should be as low as possible (<80) 
b. The image quality bar should be green for a good quality 
image and above 70% 
12. The screen will display the progress of the scan; the HRT will take at least three scans of 
the optic nerve in one session.   
a. Monitor the progress of the scan to ensure that the subject’s position and 
fixation is constant.   
b. The image series may be reviewed as a movie immediately after 
acquisition. HRT software can compensate for some movement but any 
scans containing large eye movements or blinks will have to be discarded 
and repeated.  
c. If you are satisfied with the scan select “save”. Repeat to acquire another 
scan if image quality is not adequate. 
d. Move the machine over to image the fellow eye, the HRT software will 
recognise which eye you are scanning. 
 
Checking image quality 
Images acquired using the HRT III software allow the user to check the quality of the image by 
clicking on the QC icon in the right hand corner of the image: 
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a. Ensure that all elements are ticked.  The overall quality score is given as one of 
Very Poor, Poor, Acceptable, Good, Very Good, Excellent.  Ensure the overall 
quality score is Good or higher. 
b. Check the standard deviation value displayed at the top of the topography.  A 
value of 30 or below is considered good image quality.  
c. Repeat the image acquisition if required to obtain a good image quality. 
 
d. If an acceptable image cannot be obtained after repeated attempts then 
the image acquisition should be attempted again after pupil dilation 
(please refer to study procedures document flow chart to ensure the 
order of clinical/imaging tests and visual field testing is correct) 
 
Computing the topography 
1. Once both eyes have been imaged, the topographies need to be computed.   
a. Exit from of the acquisition mode by clicking the “X” in the right hand corner of the 
acquisition window and you will be prompted to process the scans that have just 
been taken.  When the scans are processed double click on the image to bring up 
the resulting topographical data in the examination results window   
 
Drawing a contour line 
1. Using the left mouse button select at least 3 points on the optic nerve rim to 
create a contour line and reposition to ensure the optic nerve rim is 
accurately located.  Use the 3D viewer button to review your selection if 
required. 
2. When you have located the optic nerve rim select ‘Contour’ then ‘Accept 
Contour’  
3. The contour and segment lines will appear. 
 
HRT Report Printout: 
Three printouts are required for the HRT scan,  
1. Moorfields Regression Analysis (MRA) of right eye, 
2. MRA of left eye and  
3. GPS report 
  
A hardcopy of each report should be filed in the study file for each participant.   
  
 214 
 
An electronic copy of each report in JPEG format should also be saved to a memory 
stick and uploaded to the GATE study website.   
 
The naming convention for filenames of any saved reports should be followed: 
• MRA Right eye report:  ‘GATE<studyID>MRAright.jpg’ 
• MRA Left eye report:  ‘GATE<studyID>MRAleft.jpg’ 
• GPS report:   ‘GATE<studyID>GPS.jpg’ 
 
Printing a Moorfields Regression Analysis(MRA) Report  
• Click the Moorfields classification tab 
• Select ’Print’ 
• Select ‘Examination report’ 
• Ensure the ‘Moorfields report’ is selected in the reports window 
• Select ‘preview’ 
• The Moorfields report for that eye will appear 
• Select ‘Save as’ 
• Enter the filename as ‘GATE<studyID>MRAright.jpg’ for right eye (or 
GATE<studyID>MRAleft.jpg for left eye) 
• Select ‘Save’ to save the jpeg of the report 
• Select ‘print’ to print a hardcopy report for the file 
• Select other eye from Heidelberg Eye explorer window 
• Repeat from start to print/save report from the other eye. 
 
Printing a GPS report 
• To print report select ‘GPS classification’ tab 
• Select ‘Print’ 
• Select ‘Examination report’ 
To save as a jpeg file to upload to the GATE website 
• Ensure GPS report is highlighted in the report window 
• If more than one image is stored for the other eye, select the corresponding eye 
image for the GPS report 
• Select Preview 
• The GPS report will appear on the print preview screen 
• Select ‘Save as’ 
• Enter the filename as ‘GATE<studyID>GPS.jpg’ 
• Select save to save the jpeg of the report 
To print a hardcopy report 
• Select ‘Print’ 
 215 
 
HRT Data Export: 
HRT imaging data should be exported on the same day every week. Export all the 
images since the last export. 
 
1) From the main database screen select the patient you wish to export. 
2) When the patient details appear on the right hand side of the screen double click 
the patient name. 
3) Right click on the exam you wish to export and select the export option. 
4) Select yes to export the 3D image series.  Selecting this option could result in a 
prompt to retrieve the raw image data for that exam. 
5) Select a folder to export using the browse option. 
6) The file will export and appear as an *.E2E file in the selected export folder. 
7) Save with filename ‘GATE<studyID>rawHRTOS.e2e’ for left eye, and 
‘GATE<studyID>rawHRTOD.e2e for right eye 
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GDx ECC/GDx Pro 
 
Acquiring the image 
 
1. Patients should not be imaged wearing their contact lenses.  Ensure that IOP 
measurements and other contact exams like gonioscopy are performed after 
GDx imaging 
 
2. With the GDx VCC and peripherals properly connected, the Access card 
inserted and the optics unlocked turn the machine on using the power switch 
on the side. 
 
3. Disinfect face rest. 
 
4. When the warm-up test is complete, the logo screen will be displayed. Select 
“new patient”. 
 
5. The patient details need to be recorded as follows: 
o Patient ID - Use <GATE Participant study number> 
o Last name – ‘GATE’ 
o First name – <site>e.g. Aberdeen 
o Middle name – leave blank 
o DOB – enter patient date of birth 
o Doctor –use any identifier usually used or leave blank 
 
Press √ button to continue. 
 
6. Input ancestry and gender information as prompted. Press √ button to 
continue. 
 
7. Check patient information for accuracy. If changes are needed press edit. 
 
8. Select “full exam”. 
 
9. Refraction input is needed for focusing purposes. Select Refraction.  Press the 
auto-refraction button.  
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10. Position the subject in front of the GDx with the face placed comfortably 
against the face rest. For optimal positioning, ask the patient to place their 
brow bones on top of the upper rest “like wearing a mask”.  Ask the subject to 
gaze at the blinking fixation target in the red field– located to the left hand side 
for the right eye and vice versa. The exam begins with the right eye as the 
default position. 
 
11.  
• Move the joystick , by pulling forwards and backwards, to vertically align 
the white focus dot on the horizontal red line  
 
• Centre the pupil in the target by moving the joystick up/down/ left/right and 
ensure that the 2 white dots are located in the bottom 2 quadrants of the target 
 
• Once aligned, ask the patient not to blink and press the image 
acquisition button on top of the joystick to scan the eye 
• Once the refraction data is displayed on the top lhs select image 
acquisition button again to acquire refraction data from the other eye 
• Click image acquisition button a 3rd time to display the ‘modify ellipse – 
measuring cornea’ screen 
 
12.  Following a cornea measurement, the “Modify Ellipse – Measuring Cornea” 
screen appears. The macular ellipse should be centred directly over the macula 
“bowtie”-pattern.  
 
13. To change the macular ellipse position, use the arrow buttons. Do not change the 
size of the macular ellipse. 
 
14. If the macula “bowtie” is not well defined, press the “Irregular Pattern” button to 
use an alternative cornea calculation based on the macula area within the dotted 
square which does not require macular ellipse placement (press the “Macular 
Ellipse” button to re-enable the macular ellipse placement options).  
 
15. Press √ button to go to the “Modify Ellipse – Measuring Cornea” screen for the 
next eye. Optimise the placement of the cornea measurement ellipse in the same 
manner as for the first eye. Press √ button again when complete. 
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16. When ellipse modification is completed, the system displays the “Image Check-
Measuring cornea” screen. The scan quality score should be 8 and above. If 
the scan quality is less than 8 then retake the image for that eye.  
 
17. If image quality is acceptable then select “Accept”. The acquisition screen will now 
appear. If after repeating the GDx scan the image quality is still not acceptable then the 
image acquisition should be attempted again after pupil dilation (please refer to GATE 
study procedures flow chart to ensure the order of clinical/imaging tests is correct) 
 
18. Move the joystick to vertically align the white focus dot on the horizontal red line 
and centre the pupil in the reticule. Once aligned, press the image acquisition 
button on top of the joystick to scan the eye. After the first image is captured the 
system will automatically move to the other eye. 
 
19. Repeat step 18 for the left eye. 
 
20.  At the “Image Check” screen verify that the ellipses for both eyes are the correct 
size, shape and centred on the Optic Nerve Head (ONH). You can both change 
the ellipse diameter and shape using the arrow keys. (Note: While it is helpful to 
align the ellipse with the ONH margin, accurate centration is more important than 
perfect ellipse size). 
 
21. When ellipse modification is completed, verify that the scans quality scores are 8 
or above. If quality is less than 8, re-scan the patient.  Proper ONH placement can 
influence image quality scores. Verify that placement is correct before deciding to 
retake an image.  
 
22. If image quality is acceptable then select “Accept”. 
If not acceptable then the image acquisition should be attempted again after the 
clinician has dilated pupils for their routine clinical assessment (please refer to GATE 
study procedures flow chart to ensure the order of clinical/imaging tests is correct) 
 
23. Press “print” or “save only” button. 
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GDx Printout 
 
A printout of the GDx ECC report is required for the study file.  Ensure that ECC is reported in 
the middle text box (white).  
 
A hardcopy of each report should be filed in the study file for each participant.   
 
A scanned electronic copy of each report in JPEG format should be uploaded to the GATE 
study website.   
The naming convention for filenames of any saved reports should be followed: 
• GDx ECC report:  ‘GATE<studyID>GDX.jpg’ 
 
After printing out the report you should select ‘Save’ to save the file for this patient 
 
GDx Data Export 
 
Data export is done on a floppy disk.   
 
1. Select “existing patient”. 
2. Enter the patient ID number in the “Patient ID”. 
3. Press the “review” button 
4. Use “Previous” and “Next” buttons to move through the list 
5. Then using the “Select/Deselect” button highlight the chosen exam 
6. Repeat  2 and 3 to select more then one exam 
7. Press “review” button and then “export” button 
8. Choose ‘Export raw data’ 
9. You will be presented with a folder: My Computer.  Press the tab key to get into 
the folder. 
10. Using the arrow keys highlight the Floppy A Folder.  Then press enter. 
11. Name the folder (although the software will automatically save the data with 
Patient name and ID). 
12. Press “√” button or the “enter” key. 
13. You will be presented with the message: “Exporting Data” and when finished with 
the message “Export complete”. 
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Optical Coherence Tomography Using: Heidelberg Spectralis OCT 
 
Patients should not wear contact lenses   
 
Acquiring the image 
 
1. Explain examination (method and requirements) to the patient 
2.  Ensure that IOP measurements (and other contact exams like gonioscopy) are done after 
OCT imaging 
3. Disinfect chin-and forehead-supporting stand 
4. Check optics for dirt or smudges, clean if required/with lint/oil free lens paper moistened with 
a drop or two of photography quality lens cleaner 
5. Ensure that the table and headrest are the correct height for the subject.   Adjust the 
chinrest height so that the patient’s eyes are at the same level as the red canthus 
marks on the headrest posts. 
 
5. Create a new patient record by clicking on the New Patient button. 
 
In the Patient File window you should enter the following patient details 
o Patient ID - Use < Participant study number> 
o Patient Name (Surname= ‘GATE’, Forename=<site> e.g. ‘Aberdeen’) 
o DOB – enter patient date of birth 
o Enter Gender and Ethnicity information 
 
Examination Data Window 
 
The Examination Data dialog opens before each exam, but can also be opened at any 
later stage using the Examination button in the patient file. 
The respective Device Type for the examination must be selected from the dropdown 
menu; all other data is optional. 
 
1. Select Spectralis OCT 
2. Enter operator initials 
3. Enter Study name as GATE 
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Eye Data Window 
This window enables the entry of the eye parameters for both eyes. Please Note: Do NOT 
enter any data into this window. 
1. Wait for the Laser On/Off button on the Control Panel to turn from Red to Yellow.   
2. Press the Yellow On/Off button on the Control Panel to activate the Laser/OCT. Make 
sure that the OCT button is selected.  (Note - On the Control Panel, Inactive/unselected 
buttons are Red; Active/Selected buttons are Blue). 
3. Select the IR + OCT button.  
4. Make sure that the Volume button is selected. 
6. Field button should be at 30 degrees. 
7. IR Intensity button will default to 100% but should be adjusted for patient            media, 
typically 50% ‐ 75%. 
8. Always activate the ART Mean function when performing an OCT-Scan 
9. Select RNFL preset on the monitor screen  
10. Ensure HR for high resolution imaging is selected (not HS – high speed) 
11. The OCT has a blue internal fixation point which when fixated by the subject should 
bring the optic disc into view on the screen  
a) slowly bring the camera towards the patient’s eye,  
b) encourage the patient to blink just before a scan, since maintaining a good tear 
film is important for OCT image quality. In cases where the patient suffers from 
dry eye, or when the cornea cannot be kept moist enough by blinking alone, 
artificial tears may be used. 
c) Using the joystick (up, down, right or left) move the camera to the center of the 
pupil and adjust the distance between the objective and the examined eye to 
approx. 14 mm between the front edge of the objective and the cornea.   
d) Use the OCT Acquisition Window on the monitor to align the camera with the 
Optic disc Image on the left side of the window. 
e) Fine tune brightness and sharpness of the image using the focus knob. The 
 optimum camera position is reached when no dark corners and overexposed 
areas are visible. 
11.  The bar above the OCT image will appear red if the OCT image touches the upper 
border. Move the camera further away from the patient if the OCT image is shown 
inverted. If the OCT image is tilted in a horizontal direction, move the camera slightly 
left/right (if capturing a horizontal scan) or up/down (if capturing a vertical scan). (Note 
in patients with moderate myopia, the scan can be tilted). 
 
12 . The blue Quality bar in the lower part of the image indicates the signal strength. The 
quality score range is 0 (no image) to 40 (excellent quality). Acceptable quality is 
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>15. If the score is 15 or less, the quality bar turns red.   If an acceptable quality image 
cannot be obtained, imaging should be repeated after pupil dilation (see flowchart in 
study procedures manual to determine test order) 
13. To achieve optimum image quality, position the OCT image in the upper half of the 
Acquisition window. Using the joystick, move the camera slightly up/down and 
sideways until the optic disc and OCT image appear brightest and most evenly 
illuminated. 
 
14.  To acquire images, press the foot switch, the Acquire button on the control panel or the 
 central button on the joystick. After acquiring images, save them using the Save   
 images option in the top left corner of the Acquisition window. To end the acquisition 
 session, exit the Acquisition window. The camera will automatically turn off. 
 
 
OCT RNFL Basic Report OU Printout 
 
• A hardcopy RNFL Basic Report OU should be filed in the study file for each participant.   
• Add an image from each eye to the lightbox  
• Select both images in the lightbox then select Print from the context menu 
• The ‘print spectralis report’ window will appear 
• Select the RNFL Basic Report option  
• Select Preview 
• Select Save to save a JPEG format then select Print to printout a hardcopy 
• An electronic copy of each report in JPEG format should also be saved to a memory stick 
and uploaded to the GATE study website.  The naming convention for filenames of any 
saved reports should be followed: OCT report:  ‘GATE<studyID>OCT.jpg’ 
 
OCT Data Export 
 
OCT imagining data should be exported on the same day every week. Export all the images 
since the last export. 
 
1) From the main database screen select the patient you wish to export 
2) To export images and other data in an examination as an E2E file, select the desired 
thumbnail image(s) from the Patient File window, and select the item Export ► asE2E 
from the Context Menu in the Patient File. 
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3) Save with filename ‘GATE<studyID>rawHRTOS.e2e’ for left eye, and 
‘GATE<studyID>rawHRTOD.e2e for right eye 
4) The Batch ► Export E2E feature in the Database window enables export of         
multiple patient records at once. 
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Appendix 6  Further assessment of threshold effects under diagnosis 
analysis using individual parameter from the imaging tests 
As for default analysis, abnormal imaging test results were those classified as ‘outside 
normal limits’ and the corresponding reference standard definition of disease was a 
diagnosis of glaucoma of the worse eye. Only participants with an imaging test output 
with an overall classification which met the manufacturer quality cut-off were 
included in the analysis.  
 
The HRT-MRA parameters for which a ROC curve was produced and the AUC 
calculated were the Global, Temporal, Temporal superior, Temporal inferior, Nasal, 
Nasal superior and Nasal inferior areas respectively. For HRT-GPS and OCT the 
respective probabilities and the retinal fiber nerve layer thickness values were used for 
the same segments of the eye. For GDx,  the TSNIT parameters (NFI, TSNIT 
Average, Superior average, Inferior average, TSNIT standard deviation were used). 
 
The corresponding ROC curves are shown in Figures 6.1 to 6.4 below with the 
corresponding AUC with 95% CIs in Table 6.1. From visually assessment it can be 
seen that the OCT and GDx curves differed the most between parameters with the 
HRT tests, MRA and particularly GPS showing less variation in the curve shape 
between parameter. The point estimates for the AUC differed by only 0.02 for GPS 
compared to GDx for 0.1 and 0.13 for OCT. 
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Figure 6.1  ROC curve for HRT-MRA parameters 
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Figure 6.2  ROC curve for HRT-GPS parameters 
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Figure 6.3  ROC curve for GDx parameters 
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Figure 6.4  ROC curve for OCT parameters 
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Table 6.1  Area under the ROC curve using imaging test parameters for a 
diagnosis of glaucoma in the worse eye 
Test Parameter Value 95% CI 
Lower Upper  
HRT-MRA Global area 0.78 0.73 0.82 
 Temporal area 0.72 0.67 0.76 
 Temporal superior area 0.78 0.74 0.83 
 Temporal inferior area 0.79 0.74 0.83 
 Nasal 0.70 0.65 0.75 
 Nasal superior area 0.75 0.71 0.80 
 Nasal inferior area 0.73 0.69 0.78 
HRT-GPS Global probability 0.80 0.77 0.84 
 Temporal probability 0.81 0.77 0.85 
 Temporal superior probability 0.80 0.76 0.84 
 Temporal inferior probability 0.80 0.76 0.83 
 Nasal probability 0.81 0.77 0.85 
 Nasal superior probability 0.80 0.76 0.84 
 Nasal inferior probability 0.79 0.76 0.83 
GDx NFI 0.78 0.74 0.83 
 TSNIT average 0.73 0.69 0.78 
 TSNIT Standard deviation  0.74 0.69 0.78 
 Superior average 0.73 0.68 0.78 
 Inferior average 0.73 0.68 0.78 
OCT Global thickness 0.83 0.79 0.87 
 Temporal thickness 0.68 0.63 0.73 
 Temporal superior thickness 0.79 0.75 0.83 
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Test Parameter Value 95% CI 
Lower Upper  
 Temporal inferior thickness 0.82 0.78 0.86 
 Nasal thickness 0.72 0.68 0.77 
 Nasal superior thickness 0.72 0.68 0.77 
 Nasal inferior thickness 0.74 0.70 0.79 
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Appendix 7  Additional triage analysis to inform the health economic 
model 
 
Overview 
An additional set of two statistical analyses (Triage sensitivity analyses 9 and 10) 
were carried out to specifically inform the economic modelling for GATE. These 
were set up to mirror the model structure in terms of population (i.e. with the 
simplification of ignoring the presence of non-glaucoma related co-morbidities). The 
first additional analysis used a reference standard definition of disease of glaucoma, 
glaucoma suspects, OHT and PAC; the second analysis used diagnosis of glaucoma 
alone as the reference standard (see Table A.1). The test was a composite as 
previously described in Chapter 2 and 5 of the respective imaging test result, IOP and 
visual acuity measurements (referred to throughout this appendix by the name of 
imaging test used within the composite test e.g. either HRT-MRA, HRT-GPS, GDx or 
OCT). Where a classification was not provided by the imaging test, the patient was 
defined as a “For referral”. For the first analysis, borderline imaging results were also 
classified as “For referral” Whereas for the other analysis they were classified “Not 
for referral”. Triage sensitivity analyses 9 and 10, respectively represent the analyses 
used to populate the diagnostic accuracy results of the base-case and the sensitivity 
analysis scenarios (see Chapter 6 for further details). Sub-group sensitivity and 
specificity values were calculated for each diagnosis separately (e.g. glaucoma, “at 
risk of glaucoma” and neither groups) breaking down the respective performance of 
the triage test to provide estimates for the economic model. 
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Table A.1  Additional analyses carried out to inform the health economic model 
Analysis Reference standard 
definition of disease 
Test ’For referral’ 
definition 
Handling of ‘no 
result’ categories 
Figure no. Table no. 
Triage sensitivity analysis 9 Glaucoma, OHT, PAC 
and glaucoma suspects. 
Imaging (outside normal 
limits or borderline) or 
IOP>21mmHg or VA6/12 
or poorer 
A-D For referral 
E excluded 
A.1 A.2 
Triage sensitivity analysis 10 Glaucoma Imaging (outside normal 
limits) 
A-D For referral 
E excluded 
A.2 A.3 
No result categories  
A: test performed and imaging report produced but quality is lower than manufacturer quality cut-off 
B: test performed and imaging report produced but no overall classification generated by machine 
C: test performed but there was a clear imaging artefact on the report 
D: test attempted but no imaging could be acquired from the patient’s eyes – no report generated 
E: missing imaging output (due to study related or data collection issues)  
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Diagnostic performance of the triage tests 
The diagnostic accuracy results of the two analyses are given in the following two sections. 
 
Triage sensitivity analysis 9 
The flow of study participants according to triage sensitivity analysis 10 is shown in Figure 
A.1 with respective numbers of referral, not for referral and no results cases by triage test. 
The diagnostic performance for the four tests is given in Table A.2. Results showed a trade-
off between detection of patients who need to be referred and discharging those who do not 
need to be referred: HRT-MRA had the highest sensitivity (HRT-GPS was only very slightly 
lower) but also the second lowest specificity (HRT-GPS had the lowest), GDx had the lowest 
sensitivity but the highest specificity, and OCT provided intermediate results. Likelihood 
ratios (and 95% CI) showed evidence of both being able to rule in and out the presence of 
glaucoma for all 4 triage tests (CIs did not contain 1.0). DORs ranged from 4.29 for GDx to 
16.83 for HRT-MRA.  
 
From this analysis, the sensitivity for participants with glaucoma was calculated as 99, 99, 88 
and 97% for HRT-MRA, HRT-GPS, GDx and OCT, respectively; similarly the sensitivity for 
participants at risk of glaucoma was calculated as 97, 97, 77 and 87% respectively and the 
specificity for participants classified as normal (not glaucoma or ‘at risk of glaucoma’) was 
30, 28, 51 and 35% respectively for HRT-MRA, HRT-GPS, GDx and OCT. 
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Completed composite index test (imaging+IOP+VA)
n=943
Composite test not performed 
for all four index tests n=12 
Reference standard definition: glaucoma OR glaucoma suspect 
OR OHT or PAC
For referral:  imaging (outside normal limits or borderline) or 
IOP>21mmHg or VA  6/12 or poorer)
Handling of no result categories: A-D For referral
E excluded
For referral
IOP+VA+MRA(HRT) n=788
IOP+VA+GPS (HRT) n=805
IOP+VA+GDx n=624
IOP+VA+OCT n=741
Not for referral
IOP+VA+MRA(HRT) n=125
IOP+VA+GPS (HRT) n= 124
IOP+VA+GDx n=305
IOP+VA+OCT n=192
No result
IOP+VA+MRA(HRT) n=30
IOP+VA+GPS (HRT) n= 14
IOP+VA+GDx n=14
IOP+VA+OCT n=10
No reference standard
MRA n= 8
GPS n=7
GDx n=6
OCT n=7
No reference standard
MRA n=2
GPS n= 3
GDx n=5
OCT n=4
No reference standard
MRA n= 1
GPS n=1
GDx n=0
OCT n=0
Reference standard
IOP+VA+MRA(HRT) n=29
IOP+VA+GPS (HRT) n=13
IOP+VA+GDx n=14
IOP+VA+OCT n=10
Reference standard
IOP+VA+MRA(HRT) n=780
IOP+VA+GPS (HRT) n=798
IOP+VA+GDx n=618
IOP+VA+OCT n=734
Reference standard
IOP+VA+MRA(HRT) n=123
IOP+VA+GPS (HRT) n=121
IOP+VA+GDx n=300
IOP+VA+OCT n=188
NOT DISCHARGED
IOP+VA+MRA(HRT) n=517
IOP+VA+GPS (HRT) n=524
IOP+VA+GDx n=433
IOP+VA+OCT n=486
NOT DISCHARGED
IOP+VA+MRA(HRT) n=13
IOP+VA+GPS (HRT) n=14
IOP+VA+GDx n=106
IOP+VA+OCT n=53
DISCHARGED
IOP+VA+MRA(HRT) n=260
IOP+VA+GPS (HRT) n=271
IOP+VA+GDx n=183
IOP+VA+OCT n=245
NOT DISCHARGED
IOP+VA+ MRA(HRT) n=16
IOP+VA+GPS (HRT) n=8
IOP+VA+GDx n=7
IOP+VA+OCT n=7
DISCHARGED
IOP+VA+MRA(HRT) n=110
IOP+VA+GPS (HRT) n=106
IOP+VA+GDx n=192
IOP+VA+OCT n=134
DISCHARGED
IOP+VA+MRA(HRT) n=12
IOP+VA+GPS (HRT) n=5
IOP+VA+GDx n=7
IOP+VA+OCT n=3
Inconclusive
reference standard
MRA n= 3
GPS n=3
GDx n=2
OCT n=3
Inconclusive
reference standard
MRA n= 1
GPS n=0
GDx n=0
OCT n=0
Inconclusive
reference standard
MRA n= 0
GPS n=1
GDx n=2
OCT n=1
Available for index test
n= 955
Eligible patients
n= 2088
Consented
n= 966
Excluded  n= 11
• Ineligible =  10
• withdrawn = 1
Not consented
n= 1122
Figure A.1  Flow diagram Triage sensitivity analysis: 9 
 
 235 
 
Table A.2  Triage Sensitivity analysis 9 
Test Parameter Value 95% CI 
Lower 
  
Upper  
 
HRT-MRA Sensitivity - % 97.5 95.8 98.7 
 Specificity - % 29.7 25.1 34.7 
 Positive Likelihood Ratio 1.39 1.30 1.49 
 Negative Likelihood Ratio 0.08 0.05 0.14 
 DOR 16.83 9.29 30.47 
HRT-GPS Sensitivity - % 97.4 95.7 98.6 
 Specificity - % 28.1 23.6 32.9 
 Positive Likelihood Ratio 1.35 1.27 1.45 
 Negative Likelihood Ratio 0.09 0.05 0.16 
 DOR 14.64 8.23 26.05 
GDx Sensitivity - % 80.3 76.7 83.6 
 Specificity - % 51.2 46.0 56.4 
 Positive Likelihood Ratio 1.65 1.47 1.84 
 Negative Likelihood Ratio 0.38 0.32 0.47 
 DOR 4.29 3.2 5.75 
OCT Sensitivity - % 90.2 87.3 92.5 
 Specificity - % 35.4 30.5 40.4 
 Positive Likelihood Ratio 1.39 1.29 1.51 
 Negative Likelihood Ratio 0.38 0.21 0.37 
 DOR 5.02 3.52 7.14 
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Triage sensitivity analysis 10 
The flow of study participants according to triage sensitivity analysis 10 is shown in Figure 
A.2 with respective numbers of referral, not for referral and no results cases by triage test. 
The diagnostic performance for the four tests is given in Table A.3. Results generally showed 
a trade-off between detection of patients who need to be referred and discharging those who 
do not need to be referred: HRT-MRA had the highest sensitivity (HRT-GPS was only very 
slightly lower) but also the second lowest specificity (HRT-GPS had the lowest), GDx had 
the lowest sensitivity but the highest specificity, and OCT provided intermediate results. 
Likelihood ratios (and 95% CI) showed evidence of both being able to rule in and out the 
presence of glaucoma for all 4 triage tests (CIs did not contain 1.0). DORs ranged from 5.11 
for GDx to 12.83 for HRT-MRA. 
 
From this analysis, the sensitivity for participants with glaucoma was 93, 89, 49 and 83% for 
HRT-MRA, HRT-GPS, GDx and OCT respectively; the sensitivity for participants at risk of 
glaucoma was calculated as 61, 59, 17 and 36% respectively and the specificity for 
participants in the normal health state (without glaucoma or at risk of glaucoma) was 
calculated as 60, 61, 85 and 72% respectively.  
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Completed composite index test (imaging+IOP+VA)
n=943
Composite test not performed for all 
four index tests n=12 
Abnormal result
MRA(HRT) n=531
GPS (HRT) n=518
GDx n= 202
OCT n= 381
Normal result
MRA(HRT) n =  382
GPS (HRT) n= 411
GDx n= 727
OCT n= 552
No result
MRA(HRT) n= 30
GPS (HRT) n= 14
GDx n= 14
OCT n= 10
No reference standard
MRA(HRT) n=  6
GPS (HRT) n=  5
GDx n= 4
OCT n= 5
No reference standard
MRA(HRT) n= 4
GPS (HRT) n= 5
GDx n= 7
OCT n= 6
No reference standard
MRA(HRT) n= 1
GPS (HRT) n= 1
GDx n= 0
OCT n= 0
Reference standard
MRA(HRT) n=29
GPS (HRT) n=13
GDx n= 14
OCT n= 10
Reference standard
MRA(HRT) n=525
GPS (HRT) n=513
GDx n= 198
OCT n= 376
Reference standard
MRA(HRT) n= 378
GPS (HRT) n=406
GDx n= 720
OCT n= 546
Inconclusive 
reference standard
MRA(HRT) n= 3
GPS (HRT) n= 2
GDx n= 1
OCT n= 3
Inconclusive 
reference standard
MRA(HRT) n= 0
GPS (HRT) n= 2
GDx n= 3
OCT n= 1
Inconclusive 
reference standard
MRA(HRT) n= 1
GPS (HRT) n= 0
GDx n= 0
OCT n= 0
Glaucoma 
present
MRA(HRT) n= 145
GPS (HRT) n= 138
GDx n= 77
OCT n= 128
Glaucoma 
present
MRA(HRT) n=11
GPS (HRT) n= 17
GDx n= 80
OCT n= 26
Glaucoma 
absent
MRA(HRT) n=377
GPS (HRT) n= 373
GDx n= 120
OCT n= 245
Glaucoma 
present
MRA(HRT) n= 2
GPS (HRT) n=  3
GDx n= 1 
OCT n= 4
Glaucoma 
absent
MRA(HRT) n=367
GPS (HRT) n= 387
GDx n= 637
OCT n= 519
Glaucoma 
absent
MRA(HRT) n= 26
GPS (HRT) n= 10
GDx n= 13
OCT n= 6
Available for index test
n= 955
Eligible patients
n= 2088
Consented
n= 966
Excluded  n= 11
• Ineligible =  10
• withdrawn = 1
Not consented
n= 1122
Reference standard definition: glaucoma
For referral: imaging (outside normal limits or borderline)
Handling of no result categories: A-D For referral
E excluded
Figure A.2  Flow diagram Triage analysis sensitivity 10 
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Table A.3  Triage sensitivity analysis 10  
Test Parameter Value 95% CI 
Lower  Upper  
HRT-MRA Sensitivity - % 92.9 87.7 96.4 
 Specificity - % 49.3 45.7 53.0 
 Positive Likelihood Ratio 1.83 1.69 21.99 
 Negative Likelihood Ratio 0.14 0.08 0.25 
 DOR 12.83 6.84 24.08 
HRT-GPS Sensitivity - % 89.0 83.0 93.5 
 Specificity - % 50.9 47.3 54.5 
 Positive Likelihood Ratio 1.81 1.66 1.99 
 Negative Likelihood Ratio 0.22 0.14 0.3 
 DOR 8.42 4.99 14.88 
GDx Sensitivity  - % 49.0 41.0 57.1 
 Specificity - % 84.1 81.3 86.7 
 Positive Likelihood Ratio 3.09 2.46 3.89 
 Negative Likelihood Ratio 0.61 0.52 0.71 
 DOR 5.11 3.53 7.39 
OCT Sensitivity - % 83.1 76.2 88.7 
 Specificity - % 67.9 64.5 71.2 
 Positive Likelihood Ratio 2.59 2.29 2.94 
 Negative Likelihood Ratio 0.25 0.17 0.35 
 DOR 10.43 6.66 16.33 
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Appendix 8  Interim life table 
 
Age x qxa Age x qxa 
0 0.00501 51 0.00388 
1 0.00034 52 0.00424 
2 0.00019 53 0.00464 
3 0.00014 54 0.00502 
4 0.00011 55 0.00572 
5 0.00012 56 0.00625 
6 0.00011 57 0.00675 
7 0.00009 58 0.00731 
8 0.00011 59 0.00796 
9 0.0001 60 0.00876 
10 0.0001 61 0.00933 
11 0.0001 62 0.01019 
12 0.00011 63 0.0115 
13 0.00012 64 0.01272 
14 0.00014 65 0.0138 
15 0.00022 66 0.01543 
16 0.0003 67 0.01677 
17 0.00047 68 0.01894 
18 0.00056 69 0.02078 
19 0.00057 70 0.02235 
20 0.00063 71 0.02474 
21 0.00063 72 0.02746 
22 0.00061 73 0.03039 
23 0.00066 74 0.03323 
24 0.00065 75 0.03727 
25 0.00066 76 0.04157 
26 0.00074 77 0.04606 
27 0.00074 78 0.05137 
28 0.00081 79 0.05736 
29 0.00084 80 0.06507 
30 0.00092 81 0.07265 
31 0.00092 82 0.08049 
32 0.00097 83 0.08871 
33 0.00103 84 0.10089 
34 0.00116 85 0.11282 
35 0.00126 86 0.12553 
36 0.00125 87 0.13789 
37 0.00132 88 0.15117 
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Age x qxa Age x qxa 
38 0.00149 89 0.15729 
39 0.00155 90 0.16935 
40 0.00168 91 0.18235 
41 0.00179 92 0.20721 
42 0.00185 93 0.23379 
43 0.00199 94 0.25755 
44 0.00222 95 0.284 
45 0.00241 96 0.30686 
46 0.00255 97 0.33477 
47 0.00272 98 0.35701 
48 0.00294 99 0.37245 
49 0.00317 100 0.41787 
50 0.00353 
  a qx, is the mortality rate between age x and (x +1), that is the probability that a 
person aged x exact will die before reaching age (x +1). 
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Appendix 9  Cost effectiveness supplementary tables 
 
Table 1  Incremental cost effectiveness for the base case with different NHS 
reference costs applied to the triage strategies 
NHS reference cost (£) Intervention Cost (£) QALYs ICER 
10 GDX 2841 19.7701  
 OCT 2967 19.7746 27812 
 HRT MRA 3001 19.7771 13807 
 HRT GPS 3011 19.7771 Dominateda 
 Current Practice 3084 19.7780 98231 
13 GDX 2856 19.7701  
 OCT 2982 19.7746 27784 
 HRT MRA 3016 19.7771 13780 
 HRT GPS 3026 19.7771 Dominateda 
 Current Practice 3084 19.7780 80605 
16 GDX 2872 19.7701  
 OCT 2996 19.7746 27757 
 HRT MRA 3031 19.7771 13754 
 HRT GPS 3040 19.7771 Dominateda 
 Current Practice 3084 19.7780 62979 
19 GDX 2887 19.7701  
 OCT 3011 19.7746 27729 
 HRT MRA 3046 19.7771 13727 
 HRT GPS 3055 19.7771 Dominateda 
 Current Practice 3084 19.7780 45353 
22 GDX 2902 19.7701  
 OCT 3026 19.7746 27701 
 HRT MRA 3060 19.7771 13700 
 HRT GPS 3070 19.7771 Dominateda 
 Current Practice 3084 19.7780 27727 
25 GDX 2917 19.7701  
 OCT 3041 19.7746 27673 
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 HRT MRA 3075 19.7771 13673 
 Current Practice 3084 19.7780 10101 
 HRT GPS 3085 19.7771 Dominateda 
28 GDX 2932 19.7701  
 OCT 3056 19.7746 27646 
 Current Practice 3084 19.7780 8313 
 HRT MRA 3090 19.7771 Dominateda 
 HRT GPS 3100 19.7771 Dominateda 
31 GDX 2947 19.7701  
 OCT 3071 19.7746 27618 
 Current Practice 3084 19.7780 3853 
 HRT MRA 3105 19.7771 Dominateda 
 HRT GPS 3115 19.7771 Dominateda 
34 GDX 2962 19.7701  
 Current Practice 3084 19.7780 15579 
 OCT 3086 19.7746 Dominateda 
 HRT MRA 3120 19.7771 Dominateda 
 HRT GPS 3129 19.7771 Dominateda 
37 GDX 2977 19.7701  
 Current Practice 3084 19.7780 13663 
 OCT 3101 19.7746 Dominateda 
 HRT MRA 3135 19.7771 Dominateda 
 HRT GPS 3144 19.7771 Dominateda 
40 GDX 2992 19.7701  
 Current Practice 3084 19.7780 11747 
 OCT 3116 19.7746 Dominateda 
 HRT MRA 3149 19.7771 Dominateda 
 HRT GPS 3159 19.7771 Dominateda 
43 GDX 3007 19.7701  
 Current Practice 3084 19.7780 9831 
 OCT 3130 19.7746 Dominateda 
 HRT MRA 3164 19.7771 Dominateda 
 HRT GPS 3174 19.7771 Dominateda 
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46 GDX 3022 19.7701  
 Current Practice 3084 19.7780 7315 
 OCT 3145 19.7746 Dominateda 
 HRT MRA 3179 19.7771 Dominateda 
 HRT GPS 3189 19.7771 Dominateda 
49 GDX 3037 19.7701  
 Current Practice 3084 19.7780 5999 
 OCT 3160 19.7746 Dominateda 
 HRT MRA 3194 19.7771 Dominateda 
 HRT GPS 3204 19.7771 Dominateda 
52 GDX 3052 19.7701  
 Current Practice 3084 19.7780 4083 
 OCT 3175 19.7746 Dominateda 
 HRT MRA 3209 19.7771 Dominateda 
 HRT GPS 3218 19.7771 Dominateda 
55 GDX 3067 19.7701  
 Current Practice 3084 19.7780 2168 
 OCT 3190 19.7746 Dominateda 
 HRT MRA 3224 19.7771 Dominateda 
 HRT GPS 3233 19.7771 Dominateda 
58 GDX 3082 19.7701  
 Current Practice 3084 19.7780 252 
 OCT 3205 19.7746 Dominateda 
 HRT MRA 3238 19.7771 Dominateda 
 HRT GPS 3248 19.7771 Dominateda 
61 Current Practice 3084 19.7780  
 GDX 3097 19.7701 Dominateda 
 OCT 3220 19.7746 Dominateda 
 HRT MRA 3253 19.7771 Dominateda 
 HRT GPS 3263 19.7771 Dominateda 
64 Current Practice 3084 19.7780  
 GDX 3112 19.7701 Dominateda 
 OCT 3235 19.7746 Dominateda 
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 HRT MRA 3268 19.7771 Dominateda 
 HRT GPS 3278 19.7771 Dominateda 
67 Current Practice 3084 19.7780  
 GDX 3127 19.7701 Dominateda 
 OCT 3250 19.7746 Dominateda 
 HRT MRA 3283 19.7771 Dominateda 
 HRT GPS 3292 19.7771 Dominateda 
70 Current Practice 3084 19.7780  
 GDX 3142 19.7701 Dominateda 
 OCT 3265 19.7746 Dominateda 
 HRT MRA 3298 19.7771 Dominateda 
 HRT GPS 3307 19.7771 Dominateda 
73 Current Practice 3084 19.7780  
 GDX 3157 19.7701 Dominateda 
 OCT 3279 19.7746 Dominateda 
 HRT MRA 3313 19.7771 Dominateda 
 HRT GPS 3322 19.7771 Dominateda 
76 Current Practice 3084 19.7780  
 GDX 3172 19.7701 Dominateda 
 OCT 3294 19.7746 Dominateda 
 HRT MRA 3327 19.7771 Dominateda 
 HRT GPS 3337 19.7771 Dominateda 
79 Current Practice 3084 19.7780  
 GDX 3187 19.7701 Dominateda 
 OCT 3309 19.7746 Dominateda 
 HRT MRA 3342 19.7771 Dominateda 
 HRT GPS 3352 19.7771 Dominateda 
82 Current Practice 3084 19.7780  
 GDX 3202 19.7701 Dominateda 
 OCT 3324 19.7746 Dominateda 
 HRT MRA 3357 19.7771 Dominateda 
 HRT GPS 3367 19.7771 Dominateda 
85 Current Practice 3084 19.7780  
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Table 2  Incremental cost effectiveness ratios of increasing costs of triage 
strategies and not treating patients diagnosed as “at risk” 
 
Increasing cost of 
triage strategy (£) 
Intervention Cost(£) QALYs ICER 
+10 GDX 2719 19.7393  
 OCT 2840 19.7410 68260 
 HRT MRA 2869 19.7414 83488 
 HRT GPS 2879 19.7414 Dominateda 
 Current Practice 2954 19.7415 488759 
+ 13 GDX 2733 19.7393  
 OCT 2853 19.7410 68229 
 HRT MRA 2883 19.7414 83457 
 HRT GPS 2893 19.7414 Dominateda 
 Current Practice 2954 19.7415 409713 
+16 GDX 2747 19.7393  
 OCT 2867 19.7410 68198 
 HRT MRA 2897 19.7414 83426 
 HRT GPS 2906 19.7414 Dominateda 
 Current Practice 2954 19.7415 330667 
+19 GDX 2761 19.7393  
 OCT 2881 19.7410 68167 
 HRT MRA 2910 19.7414 83396 
 HRT GPS 2920 19.7414 Dominateda 
 Current Practice 2954 19.7415 251620 
+22 GDX 2775 19.7393  
 OCT 2895 19.7410 68137 
 GDX 3217 19.7701 Dominateda 
 OCT 3339 19.7746 Dominateda 
 HRT MRA 3372 19.7771 Dominateda 
 HRT GPS 3381 19.7771 Dominateda 
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Increasing cost of 
triage strategy (£) 
Intervention Cost(£) QALYs ICER 
 HRT MRA 2924 19.7414 83365 
 HRT GPS 2934 19.7414 Dominateda 
 Current Practice 2954 19.7415 172574 
+25 GDX 2788 19.7393  
 OCT 2908 19.7410 68106 
 HRT MRA 2938 19.7414 83335 
 HRT GPS 2947 19.7414 Dominateda 
 Current Practice 2954 19.7415 93527 
+28 GDX 2802 19.7393  
 OCT 2922 19.7410 68075 
 HRT MRA 2952 19.7414 83304 
 Current Practice 2954 19.7415 14481 
 HRT GPS 2961 19.7414 Dominateda 
+31 GDX 2816 19.7393  
 OCT 2936 19.7410 68044 
 Current Practice 2954 19.7415 34813 
 HRT MRA 2965 19.7414 Dominateda 
 HRT GPS 2975 19.7414 Dominateda 
+34 GDX 2830 19.7393  
 OCT 2949 19.7410 68014 
 Current Practice 2954 19.7415 8882 
 HRT MRA 2979 19.7414 Dominateda 
 HRT GPS 2989 19.7414 Dominateda 
+37 GDX 2843 19.7393  
 Current Practice 2954 19.7415 48341 
 OCT 2963 19.7410 Dominateda 
 HRT MRA 2993 19.7414 Dominateda 
 HRT GPS 3002 19.7414 Dominateda 
+40 GDX 2857 19.7393 0 
 Current Practice 2954 19.7415 42328 
 OCT 2977 19.7410 Dominateda 
 247 
 
Increasing cost of 
triage strategy (£) 
Intervention Cost(£) QALYs ICER 
 HRT MRA 3006 19.7414 Dominateda 
 HRT GPS 3016 19.7414 Dominateda 
+43 GDX 2871 19.7393  
 Current Practice 2954 19.7415 36314 
 OCT 2991 19.7410 Dominateda 
 HRT MRA 3020 19.7414 Dominateda 
 HRT GPS 3030 19.7414 Dominateda 
+46 GDX 2885 19.7393  
 Current Practice 2954 19.7415 30300 
 OCT 3004 19.7410 Dominateda 
 HRT MRA 3034 19.7414 Dominateda 
 HRT GPS 3043 19.7414 Dominateda 
+49 GDX 2898 19.7393  
 Current Practice 2954 19.7415 24287 
 OCT 3018 19.7410 Dominateda 
 HRT MRA 3048 19.7414 Dominateda 
 HRT GPS 3057 19.7414 Dominateda 
+52 GDX 2912 19.7393  
 Current Practice 2954 19.7415 18273 
 OCT 3032 19.7410 Dominateda 
 HRT MRA 3061 19.7414 Dominateda 
 HRT GPS 3071 19.7414 Dominateda 
+55 GDX 2926 19.7393  
 Current Practice 2954 19.7415 12260 
 OCT 3045 19.7410 Dominateda 
 HRT MRA 3075 19.7414 Dominateda 
 HRT GPS 3084 19.7414 Dominateda 
+58 GDX 2940 19.7393  
 Current Practice 2954 19.7415 6246 
 OCT 3059 19.7410 Dominateda 
 HRT MRA 3089 19.7414 Dominateda 
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Increasing cost of 
triage strategy (£) 
Intervention Cost(£) QALYs ICER 
 HRT GPS 3098 19.7414 Dominateda 
+61 GDX 2954 19.7393  
 Current Practice 2954 19.7415 233 
 OCT 3073 19.7410 Dominateda 
 HRT MRA 3102 19.7414 Dominateda 
 HRT GPS 3112 19.7414 Dominateda 
     
+64 Current Practice 2954 19.7415  
 GDX 2967 19.7393 Dominateda 
 OCT 3087 19.7410 Dominateda 
 HRT MRA 3116 19.7414 Dominateda 
 HRT GPS 3126 19.7414 Dominateda 
+67 Current Practice 2954 19.7415  
 GDX 2981 19.7393 Dominateda 
 OCT 3100 19.7410 Dominateda 
 HRT MRA 3130 19.7414 Dominateda 
 HRT GPS 3139 19.7414 Dominateda 
 
